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Abstract 
During the past 50 years, pharmaceutical coating has gone through the transition from 
sugar coating to organic solvent coating and aqueous coating. Since the 1990s, aqueous 
coating has largely phased out organic solvent coating as the dominate coating method for 
pharmaceutical dosage forms due to the toxicity and environmental related concerns 
caused by the organic solvents. On the other hand, although prevailing, aqueous coating 
has other major limitations such as higher energy consumption and longer processing 
time than the solvent coating. Powder coating has the benefits of both, being 
environmentally friendly, energy efficient and short processing time, while equally 
effective in modifying drug release profiles. Consequently, powder coating is pointing to 
the future as the next breakthrough in pharmaceutical coating. 
Involving three steps including preheating of the dosage forms, electrostatic deposition of 
coating powders and film formation (curing), powder coating has been studied to tablet 
coating with easily coated polymers. The objectives of the present study are to expand 
powder coating to more difficult coating materials such as ethylcellulose and cellulose 
acetate, as well as more difficult dosage forms including small pellets, and in particular, 
osmotic controlled release tablets.  
As a water-insoluble polymer, ethylcellulose (EC) is a commonly used coating material 
for sustained drug release. However, it is very difficult to coat by powder coating due to 
its high glass transition temperature (Tg). The present study was successful to coat tablets 
with fine particles of EC in a rotatable pan coater. With the proper addition of 
plasticizers, a continuous and uniform coating film was formed. Pore forming agent was 
added in the coating formulation to adjust the permeability of the coating film to allow a 
more controlled drug release rate.  
Currently, small pellets are coated by solvent coating or aqueous coating in a fluidized 
bed with a larger amount of fluidizing hot air than a pan coater, leading to an extremely 
high energy consumption. The present study utilized the pan coater instead of a fluidized 
bed to coat small pellets with powder coating, leading to a significant energy savings by 
 
ii 
 
avoiding the use of large amount of fluidizing hot air required to fluidize those pellets and 
to evaporate the organic solvent or water. Three different coating formulations containing 
Eudragit® EPO, Eudragit® RS/RL and Acryl EZE were developed to achieve immediate 
release, sustained release and delayed release, respectively.  
Particularly, as the only oral drug delivery system capable of achieving constant drug 
release rate, osmotic drug delivery system (ODDS) is considered as the ultimate ideal 
drug delivery system. However, only organic solvent coating can be currently used to 
coat ODDS due to the high Tg of the coating materials. The present study successfully 
applied powder coating to coat ODDS with cellulose acetate (CA), resulting in a 
continuous, uniform and functionally acceptable coating film. Both elementary and 
porosity ODDS were achieved by using this powder coating. Following zero order drug 
release kinetics, drug release rate from powder coated ODDS varied with different 
coating levels while was independent with other factors such as drug delivery orifice 
diameter, pH vale of the release media and agitation speed. Considering that ODDS is the 
most promising controlled drug release system, the success of powder coating ODDS is a 
big breakthrough in pharma coating. 
To fully illustrate the powder coating process, in-depth characterization was carried out to 
investigate the coating powder deposition and film formation, and their influence factors. 
Positively related to the coating efficiency, powder deposition was found to be the key of 
the whole process, which can be promoted by preheating the dosage forms, spraying 
suitable liquid plasticizer and applying electrostatics for the powder spray. A curing step 
is necessary after coating powder adhesion to allow deposited particles to coalesce and 
form a continuous coating film. Finer coating powders, higher curing temperature and 
longer curing time would lead to a more uniform and smoother coating film. 
Keywords 
Pharmaceutical solid dosage forms, powder coating, tablets, pellets, osmotic drug 
delivery system, ethylcellulose, cellulose acetate, liquid plasticizer, sustained release, 
controlled release, enteric coating, coating powder adhesion, film formation, drug release. 
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1 General introduction 
1.1 Introduction 
In the pharmaceutical industry, solid dosage forms, including tablets, pellets, and 
capsules, are always coated to enhance drug’s physical and chemical properties, to 
achieve taste masking and also to modify the drug release profiles. Nowadays liquid 
coating methods, including solvent coating and aqueous coating, are widely used in the 
pharmaceutical industry to obtain the coating film of the solid dosage forms. In the 
solvent coating process, coating polymers and other excipients are dissolved into an 
organic solvent to form a coating solution, which is sprayed onto the surface of the solid 
dosage forms to form a coating film by evaporating the organic solvent. The film 
formation from organic solvent coating occurs by a loss of organic solvent during the 
drying process and contact of individual polymer molecules [1, 2]. As a result, solvent 
coating can form a very uniform coating film. However, it can also cause many problems 
due to the presence of organic solvent such as toxicity and environmental concerns. 
Besides, the concentration of the coating solution cannot be very high owing to the 
viscosity limitation, leading to a long processing time to achieve high coating thickness. 
As a result of toxicity and environmental concerns, aqueous coating started to dominate 
in 1990s and remains the preferred approach in the present pharmaceutical industry. For 
water soluble polymers, the coating process and film formation mechanism are the same 
as organic solvent coating. For water-insoluble polymers, the coating process and film 
formation are different. Coating polymers and additives are firstly ground into fine 
powders. After being mixed together, those fine powders are dispersed into water to form 
a coating powder suspension. This suspension is then sprayed onto the surface of the solid 
dosage forms, followed by water evaporation using hot air and curing to allow the 
polymer particles coalescing into a homogeneous film. Plasticizers are often added into 
the coating formulation to reduce the glass transition temperature (Tg) of the coating 
polymer [2]. Although there is no toxicity and environmental related problems for 
aqueous coating, it still possesses many limitations. First, water is much harder to 
evaporate compared to organic solvent, leading to a much longer processing time and 
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much higher energy consumption. Also hot air and its huge handling system are 
necessary to evaporate water, which could further increase the overall cost. In addition, 
aqueous coating is not appropriate for the moisture sensitive drugs. 
In order to overcome those disadvantages caused by organic solvent and water in the 
coating process, dry coating technologies have been recently developed and reported. 
These technologies include photocuring coating, supercritical fluid spray coating, hot-
melt coating and dry powder coating [3-5]. For the photocuring coating, supercritical 
coating and hot melt coating, specific coating conditions and suitable coating materials 
are necessary but unfortunately both are very limited. Consequently, those technologies 
cannot be widely applied in the pharmaceutical industry. For dry powder coating, liquid 
plasticizers have to be sprayed onto the surface of the solid dosage forms to reduce 
minimum film formation temperature but surplus plasticizer can possibly lead to very soft 
or sticky film. So a careful balance needs to be reached between the plasticizer 
concentration for a sufficient coat thickness and that for a flexible and dry coat. And also 
the coating powder feeding cannot be well controlled and it is difficult to get a smooth 
and thickness uniform coating film. 
Compared to those dry coating technologies, electrostatic powder coating has gained 
more attention owing to its distinct advantages, such as short coating process, highly 
valued for energy savings, and significant reduction of overall operating cost. And most 
importantly, electrostatic powder coating can enhance the coating powder adhesion so as 
to increase the coating efficiency dramatically and also can well control the coating 
powder feeding and achieve a much more uniform coating film both on coating thickness 
and surface morphology than other dry coating methods. Earlier attempts on electrostatic 
coating were mainly carried out by the Phoqus Ltd. Unfortunately, those advantages have 
been compromised by the complicated coating process and added cost of the coating 
apparatus, offsetting any cost benefit to switching from liquid coating to powder coating, 
since their technology requires the use of completely different coating equipment. The 
pharmaceutical companies would prefer to accept a powder coating process operated in a 
simpler coating apparatus that can be easily adapted from their present apparatus, such as 
pan coaters, for liquid coating. 
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Researchers in our group designed and developed a novel electrostatic powder coating 
technology [6] with an apparatus similar to the traditional pan coating system. This 
technology gained more attention due to the higher coating efficiency with simpler 
coating process and little change needed when adapting from the present apparatus. By 
using this technology, several easily coating materials have been applied on tablet coating 
[7-9]. 
However, more work will need to be carried out to fully illustrate this novel electrostatic 
powder coating technology. Firstly, this technology needs to be expanded to those coating 
materials with high glass transition temperature (Tg), for example, ethylcellulose and 
cellulose acetate, which is quite difficult to be coated by powder coating.  
In addition, coating of small solid dosage forms, such as pellets, still relies on the organic 
solvent coating or aqueous coating using a fluidized bed with large amount of fluidizing 
hot air, causing extremely high energy consumption. Powder coating of small pellets in a 
simpler apparatus could bring lots of benefits, overcoming those limitations related to the 
organic solvent and water, and significantly reducing the overall coast by avoiding use of 
large amount of fluidizing hot air.  
Particularly, as the most promising oral drug delivery system, osmotic drug delivery 
system (ODDS) can only be coated with organic solvent coating due to the high glass 
transition temperature (Tg) of the coating polymers. Much previous work has been done 
on powder coating, but none of it focused on the ODDS. It would be a big breakthrough if 
the ODDS tablets could be successfully coated with powder coating.  
Last but not the least, the electrostatic powder coating process needs to be characterized 
more in-depth in order to illustrate the coating powder adhesion and film formation, and 
their influence factors. 
1.2 Objectives 
Corresponding to the needs mentioned above, the present study focuses on the following 
objectives: 
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 To coat tablets with micronized ethylcellulose by using a novel electrostatic 
powder coating technology to achieve sustained drug release, optimizing the 
coating parameters so as to form a continuous and uniform coating film. 
 To expand powder coating to small solid dosage forms such as pellets, optimizing 
the coating process and developing different coating formulations to modify drug 
release profiles. 
 To utilize powder coating for an osmotic drug delivery system (ODDS), focusing 
on the coating formulation development so as to achieve drug controlled release 
with a constant release rate. Also to clarify the drug release mechanism from those 
powder coated ODDS. 
 To in-depth characterize the electrostatic powder coating process, illustrating the 
coating powder adhesion and film formation and their influence factors. 
1.3 Thesis structure 
This thesis contains eight chapters, organized in the following structure. 
 Chapter 1 gives a brief introduction on the background of this study, introducing 
the needs of the present study. Also research objectives and thesis structure as 
well as major contributions are also given in this chapter. 
 Chapter 2 provides a detailed review on drug release types and drug release 
mechanism as well as the development of pharmaceutical coating, particularly on 
the solventless coating methods which were reported recently, introducing both 
advantages and limitation for each coating technology. 
 Chapter 3 expands powder coating to coat tablets with micronized ethylcellulose 
to achieve sustained drug release, optimizing the coating parameters and curing 
conditions so as to form a continuous and uniform coating film and achieve a 
desirable drug release time period by adjusting the coating level and the pore 
former ratio in the coating formulation. 
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 Chapter 4 expands powder coating for small pellets with three different coating 
formulations to alter drug release profiles, optimizing the coating parameters and 
curing conditions so as to form a continuous, uniform and functionally acceptable 
coating film. 
 Chapter 5 applies powder coating to coat elementary ODDS tablets with cellulose 
acetate to achieve drug controlled release, optimizing the coating parameters and 
curing conditions so as to form a continuous and uniform coating film and to 
obtain desirable drug controlled release profiles. 
 Chapter 6 focuses on powder coating of porosity osmotic pump tablets with 
cellulose acetate. Pore forming agent was added in the coating formulation to 
create micropores on the coating film (semipermeable membrane), achieving drug 
controlled release uniformly through the whole membrane instead of one orifice 
(elementary ODDS). 
 Chapter 7 characterizes the film formation mechanism in the powder coating 
process and also clarifies the influence factors that affect the coating powder 
adhesion and film formation in the coating process. Also a screen method for the 
liquid plasticizer with different coating materials is provided in this chapter. 
 Chapter 8 summarizes this project, giving conclusions and providing 
recommendations for the future work. 
1.4 Major contributions 
This project expanded a novel electrostatic powder coating technology to more difficult 
coating materials such as ethylcelluse and cellulose acetate, and also to more difficult 
solid dosage forms including small pellets, osmotic drug delivery system (ODDS). More 
specifically the contributions are as follows: 
Firstly, powder coating was applied to coat tablets with powdered ethylcellulose, 
successfully achieving sustained drug release. This study found TEC is an effective liquid 
plasticizer for the ethylcellulose, not only reducing the glass transition temperature but 
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also increasing the conductivity of the tablets, leading to enhanced coating powder 
adhesion and better film formation. Lactose also has a plasticizing effect on 
ethylcellulose, promoting film formation during the curing process. In addition, pore form 
agents could be added in the coating formulation to adjust the drug release rate. 
Small solid dosage forms, such as pellets, were successfully coated by powder coating 
using a pan coater instead of fluidized bed, significantly reducing energy consumption 
and avoiding organic solvent and/or water related issues. Three different coating 
materials were applied to alter the drug release profiles with an optimized coating 
parameters and curing conditions. Compared to the present pellet coating method (liquid 
coating in a fluid bed), this electrostatic powder coating with a rotatory pan has many 
advantages. 
Particularly, the present study made a breakthrough on the coating of osmotic drug 
delivery systems (ODDS). Presently, ODDS could only be practically coated by organic 
solvent coating. While in this project, both elementary osmotic pump tablets and porosity 
osmotic pump tablets were successfully formed by using powder coating with cellulose 
acetate. Both water soluble drug (salbutamol sulfate) and water insoluble drug 
(ibuprofen) were used as the model drugs. Drug controlled release was successfully 
achieved with a desirable time period (12 hours or 24 hours). Drug release mechanisms 
from those electrostatic powder coated ODDS were also discussed in this study. Influence 
factors that could affect the drug release rate were also clarified. 
More in-depth, the electrostatic powder coating process was characterized and fully 
illustrated by clarifying the coating powder adhesion and film formation, and their 
influence factors. Also this study provided a screening method for selecting liquid 
plasticizer for powder coating with different coating materials. 
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2 Literature review 
2.1 Drug release types 
According to the release profile, drug release could be commonly classified as 
immediate/fast release, sustained/ controlled release and delayed release (Figure 2.1). 
Drug release profiles could be altered by coating the dosage forms based on the properties 
of drug and therapeutic target. 
Time 
D
ru
g 
re
le
as
e 
(%
) 
100 %
2 hours
Sustained/controlled release
Delayed release
Immediate 
release
 
Figure 2.1 Drug release types 
2.1.1 Immediate/fast release 
Immediate/fast release means that a drug (API) could be released immediately after the 
drug entering into the gastrointestinal tract (GI tract) without any extension. This type of 
release is suitable for those drugs that could be used to treat acute diseases such as heart 
attack, hypertensive urgencies, etc. Coating for immediate release dosage forms aims to 
achieve taste and/or odor masking, drug protection from light and also for aesthetic 
purpose, etc.  
9 
 
 
Figure 2.2 Molecular structure of hydroxypropyl methylcellulose [1] 
Water-soluble polymers are usually used as the coating materials in the immediate release 
coating. Common water soluble coating materials include hydroxypropyl methylcellulose 
(HPMC), hydroxypropyl cellulose, polyvinyl alcohol, polyvinylpyrrolidone--vinyl acetate 
copolymer and polyvinyl alcohol--polyethylene glycol copolymer.  
2.1.2 Sustained/controlled release 
For sustained/ controlled release dosage forms, which is also referred to as extended 
release, the drug could be released at a predetermined rate in order to maintain a desirable 
plasma drug concentration for a specific period of time. By doing so side effects 
associated with high peak plasma concentrations could be eliminated or reduced. Also 
sustained release could decrease the dosing frequency and enhance the patient’s 
adherence to the therapeutic regimen [2]. An example of an in vitro dissolution profile 
from such sustained release systems compared to that of an immediate release product is 
shown in Figure 2.1.  
Sustained release can be achieved through coating of dosage forms with water-insoluble 
polymers such as ethyl cellulose, polymethacrylate copolymers and polyvinyl acetate. 
Eudragit® RS /RL are copolymers with quaternary ammonia groups derived from esters 
of acrylic and methacrylic acid, which is widely used for sustained release coating of 
pharmaceutical dosage forms. Drug release from those coated dosage forms is controlled 
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by diffusion. When the coated dosage forms enter the gastrointestinal (GI) tract, fluid of 
the GI tract diffuses into the core through the polymer coating film, causing the drug to 
dissolve and leading to a much higher concentration of drug inside the core compared to 
the outside. This concentration gradient will let the drug release from the inside of the 
core to the outside of the dosage form by the passive diffusion. In order to obtain a 
sustained release profile, the coating film should possess sufficient mechanical strength to 
withstand the hydrostatic pressure caused by the fluid diffused into the core, otherwise 
film cracking would occur, leading to a burst drug release.  
 
Figure 2.3 Molecular structure of ethyl cellulose [1] 
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Figure 2.4 Molecular structure of Eudragit® RL and Eudragit® RS [3] 
Rate of drug release could be affected by the following factors. First of all, film thickness 
plays a key role in controlling the drug release rate. Assuming that coating films have 
similar densities, thicker coating films create a longer, more tortuous diffusional pathway, 
making it slower for the drug to come out [4, 5]. Water solubility of the drug could also 
impact the rate of drug release. Drugs with high solubility release much faster than those 
slightly soluble or insoluble [2, 6, 7]. In order to increase the rate of drug release, water 
soluble materials could be added into the coating formulation to form micropores in the 
coating film to promote drug release. 
Osmotic drug delivery system (ODDS) nowadays has become the most promising drug 
delivery system (DDS) for the reason that it could achieve zero order drug release 
kinetics and drug release is independent from pH value, agitation speed or other GI tract 
factors. ODDS also need a coating film with water-insoluble polymers to obtain the 
controlled drug release. However, the drug release is controlled by the osmotic pressure 
gradient rather than passive diffusion. The ODDS core contains osmotic agent(s), which 
can create osmotic pressure after the GI fluid diffusing into the core. And the drug will be 
released through a delivery orifice or micropores on the coating film governed by the 
osmotic pressure. Similar with the diffusion controlled release system, thickness of the 
coating film also plays a key role in controlling the drug release rate in ODDS. Cellulose 
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esters including cellulose acetate and ethylcellulose are widely used as the coating 
materials to form the coating film of ODDS [8-13]. Eudragit® RS /RL [14] was also used 
as the coating material to form the semipermeable membrane of the ODDS pellets. The 
developed ODDS dosage forms include elementary osmotic pump [15-17], push-pull 
osmotic pump [18-20], sandwiched osmotic pump [21, 22] and porosity osmotic pump 
[23-25]. 
2.1.3 Delayed release 
Delayed release could be achieved by enteric coating with pH sensitive coating polymers. 
Those polymers wouldn’t dissolve in the gastric fluid with low pH value (pH=1.2), so the 
drug couldn’t come out. However, after the enteric coated dosage forms entering the 
intestine with a high pH value (pH=6.8), the coating film will dissolve immediately and 
drug will be completely released in a very short time. Enteric coating could provide drug 
protection from acid and enzymes in stomach with low pH value. Also it could eliminate 
the irritation or harmful effects of some drugs to stomach. In addition, enteric coating 
could achieve drug target absorption in the intestinal. 
Enteric coating materials include nature polymers such as shellac [26] and synthetic 
polymers such as poly(styrene-alt-maleic anhydride)-ethanol [27], hydroxypropyl 
methylcellulose acetate succinate [28], HPMCP and Eudragit® L [29, 30]. 
 
Figure 2.5 Molecular structure of Eudragit® L 100-55 
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2.2 Drug controlled release: mechanisms and principles 
Based on the drug release mechanism, drug controlled release systems are classified into 
diffusion, erosion and osmotic controlled systems.  
2.2.1 Diffusion controlled release 
For diffusion controlled release systems, drug molecules release out of the dosage forms 
through a polymer membrane or matrix, which is driven by diffusion (a process of 
moving molecules from a solution of high concentration to low concentration).  Diffusion 
controlled release systems could be classified into reservoir system, also called “core-
shell system” and matrix system or called “monolithic system”.  
For the reservoir system (Figure 2.6), the drug is located in the center of the dosage 
forms, where barrier materials (often polymers) form an outlayer membrane surrounding 
this drug depot to control drug release rate [31].  
Polymer barrier membrane
Drug core
 
Figure 2.6 Schematic representation of diffusion controlled drug delivery 
system (reservoir system) 
Matrix system (Figure 2.7) is also called “monolithic system” or “one-block system”. In 
this drug delivery system, drug is homogeneously distributed throughout a polymer 
matrix. Drug release rate is controlled by diffusion from the polymer and decreases as a 
function of time and distance. 
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Figure 2.7 Schematic representation of diffusion controlled drug delivery 
system (matrix system) 
2.2.2 Erosion/Degradation controlled drug release 
For this drug controlled release system, the drug can be loaded into the system by two 
ways. First one is that the drug can be physically trapped in the polymer matrix. By doing 
this, the drug could be released with the erosion of the polymer matrix. Or the drug could 
be chemically adhered to a backbone of a polymer, where the drug could be released 
when the chemical bond holding the polymer and the drug is broken down. 
According to the erosion location, erosion/ degradation controlled drug release system 
could be further classified as surface erosion and bulk erosion.  
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Figure 2.8 Schematic representation of erosion controlled drug delivery 
system (bulk erosion) [32] 
 
If water penetrated into the polymer matrix more rapidly than hydrolysis could occur, 
chain scission would be initiated everywhere in the matrix, leading to a bulk erosion 
(Figure 2.8). On the other hand, for the hydrophobic polymers, it is difficult for water to 
enter the whole matrix and the erosion would start from the surface (Figure 2.9). 
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Figure 2.9 Schematic representation of erosion controlled drug delivery 
system (surface erosion) [32] 
2.2.3 Osmotic controlled drug delivery system (ODDS) 
As one of the fundamental phenomena in biology, osmosis is the movement of a solvent 
across a semipermeable membrane toward a higher concentration of solute. Osmotic flow 
can be generated when two solutions with different solute concentrations are separated by 
a semipermeable membrane, restricting the solute but allowing passage of the solvent 
molecules (Figure 2.10 A.1). The solvent flow across the semipermeable membrane is 
directed to compensate differences in solute concentrations, leading to a hydrostatic 
pressure difference across the semipermeable membrane (Figure 2.10 A.2). 
 
Figure 2.10 Principle of osmotic flow [33] 
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Osmotic drug delivery system (ODDS) consists of an osmotic core containing the drug 
and osmotic agent(s) surrounded by a semipermeable membrane with delivery orifice(s), 
which delivers the agent by an osmotic process at a controlled rate.  
The first idea of ODDS came from Rose and Nelson, they proposed an osmotic dispenser 
[34] that is capable of delivering a drug solution with a relatively constant rate. Later in 
1970s, Takero Higuchi and Felix Theeuwes improved the osmotic dispenser [35, 36] and 
developed an elementary osmotic pump tablet [15], cooperated with the Alza 
Corporation, which is the first practical example of an osmotic pump based drug release 
system [37]. US8029822 B2 [38] used cellulose esters as the coating materials in the 
embodiment to achieve rupturing controlled release from the preformed passageways. 
US8703193 B2 [39] provided a controlled porous ODDS of high permeable drugs 
containing a porous semipermeable membrane which was formed by cellulose acetate and 
the added pore-forming agents. By doing so gastro-intestinal (GI) irritation could be 
minimized or eliminated. 
As the only drug delivery system that could release a drug with a constant rate, ODDS 
has gained tremendous attention as a promising drug carrier owing to its distinct 
characteristics, such as zero order drug release kinetics, independent drug release of pH 
and other physiological parameters. 
2.3 Historical development of pharmaceutical coating  
As an old pharmaceutical process, coating of solid dosage forms has seen significant 
advances in both development of coating materials and the equipment design during the 
past 50 years [40]. Pharmaceutical coating has undergone transition from sugar coating in 
conventional pans to film coating based on organic solvent and water in perforated 
coating pans or in modern fluidized beds with high drying efficiencies. At present, 
aqueous film coating has replaced organic film coating in the dominate position of 
pharmaceutical coating due to the toxicity and environmental related concerns caused by 
the organic solvent. On the other hand, it still possesses many limitations such as much 
longer processing time and much higher energy consumption than solvent coating, and 
inappropriate for the moisture sensitive drugs. So recently many solventless or dry 
18 
 
coatings have been developed and reported to avoid using organic solvent and water. 
Among those reported solventless coatings, powder coating has the benefits of both 
solvent coating and aqueous coating, being environmentally friendly, energy efficient and 
short processing time, while equally effective in modifying drug release profiles. 
Consequently, powder coating is pointing to the future, as the next breakthrough in 
pharmaceutical coating. 
 
Figure 2.11 Historical development of pharmaceutical coating 
2.3.1 Sugar coating 
Beginning in the 19th century, sugar coating is mainly used to increase the palatability of 
bitter medicaments [41]. In total, there are four steps in a sugar coating procedure, 
including sealing, subcoating, syruping and polishing. Although sugar coating could 
produce a very elegant product, its limitations are obvious. With a complicated coating 
process, the processing time of sugar coating could last up to five days, making it difficult 
for the application. And also sugar coating requires the operators with a high level of 
expertise. In addition, it is difficult to standardize the coating procedure. And the 
possibility of bacterial and mold growth in sugar solutions, sealing the tablets before 
coating and a lack of automation in the process led to the search for alternative coating 
methods [42]. 
Powder 
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2.3.2 Solvent coating 
The development of polymer industry, particularly novel polymer synthesis and 
preparation, led to a big progress in pharmaceutical coating. A wide variety of coating 
materials, for example, the cellulose derivatives, made it possible for the appearance of 
film coating. Solvent film coating firstly appeared in 1930 and was commercially 
available in 1954 by Abbott Laboratories. They used a fluidized bed coating column 
based on the Wurster principle [43]. Later a rotatory pan coating system was developed 
for the tablet coating with organic solvent.  
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Figure 2.12 Solvent coating process 
Coating polymers and other excipients were mixed and dissolved into an organic solvent 
to form a coating solution, which is then sprayed onto the surface of the solid dosage 
forms. The coating film was formed after the evaporation of organic solvent. 
Promoting by the design and development of more efficient and precise coating apparatus 
and also by the introduction of many polymers, film coating developed rapidly and 
significantly changed pharmaceutical coating. It not only offered an increased process 
control, and better reproducibility, but also can be applied on a variety of dosage forms 
including larger ones like tablets and smaller ones like pellets and beads. 
However, film coating based on solvent suffer from many limitations. First of all, organic 
solvents are toxic and flammable, causing toxicity and environmental related issues. Also 
the concentration of coating solution cannot be too high due to the viscosity limit, 
otherwise it may block the spray nozzle. As a result, it takes a very long processing time 
to achieve a thick coating film. In addition, the whole process needs a large amount of 
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organic solvents and the after-treatment and recovery of the organic solvent are very 
expensive, which could significantly increase the overall cost. 
2.3.3 Aqueous coating 
Those disadvantages of organic solvent coating make the film coating based on aqueous 
more acceptable for the pharmaceutical industry and it remains the domination position in 
the present industry. Aqueous coating uses the existing coating pans, which is the same as 
solvent coating. The only difference is that water is used to dissolve or disperse the 
coating materials. For water soluble coating polymers, the coating process and film 
formation mechanism are the same as solvent coating. For water insoluble coating 
materials, coating polymers as well as additives and excipients are first milled into very 
fine particles and then a mixture of those fine particles are dispersed into water to form a 
coating dispersion. An atomizing nozzle was used to spray this coating dispersion onto 
the surface of the solid dosage forms, followed by a water evaporation process. 
Simultaneously, coating particles coalesced together and fused into a coating film with 
the heat provided by hot air. 
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Figure 2.13 Aqueous coating process for water-insoluble coating polymers 
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Figure 2.14 Schematic presentation of the film formation mechanism of  
(a) aqueous coating (b) and solvent coating 
In the aqueous coating process (water insoluble coating materials), coating polymer is 
present as a number of discrete particles in a wet state. Those wet particles would have to 
coalesce, deform and fuse together to form a coating film. Capillary force between 
particles and substrate caused by the water evaporating could significantly promote the 
coalescence of particles. Hot air is necessary in the coating process to carry out the 
moisture and to provide heat for the deformation and fusion of coating particles. 
Although aqueous coating now remains as the preferred coating method compared to 
solvent coating, it still possesses a number of disadvantages. First of all, it takes a much 
longer time for water to be evaporated compared with organic solvent, leading to a much 
longer processing time. Also water evaporation needs much more energy consumption. In 
addition, hot air handling and equipment cleaning would further increase the overall cost 
of the process. Last but not the least, aqueous coating is not suitable for the moisture 
sensitive drugs. 
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2.4 Solventless coating 
In order to overcome those limitations caused by the solvent or water, many efforts have 
been made to develop solventless coating technologies. Those reported solventless 
coating technologies include compression coating, photocuring coating, supercritical fluid 
coating, hot-melt coating, dry powder coating. 
2.4.1 Compression coating 
Compression coating, also named press coating, is mainly applied for the coating of 
tablets [44]. It is comprised of a drug core and an outer shell. The drug core is enclosed in 
the outer shell and thus different drug release patterns can be modulated by the selection 
of inner drug cores and outer layer materials. Also, the outer shell has great influence on 
the mechanical strength and stability of the coated tablets. 
In the compression coating process, the mixture of core formulation is firstly compressed 
into an inner layer core and then coating material(s) is compressed around the core to 
form an outer layer film. The main problem for the compression coating is that the 
coating thickness is not uniform owing to the reproducibility issues of placement of the 
core in the center [42, 45], which is called a decentralized core. In order to overcome this 
limitation, Ozeki et al. developed a one-step dry- coated (OSDRC system) [46] tablet 
manufacturing method. The OSDRC-system does not require preparation of core tablets 
beforehand, allowing dry-coated tablets be made in a single process.  
However, its use has largely been restricted to specific applications due to the problem of 
large coating thickness, which could limit the drug loading.  
2.4.2 Photocuring coating 
Photocuring coating involves a free-radical polymerization reaction of photocurable 
materials to form a crosslinked network [47-49]. There are three major components in 
photocuring systems including a UV/visible light source, specially functionalized liquid 
prepolymers or monomers, and an initiator [42].  
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Figure 2.15 Schematic process of photocuring coating 
This coating process can be performed rapidly at room temperature or below, which is 
suitable for temperature sensitive drugs. It is the only reported chemical approach so for 
to form the coating film. Both tablets coating and pellets coating can be achieved with 
this technique. But this coating method is not suitable for the photosensitive drugs. Also 
its use is limited by the specific photocurable materials and coating equipment. 
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2.4.3 Supercritical fluid coating 
 
Figure 2.16 Supercritical state 
When both the temperature and pressure of a substance are greater than its critical 
temperature (TC) and critical pressure (PC), this state is defined as the supercritical state. 
The thermal and physical properties of supercritical fluids fall in between pure liquids and 
gases. In a supercritical state, many properties of the substance including the density, 
viscosity, diffusivity, and other physical properties, such as solvent strength and dielectric 
constant, can be varied in a range from gas-like to liquid-like [42]. 
In the supercritical fluid coating process, the coating materials are solubilized in 
supercritical fluid (such as carbon dioxide) in a vessel with high pressure. The drugs 
(active agents) are dispersed in the supercritical solution. When the suspension is rapidly 
expended, the solvent power of carbon dioxide is reduced, leading to a precipitation of 
coating materials onto the surface of the drug particles dispersed in the medium. This is 
called rapid expansion of supercritical solutions (RESS) [50], which is the most common 
supercritical fluid process in pharmaceutical applications. For this method, the coating 
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materials must be soluble in supercritical fluid such as carbon dioxide and also the drug 
must be insoluble in the supercritical fluid. 
Supercritical fluid coating can be used to coat small particles uniformly by encapsulating 
each core with coating materials under a supercritical condition. However, the application 
of this coating method is limited due to the poor solubility of most coating materials in 
supercritical fluid and also the requirement of the core to be insoluble.  
2.4.4 Hot-melt coating 
For the hot-melt coating, coating materials are applied in their molten state. The coating 
process includes several steps. Firstly, the coating equipment is warmed, and then 
substrate is preheated. Coating materials are melted and sprayed onto the surface of the 
substrate, followed by the cooling step to allow the film formation. 
 
Figure 2.17 Schematic process of hot-melt coating 
Lipids were reported as excellent coating agents for hot-melt coating due to their low 
melting point. A number of works have been reported so far [51, 52]. Those works 
include coating waxes [53], vegetable oils and their derivatives [54], polyoxylglycerides 
[55] and fatty acids [56] for the purpose of sustained release, taste masking, ect. 
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Figure 2.18 Schematic process of the hot-melt coated particles: the 
deposition of lipid droplets (white) at the surface of the substrate (blue) [51] 
However, hot melt coating method is only suitable for the drug with stable properties at 
or below the congealing point of the coating materials. 
2.4.5 Powder coating 
For the powder coating, coating polymers and other excipients are first milled into fine 
particles and then a mixture of those fine particles are sprayed onto the surface of the 
solid dosage forms, followed by an oven curing step to allow film formation. Basically 
there are two steps in dry powder coating process: coating powder adhesion to the surface 
of solid dosage forms and film formation. The coating powder adhesion is the key for the 
whole dry powder coating method because a better powder adhesion could lead to a high 
coating efficiency. Kablitz et al. [57] concluded that the film formation for dry powder 
coating was resulted from viscous flow and particles deformation, which could be 
improved by combination of plasticizers and heat. 
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Many reported powder coating technologies [28, 57-60] used liquid plasticizers to 
facilitate coating powder adhesion and film formation for the reason that those liquid 
plasticizers could not only reduce the glass transition temperature of coating polymers, so 
as to decrease the curing temperature to protect drugs, but also provide the capillary force 
between the coating particles and the dosage forms, significantly promoting coating 
powder adhesion. The coating process can be seen as Figure 2.19. 
 
Figure 2.19 Schematic process of plasticizer dry powder coating 
Water could also be used as liquid plasticizer in the dry powder coating process. Obara et 
al. [28] reported that the quality of the coating film could be significantly improved by 
spraying a small amount of water or hydroxypropyl methylcellulose (HPMC) solution to 
the HPMCAS-coated spheres. Other reports [58] also found that film formation could be 
obviously accelerated by moisture. Also the smoothness and integrity of coating film 
could be optimized by spraying different amount of moisture. This is similar to the 
aqueous coating process in which water plays a key role of coalescing agent, facilitating 
the coalescence of coating particles and the fusion of polymer chains. 
While for those dry powder coating technologies, surplus liquid plasticizers sprayed onto 
the surface of the solid dosage forms can possibly lead to very soft or sticky film, so a 
careful balance needs to be reached between the plasticizer concentration for a sufficient 
coat thickness and that for a flexible and dry coat. And also the coating powder feeding 
cannot be well controlled and it is difficult to get a smooth and thickness uniform coating 
film. And a coating process that involves water still isn’t suitable for the moisture 
sensitive drugs. 
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Cerea et al. [61] developed a totally dry powder coating method without using any 
solvent or water in the coating process. As shown in Figure 2.20, the coating apparatus 
includes a rotating disk, an infrared lamp, a single screw powder feeder, a temperature 
probe and a glass cover. Firstly, the solid dosage forms were loaded into the system and 
preheated by the infrared lamp for a certain time period. Then the coating powders were 
fed into the surface of the dosage forms by using the motorized single screw feeder to 
achieve the coating powder adhesion. The infrared lamp positioned on the top of the 
spheronizer was the only heating source which could be used to promote the coating 
powder adhesion as well as to provide heat for the curing and film formation. 
 
Figure 2.20 Schematic representation of the laboratory scale spheronizer 
used for the powder coating process: (1) rotating disk; (2) infrared lamp; (3) 
powder feeder; (4) temperature probe; (5) coating cores; (6) glass cover 
In this coating process, Eudragit® EPO (a copolymer based on dimethylaminoethyl 
methacrylate and methacrylates) was used as the coating material due to its low glass 
transition temperature. 
This technology provided a totally dry coating method without using any solvent or water 
in the coating process, but similar with hot-melt coating, it is only suitable for the drugs 
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that are not temperature sensitive and coating materials with very low glass transition 
temperature. 
2.5 Electrostatic powder coating  
The concept of electrostatic powder coating came out in the 1950s in USA, and now it is 
widely used in the metal and wood finishing industries.  
In the electrostatic powder coating process (Figure 2.21), dry powders are charged by an 
electrostatic spray gun and then move and adhere to the grounded substrate surface 
without using any solvent or water. And then the grounded substrate with deposited 
coating powder is put in an oven and cured for a certain period of time under high 
temperature to allow film formation. 
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Figure 2.21 Schematic representation of electrostatic powder coating 
process 
Three steps are involved in the coating powder deposition process [62]. Firstly, charged 
particles are sprayed onto the surface of the grounded substrate with combination of 
mechanical forces and electrostatic attractions. And then particles accumulate on the 
substrate before the repulsion force of the deposited particles against the coming particles 
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increase and exceed the electrostatic attraction of the grounded substrate to the coming 
particles. Finally, once the said repulsion force becomes equivalent to the said attraction, 
particles cannot deposit any more [63]. 
In order to successfully carry out the electrostatic spraying process, a powder charging 
unit is needed and the particles of coating material should be able to be charged. Also 
there should be a grounded conductivity substrate. According to the charging mechanism, 
basically there are two types of electrostatic spray units, corona charging and tribo 
charging. Corona charging process involves the electrical breakdown and ionization of air 
by imposing a high voltage on a sharp pointed needle-like electrode. As a result, there 
will be an electrical field between the gun and substrate which can promote the coating 
powder adhesion. When powder particles passing through the gun, they will pick up those 
negative ions on their way to the substrate. While tribo charging is related with the 
principle of frictional charging associated with the dielectric properties of solid materials. 
Consequently, there are no free ions and electrical field between electrostatic gun and the 
substrate. 
For the coating process by tribo charging gun, the movement of coating particles between 
the gun and the substrate is mainly governed by the mechanical force, which is produced 
by the air blowing the powder towards the substrate from the tribo gun. While for the 
corona charging gun, besides the mechanical force, electrical force will enhance the 
movement of coating particles from the gun towards the substrate owing to the presence 
of electrical field between the charging gun and the grounded substrate.  
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Figure 2.22 Effect of electrical conductivity on powder deposition  
in electrostatic powder coating process 
In the electrostatic powder coating process, the solid dosage forms must possess certain 
conductive properties or be modified to be conductive owing to the significant influence 
to the coating powder deposition on solid dosage forms. As shown in Figure 2.22, for 
more conductive dosage forms, the electrical charge of the deposited particles will 
dissipate quickly due to the grounding, so that additional layers of coating powder can be 
attracted and deposited onto the dosage form surface. For the less conductive dosage 
forms, electrical charge of the deposited particles will not dissipate and tends to build up 
on the surface of the dosage forms, which will impede further deposition of coating 
powder. 1×109 Ωm is said to be the maximum electrical resistivity to allow the above 
process to happen [57]. Unfortunately, for most of the pharmaceutical solid dosage forms, 
the electrical resistivity is much higher than 1×109 Ωm because they contain the 
excipients with high electrical resistivity. 
There are several methods to decrease the electrical resistivity of the solid dosage forms. 
First, the solid dosage forms can be wetted with water, because the layers of moisture 
increase the electrical conductivity. In the coating process, this can be performed by 
exposing solid dosage forms to high humidity for a very short time before coating. The 
electrical conductivity of solid dosage forms can be increased by adding some certain 
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excipients such as dicalcium phosphate and ionic salts (1-3%) due to their conductive 
properties [42]. Surface modification with polar groups (e.g., quaternary ammonium 
compounds) could also increase the electrical conductivity of the solid dosage forms. 
These compounds can be dissolved in volatile solvent and then applied to the surface 
where it deposits as a thin film after solvent evaporation, which can absorb moisture from 
the atmosphere and forms an electrically conductive layer [64].  
2.5.1 Film formation mechanism 
The film formation mechanism for organic and aqueous-based systems is fundamentally 
different [58]. For the conventional solvent coating, coating materials, mixed with other 
excipients including additives and pigments, are molecularly dissolved in the appropriate 
organic solvent to form a coating solution, which is then sprayed onto the surface of the 
solid dosage forms. Film formation is achieved by a loss of solvent and contact of 
individual polymer molecules. In the aqueous coating process, a dispersion of coating 
materials and other excipients is sprayed onto the surface of the solid dosage forms. After 
the evaporation of water, particles of coating materials have to coalesce into a 
homogeneous film. Film formation of polymer particles in the dry state results from 
deformation and viscous flow [57, 65, 66]. Solid or liquid plasticizers always have to be 
added to decrease the glass transition temperature of the coating polymers. For aqueous 
coating, capillary force also plays a significant role in coating particle coalescence and 
film formation [67].  
Similar to aqueous coating, film formation of dry powder coating also relies on the 
deformation and viscous flow of coating polymers [30, 57]. As being reported from 
previous studies, softening, melting and curing are the principal stages in the film 
formation during dry powder coating [68-70]. In those reported dry powder coating 
process, the substrates are often preheated above the glass transition temperature of the 
coating polymers so that the polymer powders can easily soften and adhere to the 
substrate. It was reported [69] that melt surface tension plays a decisive role in the film 
formation in dry powder coatings process. The surface tension could be controlled and 
adjusted by modifying coating formulations, for example, add some leveling additives to 
the formulations.  
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Liquid plasticizer is commonly added before spraying coating powders in dry powder 
coating processes to reduce the glass transition temperature (Tg) of coating polymer and 
enhance coating powder adhesion [28, 57, 58, 60, 61]. Further studies [67, 71] suggested 
that those liquid plasticizers could also promote capillary forces between the coating 
particles, leading to enhanced coating powder adhesion and increased coating efficiency. 
Obara [28] suggested that the use of a second liquid component in the dry coating process 
could reduce the contact angle of the liquid on the polymer and promote capillary forces 
between the polymer particles and the dosage forms.  
The film formation mechanism in electrostatic powder coating process is similar with 
other dry coating technologies. However, by applying electrostatic spraying process, 
coating powder adhesion will be significantly promoted by the combination use of 
electrical and mechanical forces, hence coating efficiency would be increased 
dramatically. Also coating powder adhesion and film formation could be further 
enhanced by increasing the conductivity of solid dosage forms and coating powders. It 
has been reported that surface tension would promote coating powders’ flow and 
coalescence while viscosity would retard it [72]. Consequently, a better surface coverage 
and uniform coating film could be formed by adding some flow modifiers (e.g., polyvinyl 
butyral and cellulose acetate butyrate) in the coating formulation to reduce the viscosity 
of the melted polymer [64]. 
Particle size of coating powders will also play a critical role to the film formation in the 
electrostatic powder coating process. Misev [62] carried out a study on the relationship 
between charging efficiency and particle size and obtained the following equation:  
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In the equation, E is the electric field to which the particles are subjected, ε0 is the 
permittivity of free space while εr is the relative permittivity of powder particles, ρ0 is the 
density of the particle and dp is the particle diameter. According to this equation, a higher 
charging efficiency could be achieved by using a smaller coating particle. Also a smaller 
particle has a larger specific surface area, which could make the wetting much easier by 
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the liquid and softening and melting by heat, so as to enhance the coating powder 
adhesion and film formation. Basically fine powder with a diameter less than 100 µm is 
preferable for dry powder coating. While more uniform and thickness controlled coating 
film could be achieved by applying ultrafine powders (less than 30 µm). However, those 
ultrafine powders are Group C powder, which is cohesive with poor flowability. In order 
to prevent the agglomeration and effectively improve the flowability of ultrafine powders, 
flow agent with nano-size could be added into the coating formulation [73-75]. 
2.5.2 Processing apparatus 
Phoqus Ltd., which has been, in recent years, devoting great efforts to design both 
apparatus and formulations for electrostatic powder coating. Their approach involves 
design of a dry powder coating apparatus to increase coating efficiency by increasing 
electrostatic attractions, to overcome the difficulty of charging poorly electrically 
conductive pharmaceutical solid dosages and to increase the mobility of relatively small 
sized particles with irregular shapes.  
One of the apparatus (Figure 2.23) designed by Phoqus Ltd. includes two occluding 
rotary drums, two electrostatic spray guns, two infrared ray-based fusion stations: infrared 
ray heater, two cooling stations, a tablet feeding chute and a tablet collection chute. This 
apparatus can make every tablet effectively grounded and can direct and restrict the 
charged particles onto the surface of tablet core without spraying onto the surrounding, so 
that the coating efficiency can be significantly improved. And also, the two sides of a 
tablet can be coated with different formulation or different color. However, not all the 
charged particles are deposited onto the tablet core because the drum will also receive 
some, leading to a waste of coating powder. Also cleaning the apparatus is time 
consuming, which could increase the overall cost. 
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Figure 2.23 Schematic of an electrostatic coating apparatus for solid 
dosage forms. (10) tablet feeding chute; (12, 12’) rotary drum; (16, 16’) 
electrostatic spraying gun; (18, 18’) tray to hold particles; (20, 20’) infrared 
ray heater; (22) tablet collection [76-79] 
US 20120012055 [80] reported an electrostatic coating apparatus (Figure 2.24) for 
pharmaceutical solid dosage forms. The apparatus contains a plurality of platens, each 
platen being arranged to hold a plurality of tablets. And each platen comprises an 
electrically conducting platen base and an electrically conducting platen shield located on 
the platen base. Consequently, the apparatus can control the electrostatic application of 
the powder more effectively by establishing an electrical difference between the platen 
base and the platen shield during the coating process. 
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Figure 2.24 Perspective view of a solid dosage form and a platen shield [80] 
US 20060099350 [81] designed a pattern on a solid dosage form, in which powder 
material can be applied in the pattern to the solid dosage forms. There is a mask with an 
aperture between a source of the powder material and the solid dosage form so that the 
powder materials can be applied to the dosage forms through the mask. 
US 6806017 [82] introduced another electrostatic coating apparatus based on a 
photoconductive drum. The charged powder material is firstly applied to the 
photoconductive drum and transferred to an intermediate belt and then to a solid dosage 
forms. By doing this, it can provide an arrangement in which the location of the 
deposition of the powder material can be closely controlled, enabling coating powder 
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deposition on a solid dosage form in a precise pattern. Also it can facilitate the powder 
deposition on a three dimensional surface. 
Compared to the conventional coating process, those apparatuses designed by Phoqus 
Ltd. do have many advantages. First of all, those apparatuses can handle the dosage forms 
individually and gently so that dosage forms can be less robust. The coating process is 
continuous and can be performed at ambient conditions. And coating film formed by this 
technology is quite uniform with a significantly increased coating efficiency and well 
controlled coating film thickness. Also, tablets could be coated with different color or 
formulation. Unfortunately, those advantages have been compromised by the complicated 
coating process and added cost of the coating apparatus, offsetting any cost benefit to 
switching from liquid coating to powder coating, since their technology requires the use 
of completely different coating equipment. In addition, adoption of new equipment not 
only incurs extra capital costs, but also introduces additional complications in operation. 
The pharmaceutical companies would prefer to accept a powder coating process operated 
in a simpler coating apparatus that can be easily adapted from their present apparatus, 
such as pan coaters, for liquid coating.  
Zhu [83, 84] designed and developed a novel electrostatic powder coating technology 
with an apparatus similar to the traditional pan coating system (Figure 2.25).  
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Figure 2.25 A pan coater apparatus for powder coating solid dosage forms 
According to this invention, a pan coater representation is shown generally at 30 in Fig. 6. 
This coating apparatus (30) includes a rotary coater chamber (32), which is electrically 
grounded and holds the solid dosage forms (28), an atomizer (34) for spraying the 
plasticizer, an electrostatic spray gun (36) for spraying the film forming polymer powder, 
and a heating source (38) for heating the solid dosage contents in chamber (32).  
This invention provides a method to coat solid dosage forms without using any solvent or 
water. The coating process comprises several steps (Figure 2.26). Firstly, solid dosage 
forms are loaded into the rotatable, electrically grounded coating pan and preheated for a 
certain period of time. And then a spraying cycle including a film forming polymer 
powder spraying and liquid plasticizer spraying is performed to allow coating powder 
deposition. The last step is curing. After coating powder deposition, solid dosage forms 
will remain in the coating pan for a certain period of time under a certain temperature to 
allow the film formation.  
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Figure 2.26 Schematic of electrostatic powder coating process 
This invention possesses many advantages. First of all, the processing time is much 
shorter than the traditional liquid coating due to the absence of solvent or water in the 
process. As a result, the coating efficiency is significantly improved since there is no need 
to evaporate solvent or water in the process. Furthermore, the coating thickness or coating 
level can be regulated in a wide range through changing the charging voltage or 
plasticizer feed without causing any other issues such as sticky film. 
2.5.3 Coating formulations 
For electrostatic powder coating technology, the development of coating formulation 
should take the charging process into consideration to form a desirable coating film. In 
other words, coating powder in the formulation should be able to be charged by the 
electrostatic spray gun. Also, similar to other coating processes, coating powder 
deposition and film formation are critical for the formulation design. For the ultrafine 
powder, additives may be necessary to prevent coating powder agglomeration. 
Besides the great efforts in apparatus designing, Phoqus also devoted itself in coating 
formulation designing and development, aiming to make the coating powder more easily 
charged or more suitable for the electrostatic powder coating process so as to improve the 
coating quality and efficiency [85, 86]. In their coating process, of Eudragit® RS was used 
as the film formation material and the active ingredients could be in the tablet core or in 
the coating or both depending on their nature and use. When the active ingredients were 
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applied in the coating, the amount of them could be accurately controlled, leading to 
improved dose reproducibility. 
US 6372246 [87] developed a coating formulation containing micronized polyethylene 
glycol (PEG) for the electrostatic powder coating process. PEG material, with a 
molecular weight in the range of 1,000 to 20,000 and a melting point in the range of 50-
63°C, was micronized by jetmill, to a particle size of 1-100μm, preferably 5-10μm and 
then was triboelectrically charged and deposited onto the dosage forms. This invention 
related to a technology of reversing negative charge of medicaments so that they can be 
electrostatically deposited on a negatively charged substrate. The coating film formed by 
PEG will not delay the dissolution of drug products. Also this coating formulation and 
process can provide a pharmaceutically elegant cosmetic coating film. 
Qiao [88] developed a coating formulation containing of Eudragit® RS and RL to achieve 
drug sustained release. In this study, ibuprofen was used as the API (active 
pharmaceutical ingredient), triethyl citrate (TEC) was used as the plasticizer. The coating 
formulation also contained talc powder as anti-tack agent. Before coating, particle size of 
Eudragit® RS and RL as well as talc were reduced by using a grinder mill and after 
which, the average particle size was 18.4 μm, 16.5 μm, and 28.9 μm, respectively. The 
tablets were loaded into the coating pan and preheated first. And then coating powder 
were sprayed onto the surface of the tablets with liquid plasticizer, followed by a curing 
step to allow the film formation. According to this study, the drug release rate from 
electrostatic powder coated tablets could be adjusted by changing the coating level 
(weight gain) or of Eudragit® RS/RL ratio. Similarly in equipment and procedure, 
Eudragit® L 100-55 [30] was used as the coating material to form an enteric coating film.  
2.6 Summary 
Pharmaceutical dry powder coating technology has developed noticeably over the last 
decade. Particularly electrostatic powder coating, which has gained tremendous attention 
due to its phenomenal advantages such as high coating efficiency, uniform coating film 
and low overall cost, has become the most promising pharmaceutical dry coating 
technology. Despite the difficulty related with the weak conductivity of solid dosage 
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forms, the benefits of electrostatic dry powder coating have been encouraging researchers 
to devote efforts to make breakthrough in such area. Technologies and formulations 
developed by Phoqus Ltd. are quite impressive, but the additional cost of complicated 
equipment and IR curing step has limited its use in commercial applications. The novel 
electrostatic powder coating technology developed by Zhu’s group has been able to 
differentiate itself from other counterparts owing to its simpler coating apparatus that can 
be easily adapted from the present apparatus such as pan coater systems for liquid 
coating.  
However, more work still need to be carried out to fully illustrate this novel electrostatic 
powder coating technology. Firstly, this technology needs to be expanded to those coating 
materials with high glass transition temperature (Tg), for example, ethylcellulose and 
cellulose acetate, which is quite difficult to be coated by powder coating. In addition, 
coating of small solid dosage forms, such as pellets, still relies on the organic solvent 
coating or aqueous coating using a fluidized bed with large amount of fluidizing hot air, 
causing extremely high energy consumption. Powder coating of small pellets in a simpler 
apparatus could bring lots of benefits, overcoming those limitations related to the organic 
solvent and water, and significantly reducing the overall coast by avoiding use of large 
amount of fluidizing hot air. Particularly, as the most promising oral drug delivery 
system, osmotic drug delivery system (ODDS) can only be coated with organic solvent 
coating due to the high glass transition temperature (Tg) of the coating polymers. Many 
previous work have been done on powder coating, but none of them focusing on the 
ODDS. It would be a big breakthrough if the ODDS tablets could be successfully coated 
with powder coating. Last but not least, the electrostatic powder coating process needs to 
be characterized more in-depth in order to illustrate coating powder adhesion and film 
formation, and their influence factors. 
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3 Tablet Coating – Sustained Drug Release 
In this chapter, tablets were successfully coated with ultrafine ethylcellulose powders by 
using a novel electrostatic dry powder coating technology and sustained drug release was 
successfully achieved. The angle of repose (AOR) of the ultrafine powders of 
ethylcellulose was significantly reduced by adding nano sized colloidal silicon dioxide, 
indicating a significant improvement of flowability. Variations in charging voltage of the 
electrostatic gun had a significant influence on the coating powder adhesion and coating 
efficiency. Lactose and triethyl citrate (TEC) were used as the solid and liquid plasticizers 
to reduce the glass transition temperature (Tg) of ethylcellulose. The presence of liquid 
plasticizer could also increase the electrical conductivity of drug tablets so as to promote 
the coating powder adhesion. Other factors that affect the film formation include curing 
time and curing temperature. The permeability of the EC coating film was adjusted with 
the addition of pore forming agent (PVA-g-PEG) in the coating formulation, leading to a 
more controlled drug release rate.  
3.1 Introduction 
In pharmaceutical industry, solid dosage forms are commonly coated with polymers to 
achieve drug sustained release [1, 2], to alleviate the side effects caused by the high drug 
plasma concentration due to the immediate release. Several polymers are commercially 
available for sustained release coating like acrylic acid derivatives, poly (vinyl acetate) 
and cellulose derivatives, such as ethylcellulose. Among those, ethylcellulose is 
particularly appropriate for the sustained release coating due to its excellent robust 
properties such as nontoxic, nonallergenic and nonirritant [3, 4]. It can be applied either 
from organic solvent solutions or from aqueous dispersions. For solvent coating, 
ethylcellulose as well as other excipients are dissolved into an organic solvent to form a 
coating solution and then the solution is sprayed onto the surface of the solid dosage 
forms to form the coating film by evaporating the solvent. This method can obtain a very 
smooth and uniform coating film. However, the presence of the organic solvent could 
cause safety and environmental issues. For aqueous coating, ethylcellulose particles, 
pigments and additives are firstly milled into fine powders and mixed together and then 
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they are dispersed into water to form a coating suspension, which is sprayed onto the 
surface of solid dosage forms to form a coating film by evaporating the water. Aqueous 
coating remains the preferred approach to obtain the coating film with ethylcellulose 
because it can eliminate those environmental related problems caused by the organic 
solvent. However, it still possesses many limitations such as higher energy consumption 
and longer processing time with hot air handling and equipment cleaning. Also aqueous 
coating is not suitable for the moisture sensitive drugs.  
In order to overcome these limitations, several earlier attempts of dry coating methods 
have been reported, trying to coat solid dosage forms with ethylcellulose (EC). Lin [5] 
used a direct compression method to coat tablets with micronized EC to form the outer 
layer of the tablet core. In this coating process, the tablet core was precisely positioned in 
the center of the die, encapsulated by the EC powder and then they were compressed to 
form the out layer film. This is a total dry coating method without using any solvent or 
water and it could form a very thick coating film with very high coating efficiency. 
However, the thickness of the film was reported to be not uniform owing to the difficulty 
of placing the core tablet in the center of the die.  
Different from Lin’s work, Nantharat Pearnchob and Roland Bodmeier [6] developed a 
dry powder coating technology to coat dosage forms with micronized ethylcellulose 
particles, which was further optimized by Ildikó Terebesi and Roland Bodmeier [7]. In 
their technology, the coating formulation contained two components, one was a powder 
mixture (coating polymer plus talc) and the other was a mixture of liquid materials 
(plasticizer plus binder solution). They were sprayed separately into a coating chamber of 
a fluidized bed coater, followed by an oven-curing step under different conditions (60-
80◦C, 2-24 h). Although drug extended release was achieved by using this coating 
technology, it was unable to form a uniform coating film and acceptable surface 
morphology of the coated pellets. Also the oven curing temperature is too high (up to 
80◦C) and the curing time is too long (up to 24 h), making it difficult for the industrial 
application. 
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Researchers of Particle Technology Research Centre (PTRC) in Western University 
developed a novel electrostatic dry powder coating technology by combination of 
plasticizer, electrostatic and heat to promote the coating powder adhesion and film 
formation under a lower curing temperature with a shorter processing time. The 
electrostatic coating method is adapted to create an electrical field between the 
electrostatic gun and grounded solid dosage forms, directing the flow of coating powders 
so as to enhance the coating powder adhesion on the solid dosage forms. Also the coating 
film is more uniform due to a better distribution of deposited coating powders resulting 
from the repulsive force among the charged particles. 
The objectives of this chapter is to coat tablets with powdered ethylcelluose using this 
electrostatic powder coating technology to achieve sustained drug release, and also to 
characterize influences of plasticizers including liquid and solid ones on the film 
formation in the electrostatic powder coating process. 
The Figure 3.1gives an outline of this chapter. 
Ethylcellulose
Electrostatic powder coating
Tablet core preparation
Coating formulation
Coating process
Dissolution test
Mixing
Granulation
Compression
Temperature
Curing time
Plasticizers
Charging voltage
Coating powder size reduction
Sustained drug release Film formation
Flowability improvement of micronized coating powder
 
Figure 3.1 Schematic diagram of study on drug sustained release from 
electrostatic powder coated tablets with EC powder 
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3.2 Materials and methods 
3.2.1 Materials 
Ethylcellulose was provided by Colorcon, Inc. (US). Talc powder was purchased from 
Mallinickrodt Baker Inc. (Canada). Triethyl citrate (TEC) was purchased from Caledon 
Laboratories Ltd. (Ontario, Canada). Lactose was obtained from GlaxoSmithKline, Inc. 
(Canada). Colloidal silicon dioxide (AEROSIL® 200 Pharma) was donated by Evonik 
Degussa Corporation (Germany). Salbutamol sulfate was provided by Nanjing 
Pharmaceutical Factory (Nanjing, China). Avicel® Microcrystalline cellulose PH-102 was 
purchased from FMC Corporation (USA), plasdone K-29/32 was purchased from ISP 
technologies, INC. and Magnesium Stearate was purchased from Alfa Aesar 
(Massachusetts, USA). Placebo tablets were obtained from Pathon (Ontario, Canada). 
PVA-g-PEG (PVA-PEG graft copolymer, Kollicoat® IR) was purchased from BASF 
(Ludwigshafen, Germany).  
3.2.2 Particle size reduction and analysis 
A blade grind mill was used to reduce the particle size of coating materials, after which a 
particle size analyzer (TSI Corporation, Model 3603, Shoreview, MN, USA) was used to 
confirm the particle size of the coating particles. The average particle size in this study is 
the size at 50 % of total weight fraction, which is given by Table 3.1. 
 
Table 3.1 Average particle size of coating powders 
Materials Average particle size (µm) 
Ethylcellulose 25.8 
Lactose 29.1 
PVA-g-PEG 21.8 
Talc 28.6 
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3.2.3 Angle of repose (AOR) 
In order to characterize the flowability of coating powers before and after the size 
reduction and also to investigate the influence of nano sized additives on the flowability 
of ultrafine powders, measurement of the angle of repose was carried out using a PT-N 
Hosokawa Powder Characteristic Tester, following the standardized testing procedures of 
ASTM D6369-08 (ASTM Standard D6369-08, 1999). As the largest angle at which 
powders could pile up, angle of repose is related to the powder’s cohesiveness and 
internal friction. And it is widely used to characterize the flow properties of powders. 
During each test, a powder sample was first loaded onto a screen mounted with a vibrator. 
Under the screen there is a mounted funnel, which is used to let the powder sample fall 
through down to a plate which was aligned with the funnel. Powder flow rate could be 
controlled and adjusted by changing the vibration intensity. When the whole plate was 
covered with the powders, angle of repose was obtained by measuring the largest angle 
between the powder pile surface and the horizontal plane. In order to achieve an accurate 
result, each test was repeated 3 times and the average was used. 
3.2.4 Differential scanning calorimetry (DSC) 
Glass transition temperature of pure coating materials (ethylcellulose) and the mixture of 
coating materials with plasticizers (TEC and lactose) at different weight ratio were 
investigated using the differential scanning calorimetry (DSC) analysis (Mettler Toledo, 
DSC822, Mississauga, Canada). The weight for each sample was 10 mg and nitrogen was 
used as the test atmosphere. The heating rate for the test was 2 ◦C /min over the 
temperature range of 20 to 200 ◦C. 
3.2.5 Tablets preparation 
The component of the tablets core, which can be seen as the table 3. 2, includes drug 
(salbutamol sulfate), sodium chloride, microcrystalline cellulose, PLASDONE® K-29/32 
(PVP) and magnesium stearate. A mixture of drug, sodium chloride, microcrystalline 
cellulose and PLASDONE® K-29/32 (PVP) were dry granulated using a high shear 
granulator (Mechanomill MM-20N, OKADA SEIKO Co. Ltd, Iwate, Japan) and then 
mixed with magnesium stearate, after which the powder mixture was compressed into 
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convex tablets with 5 mm (diameter) concave punches using a single punch tablet 
machine (Shanghai Tianxiang & Chentai Pharmaceutical Machinery Co. Ltd, Shanghai, 
China). The weight for each tablet is 160±2 mg. 
Table 3.2 Optimized formulation of the tablet core 
Ingredient % w/w 
Salbutamol Sulfate 60% 
Microcrystalline cellulose PH102 30% 
PLASDONE® K-29/32 (PVP) 9% 
Magnesium stearate 1% 
 
3.2.6 Electrical resistivity tests  
After loaded in the pan coater, the tablets were preheated for 10 minutes. Then liquid 
plasticizer (TEC) was sprayed onto the surface of the tablets (0.50 g/min). At different 
spraying time intervals (0, 1, 2 and 3 min), given number of tablets were taken out from 
the pan coater and were tested to measure the electrical resistivity using an electrometer 
(Keithley 610B, Keithley instruments, Inc., USA). These tests were operated three times 
for the accuracy. 
In order to measure the electrical resistivity of the tablets, we made a very simple 
equipment, shown as Figure 3.2. Drill a hole (cylinder) on an organic glass plate with a 
certain diameter and prepare two poles (Cu, cylinder with the same diameter) welded 
with cables. Then fix one of the poles on one side of the hole, put the tablet (cylinder with 
the same diameter) into the hole and then cover the tablet with the other pole (make it 
contact with the tablet), connect those two poles with the electrometer used in our lab 
(Keithley 610B, Keithley instruments, Inc., USA) to measure the electrical resistivity of 
the tablet. 
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Figure 3.2 Schematic diagram of electrical resistivity tester 
3.2.7 Electrostatic powder coating process 
The electrostatic powder coating process (Figure 3.3) was performed in a laboratory scale 
pan coating system, which consists of a rotatory coating pan, a powder feeder, an 
electrostatic spray gun (Nordson Corporation, USA) and liquid plasticizer spray system. 
After being loaded into the coating pan, tablets (60 g placebo tablets and 20 g salbutamol 
sulfate tablets) were preheated for 10 min at a certain temperature. Then a certain amount 
of liquid plasticizer was sprayed onto the surface of the tablets, followed by the spray of 
coating powders by the electrostatic spray gun immediately to achieve coating powder 
adhesion. The process of loading liquid plasticizer and coating powder can be repeated 
several times to obtain a higher coating level. After finishing the coating powder 
adhesion, keep the temperature of the coating pan for a certain period of time to allow 
deposited coating particles to coalesce and form a uniform coating film. 
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Figure 3.3 Schematic of the electrostatic powder coating process 
Table 3.3 gives the formulations of the coating powder, which contains ethylcellulose, 
talc powder, nano silica and pigment. The coating level (%) was calculated from the 
weight gain of coated tablets divided by the weight of uncoated tablets. Placebo tablets 
were used to maintain the volume of the substrates so that the drug tablets could be 
conserved. 
Table 3.3 Formulation of the tablet coating with EC 
 Ingredient (% w/w) 
Formulation Ethylcellulose Lactose PVA-g-PEG Talc SiO2, Pigment 
A 75% 5% 0% 18% 1%, 1% 
B 70% 5% 
C 65% 10% 
D 60% 15% 
 
3.2.7.1 Optimization of coating process parameters 
In the electrostatic coating process, charging voltage of the electrostatic gun and the 
amount of sprayed liquid plasticizer are the two main parameters that affect the coating 
powder adhesion rate (weight gain of the loaded tablets divided by the total weight of 
sprayed coating powders). In order to obtain a good coating powder adhesion rate, 
experiments with different charging voltage and liquid plasticizer spray rate were carried 
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out. Table 3.4 gives the details parameters. For each experiment, tablets (60 g placebo 
tablets and 20 g salbutamol sulfate tablets) were loaded into the coating pan and were 
preheated for 10 min at a predetermined temperature. And then liquid plasticizer was 
sprayed onto the surface of the tablets with a predetermined flowrate with different 
spraying time, followed by the spraying of coating powders with a predetermined 
charging voltage. After 10 min, compressed air was used to blow away the redundant 
powders in the coating pan and then those drug tablets were taken out and weighed to 
calculate the coating powder adhesion rate. 
Table 3.4 Coating process parameters of tablet coating with EC 
Charging voltage (kV) 0, 20, 40, 60, 70 
Liquid plasticizer flow rate (g/min) 0.5 
Liquid plasticizer spray time (min) 0, 1, 2, 3, 4 
Pan speed during coating (rpm) 28-32 
Pan speed during curing (rpm) 10-15 
 
3.2.7.2 Optimization of curing parameters 
After coating powder adhesion, a curing step is needed to turn the deposited coating 
particles into a continuous coating film. In this process, curing temperature and curing 
time are the two critical parameters. In order to clarify the influences of curing 
temperature and curing time on the film formation, experiments with different curing 
conditions were carried out. Table 3.5 gives the curing condition details for each 
experiment. 
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Table 3.5 Curing parameters of tablet coating with EC 
Curing temperature (◦C) Curing time (h) 
40 0 
50 0 
60 0 
40 1 
50 1 
60 1 
40 2 
50 2 
60 2 
 
3.2.8 Scanning electron micrographs 
Scanning electron microscopy (SEM) was used to observe the coating film achieved by 
the electrostatic powder coating process. Samples were firstly sputter coated with gold for 
120 seconds using Emitech K550 sputter coater (Emitech Ltd., Ashford, UK) and then 
they were observed with a scanning electron microscope at 5.0 kV (S-2600N Hitachi, 
Ontario, Canada). 
3.2.9 Calibration curve of drug 
A standard stock solution with a concentration of 200 ppm (μg/ml) was prepared by 
dissolving salbutamol sulfate in PBS solution with a pH value of 7.2. And then it was 
diluted with pH 7.2 PBS solution separately to obtain the solution with a concentration of 
5, 10, 20, 50, 80, 100, 120 respectively. A 8453 UV-Visible Spectrophotometer (Agilent 
Technologies, Mississauga, Canada) was used to find the maximum absorbance, which is 
at 276 nm. Then the absorbance was obtained at 276 nm against pH 7.2 PBS solution as 
blank. The calibration curve was prepared by plotting absorbance versus concentration 
(ppm) of salbutamol sulfate. 
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The calibration curve of salbutamol sulfate at the wavelength of 276 nm is shown as 
Figure 3.4. This curve would be used to calculate the unknown concentrations of 
salbutamol sulfate released from electrostatic powder coated tablets. 
 
Figure 3.4 Calibration curve of salbutamol sulfate  
in PBS with a pH 7.2 at 276 nm 
3.2.10 Dissolution tests 
Drug dissolution tests were performed by following the United States Pharmacopeia 
(USP) apparatus (Apparatus 2, paddle; Huanghai Rcz-6c2, Shanghai, China). The release 
media were 900 mL of pH 7.2 phosphate buffer solution. By using a 10 mL syringe, 
samples were withdrawn and filtered (refills with the same amount of fresh release 
medium) at predetermined intervals and assayed using an 8453 UV-Visible 
Spectrophotometer (Agilent Technologies, Mississauga, Canada) at a wavelength of 
276nm. 
0 40 80 120 160 200
0.0
0.3
0.6
0.9
1.2
 
 
y=0.0059x+0.0091
R
2
=0.9995
A
b
so
rv
an
ce
Concentration of Salbutomal sulfate (ppm)
60 
 
3.2.11 Stability tests 
Electrostatic dry powder coated tablets with ethylcellulose and Eudragit® RS/RL were 
placed in HDPE vials (75 mL) and sealed with aluminum film and then were stored at 
40◦C /75% RH for 1 month. The dissolution tests of those powder coated tablets before 
and after storage were examined. 
3.2.12 Statistical analysis 
In the present study, all the experimental results were expressed as mean ± Standard 
Deviation (S.D.) values. While in the stability tests, “similarity factor” f2 was used to 
compare the drug release profiles before and after storage. The value of f2 is between 0 to 
100, if f2 is larger than 50 (between 50 to 100), these two release profiles were considered 
to be similar. If f2 is close to 100, the two release profiles were considered as identical. 
The following equation gives the method to calculate the f2. 
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In this equation, n is the total number of sampling times, Rt and Tt is the accumulated 
drug release percentage at time t for the reference and test products, respectively.  
3.3 Sustained release from ethycellulose coated tablets 
3.3.1 Flowability improvement of ultrafine coating powders 
Presently, the powder size in electrostatic powder coating varies mainly in a range from 
40 to 60 µm, leading to a rougher film than liquid coating. Also for electrostatic powder 
coating, ultrafine powder is more uniform in charging deposited particles [8]. This is 
mainly because ultrafine powders have greater particle numbers and higher specific 
surface area but less mass. So there has been a strong trend to use ultrafine powders 
(smaller than 30 µm) to improve the surface quality of the final product [9-12]. However, 
the poor flowability of ultrafine powders cause many problems in the electrostatic powder 
coating process such as poor fluidization and uneven transportation and spray. Zhu and 
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Zhang [13, 14] developed an innovative ultrafine powder coating technology, which uses 
paint powders with mean particle diameter less than 20 µm and also introduced a series of 
criteria during the processes of manufacturing powders on how to choose and blend flow 
additives so as to control the flow properties. This novel technology has many advanced 
features in surface quality and it is ready for commercial use [12]. 
For the pharmaceutical coating, it is not necessary to make the coating surface as fancy as 
automobile industry, but a uniform coating film is still needed to modify the drug release 
profiles and to control the drug release rate. In this project, ultrafine coating powders 
were used for all of the coating processes. Before being applied in the coating 
formulation, the flowability of those ultrafine powders needs to be improved first. 
Nanoparticles are widely used to promote the flowability of ultrafine powders. It is 
effective but the mechanism is still not very clear. Some researchers suggested that those 
nanoparticles act as a neutralizer of electrostatic charge [15]. Some others proposed 
another explanation that those nanoparticles could roll between the ultrafine powders as 
lubricants, reducing the internal friction of them so as to improve the flowability [16, 17]. 
Another explanation, which is more widely accepted so far, said that those nanoparticles 
could reduce the van der Waals force between two fine particles by either increasing the 
separation distance [18] or increasing the local radius of curvature and increasing the 
hardness at the contact of two fine particles [19]. 
AEROSIL® 200 Pharma is a high purity amorphous anhydrous colloidal silicon dioxide 
(CSD) for use in pharmaceutical products, which is produced by Evonic Inc. in Germany. 
It fulfils the analytical requirements of the currently valid versions of the United States 
Pharmacopeia (USP/NF), European Pharmacopeia (Ph. Eur.) and Japanese Pharmacopeia 
(JP) and it is tested and certified according to pharmacopoeia methods. It is widely used 
in the current pharmaceutical industry to improve the flow properties of fine powders. 
Jonat and Hasenza [20] did a study on the effect of colloidal silicon dioxide types (CSD) 
on the flow characteristics of microcrystalline cellulose (MCC) under different mixing 
conditions using the angle of repose method. Their results indicated that adding some 
colloidal silicon dioxide types (CSD) could significantly reduce the angle of repose of 
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MCC, from 47o to between 36 o and 38 o, which was further supported by SEM images 
and AFM measurements.  
 
Table 3.4 Particle size and angle of repose of EC powder  
before and after size reduction 
 Particle size (µm) Angle of repose (°) 
Before size reduction 75.3±2.51 36.2±0.68 
After size reduction 25.8±1.94 47.1±0.56 
 
In the present study, we also choose the colloidal silicon dioxide (AEROSIL® 200 
Pharma) as the additives to improve the flowability of the micronized coating powders. 
Those nano particles were added and blended into a micronized coating powder to form 
modified samples, which were further characterized to obtain the angle of repose.  
Table 3.4 gives the particle size and angle of repose before and after size reduction of the 
EC powders. The effect of the nano particle ratio on the angle of repose of the micronized 
coating powders is shown by Figure 3.5. 
 
63 
 
 
Figure 3.5 The effect of nano particle (colloidal silicon dioxide) ratio  
on the angle of repose of micronized EC powders 
As shown in Figure 3.5, the original angle of repose of the micronized coaitng powders 
without adding nano particles is around 47.2°, which is very high for the electrostatic 
coating process. When the nano particle ratio was firstly increased from 0 to 1% (w/w, 
based on the weight of coating powder), the angle of repose of coating powders was 
significantly reduced to 41.2°. This is because nanoparticles could reduce the van der 
Waals force between two fine particles by increasing the separation distance [18], which 
could be shown as Figure 3.6. With further increase in the nanoparticle ratio, the angle of 
repose was not decreased any further and remained around 41.5°. 
In order to minimize or eliminate the agglomeration and the formation of the large 
clumps in the coating formulation, the angle of repose of the coating powder needs to be 
lower than 42° [21]. So for the coating powders with EC, the nanoparticle ratio needs to 
be at least 0.5%. 
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Figure 3.6 Schematic representation of the interparticle forces that can 
affect the flowability of micronized coating powder. Left: without adding 
nanoparticles; Right: with AEROSIL® colloidal silicon dioxide 
 
In order to confirm the flowability improvement of coating materials, SEM micrographs 
of micronized EC with and without nano CSD particles were observed. As shown in 
Figure 3.7 A, without adding nano CSD particles, there are some obvious particle 
agglomerations with a nonuniform particle distribution. On the other hand, after adding 
nano CSD particles Figure 3.7 B, particle agglomerations became less and the distribution 
of those fine particles is more uniform. 
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Figure 3.7 SEM micrographs of EC fine powders before (A) and after (B) 
adding AEROSIL® colloidal silicon dioxide 
 
3.3.2 Glass transition temperature reduction by plasticizers 
Plasticizer is commonly used in the pharmaceutical industry due to its excellent ability to 
reduce the glass transition temperature (Tg) of coating polymers so as to guarantee that 
that the coating process can be performed in a relatively low temperature.  
Ethylcellulose is widely used in the pharmaceutical industry and can form a hard, robust 
film when coated onto solid dosage forms. While because the glass transition temperature 
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(Tg) of ethylcellulose is too high (129.8
◦C), both solid and liquid plasticizers are added 
into the coating formulation to reduce the glass transition temperature (Tg) and also to 
make coating film of ethylcellulose elastic and less brittle. Triethyl citrate (TEC) and 
lactose are reported as efficient plasticizers for ethylcellulose [22].   
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Figure 3.8 Effect of plasticizers on the glass transition temperature of EC 
Figure 3.8 shows the reduction of the glass transition temperature (Tg) of ethylcellulose 
by TEC and lactose using differential scanning calorimetry (DSC). The glass transition 
temperature (Tg) of ethylcellulose was dramatically reduced from 129.8
◦C to 48◦C by 
increasing the TEC’s ratio from 0% to 50%. When further increasing TEC’s ratio to 75%, 
Tg of ethylcellulose was slightly decreased to 42 
◦C. And when increasing the lactose’s 
ratio from 0% to 20%, Tg of ethylcellulose was declined from 129.8 
◦C to 51◦C and was 
further reduced to 46◦C by increasing the lactose’s ratio to 30%. By adding lactose in the 
coating powder and spraying TEC onto the surface of tablets can guarantee that the film 
formation could occur under a relatively low temperature. 
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3.3.3 Coating powder adhesion 
The present study utilized the electrostatic spray gun to feed the coating powder into the 
coating pan. The coating particles were firstly negatively charged at the tip of the gun by 
a high voltage and generated an electrical field between the tip of the gun and the 
grounded coating pan, which can direct the powder flow along the direction of the 
electrical field to the surface of the tablets. In this case, the drug tablets loaded in the 
coating pan should be electrically conductive to ensure that they are grounded so as to 
allow further particle deposition. The maximum electrical resistivity that meet the above 
requirement is 1×109 Ωm [23]. Unfortunately, the electrical resistivity of tablets used in 
the present study is 1×1016 Ωm, which is too high for the electrostatic spray coating 
process.  
However, it was found that by spraying a certain amount of liquid plasticizer in the 
coating process, the electrical resistivity of tablets could be reduced dramatically. As 
shown in Figure 3.9, the electrical resistivity of drug tablets declined from 1×1016 Ωm to 
1×108 Ωm by increasing the spraying time of TEC from 0 to 3 minutes with a given flow 
rate (0.50 g/min), which is suitable for the electrical spraying coating process. 
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Figure 3.9 The effect of liquid plasticizer (TEC)  
on electrical resistivity of drug tablets 
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Figure 3.10 The effect of charging voltage  
on the coating powder adhesion rate 
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The influence of charging voltage on the coating powder adhesion rate is shown in Figure 
3.10. When the charging voltage was increased from 0 to 60 kV, coating powder adhesion 
rate increased from 62.5% to 92.1%. While when the charging voltage was further 
increased to 70 kV, there was no more increase for the coating powder adhesion rate. The 
coating powder adhesion obtained at 0 V reflected the particle adhesion caused by liquid 
plasticizer. Spraying liquid plasticizer onto the surface of the tablets generated capillary 
force between the interface of liquid plasticizer and coating powders, which could 
promote the coating powder adhesion. Higher coating powder adhesion rate obtained with 
increasing the charging voltage to 60 kV indicates that the coating powder adhesion was 
enhanced by the electrical field between the tip of the electrostatic gun and the coating 
pan. The coating powder adhesion rate was not increased after the electrical charge 
reached a certain value, this is because higher charging voltage means more free ions 
produced, leading to an increase of the cumulative charge of the coating layer and back 
ionization, which could reduce the powder deposition. 
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Figure 3.11 The effect of liquid plasticizer  
on the coating powder adhesion rate 
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Besides the charging voltage of the electrostatic spray gun, liquid plasticizer could also 
do a big influence on the coating powder adhesion. As shown in Figure 3.11, when there 
was no liquid plasticizer sprayed, the coating powder adhesion rate was only 21 % with a 
charging voltage of 60 kV, which is too low to produce a good coating film. When the 
liquid plasticizer spray time was increased from 0 min to 2 min, the coating powder 
adhesion rate was significantly increased from 21 % to 83.2 %. When further increasing 
the liquid plasticizer spray time to 3 and 4 min, the coating powder adhesion rate was 
slightly increased to 92.1 % and 93.3 %, respectively. But in the coating process, when 
the liquid spray time was 4 min, sticky film was observed. So the spray time could be 
optimized as 3 min. 
From Figure 3.9, Figure 3.10 and Figure 3.11 we conclude that both charging voltage of 
the electrostatic spray gun and the liquid plasticizer have a big influence on the coating 
powder adhesion rate. The charging voltage of electrostatic spray gun could be optimized 
as 60 kV according to Figure 3.10. While for the liquid plasticizer, when its flow rate is 
0.5 g/min, the spray time needs to be 2 min or more than 2 min to guarantee a high 
enough electrical conductivity of the tablets so as to achieve a high coating powder 
adhesion rate. However, sticky film was observed when the spray time was increased to 4 
min. Consequently, the liquid plasticizer spray time could be optimized as 3 min with a 
flowrate of 0.5 g/min. 
3.3.4 Film formation 
Film formation in dry powder coating occurs when the curing temperature is higher than 
or close to the Tg of the coating polymer [23]. As the most critical parameters, curing 
temperature and curing time can have a big impact on the film formation process in the 
dry powder coating technology. The surface morphology of the coated tablets with 
different curing temperature and curing time was observed using a scanning electron 
microscope (SEM). 
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Figure 3.12 SEM micrographs of dry EC powder coated tablets: (A) 40◦C, 
120 min; (B) 50◦C, 120 min; (C) 60◦C, 120 min 
As shown in Figure 3.12, when the curing temperature was low (Figure 3.12A, 40 ◦C), the 
deposited particles are clearly visible, indicating an uncured film with rough pores on the 
surface. As the curing temperature increased to 50 ◦C (Figure 3.12B), deposited particles 
were less clear but there are still some boundaries in the film. When the curing 
temperature was increased to 60 ◦C (Figure 3.12C), boundaries between particles 
disappeared and the coating film became smooth and uniform. 
72 
 
 
Figure 3.13 SEM micrographs of dry EC powder coated tablets: (A) 60 ◦C, 0 
min; (B) 60 ◦C, 60 min; (C) 60 ◦C, 120 min 
Curing time also has a significant influence on the film formation in the electrostatic 
powder coating process. From Figure 3.13 we can conclude that a longer curing time 
leads to a more uniform and smoother coating film. 
3.3.5 Drug release from dry powder coated tablets 
The drug release profiles from dry powder coated tablets with different coating 
formulations and curing conditions were investigated through the dissolution tests.  
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Figure 3.14 Drug release profiles from EC powder coated tablets at different 
coating levels (Lactose 5%; Pore former 5%; 60 ◦C, 120 min) 
As shown in Figure 3.14, drug release finished within 1 hour from uncoated tablets. For 
dry ethylcellulose powder coated tablets with a coating level of 1% and 1.7%, drug 
release was completed within 4 hours and 12 hours, respectively. By further increasing 
the coating level to 2.8%, drug release rate was much slower and only 75% of drug 
released within 24 hours. Drug release from film controlled dosage forms is governed by 
the diffusion through an intact polymeric coating film as well as diffusion through water 
filled cracks, which can be induced by a mechanically unstable coating film [4]. 
Immediately after the tablets contact with aqueous media, water diffuses into the tablets 
and an increasing hydrostatic pressure is generated inside the tablets. If this hydrostatic 
pressure exceeds the mechanical stability of the film coating, film cracks will be formed 
and drug release does not have to diffuse through the polymer network, leading to a 
greatly accelerated release rate (1%, 1.7%). When the coating level is high enough 
(2.8%), the coating film is mechanically stable and can withstand the hydrostatic pressure 
built up inside the tablet core. Consequently, drug release was well controlled by the 
diffusion through the coating film and allowed a much slower release rate. 
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Solid plasticizer also could be used in the powder coating process to reduce the coating 
temperature and promote the film formation during the curing step. In the present study, 
lactose was used as solid plasticizer and drug release profiles from powder coated tablets 
with different lactose ratio in the coating formulation could be seen as Figure 3.15. When 
the lactose was not used in the coating process, coating film with a coating level of 2.8% 
couldn’t withstand the hydrostatic pressure caused by the water diffused into the core. 
There was a burst release at around 2 hours and drug release completely within 10 hours. 
When 3% lactose was added into the coating formulation, coating film became better and 
stronger than those without lactose, drug release could be prolonged to 24 hours. And 
when the lactose ratio was further increased to 5%, coating film became much stronger, 
leading a constant drug release rate and only allowing 50% drug release within 24 hours. 
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Figure 3.15 Drug release profiles from EC powder coated tablets with 
different lactose ratio 
(Coating level 2.8%; Pore former 0%; 60◦C, 120min) 
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Figure 3.16 Drug release profiles from EC powder coated tablets with 
different pore former ratio (Coating level 2.8%; Lactose 5%; 60◦C, 120min) 
As a pore former, PVA-g-PEG was added into the coating formulation to adjust the drug 
release profiles. In contrast to the frequently used pore former hydroxypropyl 
methylcellulose (HPMC), PVA-g-PEG does not cause flocculation of the coating 
dispersions (aqueous coating) and can also provide a long-term stable drug release 
profile, even upon open storage under stress conditions [3, 4]. In the present study, the 
inclusion of pore formers in the coating formulation appears to assist the drug release. As 
shown in Figure 3.16, variations in pore former content in coating formulation had 
significant effect on the drug release profiles from dry powder coated tablets. For the 
tablets coated without pore former, the drug only released 49% within 24 hours. While by 
increasing the pore former content from 5% to 10%, the drug released 77% and 100%, 
respectively. When the pore former content was further increased to 15%, drug release 
was completed within 12 hours. The increased pore former content can create more 
channels and more opportunity of water permeation through the film, leading to an 
increase of drug release rate. 
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The influence of curing temperature and curing time on the film formation was confirmed 
by the dissolution tests. As shown in Figure 3.17, when the curing temperature was low 
(40 ◦C, 50 ◦C), drug release completed within 6 hours and 14 hours, indicating a 
mechanically unstable coating film. While when the curing temperature was 60 ◦C, drug 
release was prolonged to 24 hours. This is because higher curing temperature allows 
completed film formation and mechanically stable coating film. 
0 5 10 15 20 25
0
20
40
60
80
100
Curing for 120 min
Coating level: 2.8%
Lactose: 5%
Pore former: 10%
 
 
C
u
m
u
la
ti
ve
 r
el
ea
se
 (
%
)
Time (h)
 Curing temperature 40°C
 Curing temperature 50°C
 Curing temperature 60°C
 
Figure 3.17 Influence of curing temperature on drug release  
from EC powder coated tablets  
(Lactose 5%; Pore former 10%; Coating level 2.8%; Cured for 120min) 
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Figure 3.18 Influence of curing time on drug release  
from EC powder coated tablets  
(Lactose 5 %; Pore former 10%; Coating level 2.8 %; Curing at 60 ◦C) 
As shown in Figure 3.18, when there was no curing step (0 min), drug release was 
completed within 2 hours, indicating that the coating film was mechanically unstable. 
When the curing time was increased to 60 min, drug release was completed within 12 
hours, which means the coating film became stronger than uncured ones. While when the 
curing time was further prolonged to 120 min, drug release was extended to 24 hours. 
This is because longer curing time allows completed film formation and mechanically 
stable coating film. 
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Figure 3.19 Relationship between coating level and drug release time 
(Lactose 5%; Pore former 5%; 60 ◦C, 120 min) 
Drug release from electrostatic powder coated tablets can be influenced by coating level, 
pore former ratio, curing temperature and time. With the same curing temperature and 
time, drug release rate could be adjusted and controlled by changing the coating level or 
pore former ratio in the coating formulation. Figure 3.19 & Figure 3.20 give a 
relationship between drug release time needed for both 100% release and 50% release and 
coating level and pore former ratio. Those figures can tell a prediction on drug release 
profiles with different coating level and pore former ratio and also can predict in which 
coating levels and pore former ratios drug could be released within a target period of time 
such as 12 and 24 hours. For example, in Figure 3.19, when the pore former ratio is 5% in 
the coating formulation and the curing temperature and time are 60 ◦C and 120 min, drug 
release could be designed within 24 hours at a coating level around 2.5%.  
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Figure 3.20 Relationship between pore former ratio (w/w) and drug release 
time (Coating level 2.8%; Lactose 5%; 60◦C, 120 min) 
 
3.4 Stability of the electrostatic powder coated tablets 
The drug release profiles of electrostatic dry powder coated tablets (cured at 60◦C for 120 
min) before and after storage are shown in Figure 3.21. And the similarity factor f2 values 
are shown in Table 3.5. 
For EC coated tablets, there was no significant difference in the drug release profiles 
before and after storage with different coating levels. The similarity factor f2 values are 
84.14, 84.32 and 83.83 for coating level of 1%, 1.7% and 2.8%, respectively, indicating 
that those electrostatic powder coated tablets with EC fine powder exhibited an excellent 
stability over 1 month at 40 ◦C /75% RH. 
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Figure 3.21 Release profile of salbutamol sulfate from powder coated 
tablets with EC cured at 60 ◦C, 120 min  
(*: after storage at 40 ◦C, 75% RH for 1 month) 
 
Table 3.5 Similarity factor f2 values between drug release profiles  
before and after storage with different coating levels (EC) 
Coating level f2 
1% 84.14 
1.7% 84.32 
2.8% 83.83 
 
3.5 Conclusion  
Using a novel electrostatic dry powder coating technology, ultrafine ethylcellulose 
powers was successfully coated onto tablets to obtain drug sustained release over a 
prolonged time period. The flowability of the ultrafine coating powders could be 
significantly improved by adding nano sized colloidal silicon dioxide. By utilizing an 
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electrostatic gun, an electrical field between the gun and the tablets was created to direct 
the movement of coating powders towards the tablets, leading to a better coating powder 
adhesion. Lactose and TEC are two effective plasticizers for ethylcellulose that could 
significantly reduce its glass transition temperature (Tg), thus film formation could be 
achieved under a relatively low temperature. Also spraying liquid plasticizer could 
increase the electrical conductivity of tablets so as to promote the coating powder 
adhesion through the electrostatic gun. Film formation could be enhanced by increasing 
curing temperature or prolonging curing time. Sustained drug release was successfully 
achieved and the drug release rate could be adjusted by changing the coating level or by 
altering the pore former ratio in the coating formulation. Ethylcellulose powder coated 
tablets exhibited an excellent stability over 1 month at 40 ◦C /75% RH. Based on these 
results, this novel electrostatic powder coating provides a competent dry coating method 
to coat tablets with ultrafine powder of ethylcellulose. 
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4 Pellet Coating – Immediate, Sustained and Delayed 
Drug Release 
The present study aims to apply a novel electrostatic powder technology to coat small 
pellets with different coating materials. Piroxicam, a non-steroidal anti-inflammatory 
drug, was used as the active pharmaceutical ingredient (API). Eudragit® EPO, Eudragit® 
RS /RL and Acryl EZE were used as the coating materials to achieve immediate release, 
sustained release and delayed release, respectively. Three steps including preheating, 
powder adhesion and curing were carried out to form the coating film while liquid 
plasticizers were used to decrease the glass transition temperature of coating powders and 
also served to reduce the electrical resistivity of pellets. Results of SEM indicated coating 
film could be better formed by increasing curing temperature or extending curing time. 
Dissolution tests showed that three different drug release profiles, including immediate 
release, sustained release and delayed release, were achieved by this coating technology 
with different coating formulations. The dry powder coated pellets using this developed 
technology exhibited an excellent stability with 1 month at 40 ◦C /75% RH. The coating 
procedure could be shortened to within 120 minutes and the use of fluidized hot air was 
minimized, both cutting down the overall cost dramatically compared to organic solvent 
coating and aqueous coating. All results demonstrated that the novel electrostatic dry 
powder coating method is a promising technology in the pharmaceutical coating industry. 
4.1 Introduction 
In the pharmaceutical industry, solid dosage forms including tablets and pellets are 
commonly coated to achieve taste masking, chemical and physical protection and 
modification of drug release characteristics. Presently, liquid coating is most widely used, 
where the coating materials are dissolved /dispersed into organic solvent /water to form a 
solution /suspension, then spayed onto solid dosage forms to achieve a coating film. 
Organic solvent based coating can make the film formation faster and more uniform due 
to the dissolved nature of coating polymers. However, the toxicity of organic solvent does 
decrease the safety of the drug and cause environmental related problems. As a result, 
aqueous coating, where water is used as the solvent, started to dominate in 1990s and 
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remains the preferred approach in the pharmaceutical industry. Nevertheless, aqueous 
coating still possesses many limitations such as longer processing time and higher energy 
consumption. Also aqueous coating is not appropriate for the moisture sensitive APIs.  
On the other hand, coating of smaller solid dosage forms like pellets, being solvent 
coating or aqueous coating, is currently carried out in a fluid bed coater in the present 
pharmaceutical industry, because those small pellets are very easy to agglomerate and 
that prevents uniform coating. Based on the spraying location, there are three different 
types fluid bed coaters including top-spray, side-spray and bottom spray. The bottom-
spray is named as the Wurster apparatus that invented by Wurster in 1966 [1]. Today, it is 
one of the most common coating equipment for pellets coating in the pharmaceutical 
coating industry. 
 
Figure 4.1 Schematic representation of a fluid bed with Wurster insert apparatus 
As shown in Figure 4.1, a typical the Wurster apparatus consists of a spray nozzle located 
at the bottom that is used for the spraying of coating solution, a Wurster tube that is 
placed in the center of the column and a distributor plate. In the coating process, the 
pellets are firstly fluidized and then coated by spraying the coating solutions into the 
column with the spray nozzle. The fluidized pellets could be circulated between the 
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Wurster tube and the outside of the column due to the unique structure, leading to a more 
uniform and continuous coating film. However, there are many limitations for this pellet 
coating equipment. First of all, in order to fluidize those small pellets and also to carry 
moisture out of the system, a large amount of hot fluidizing air is necessary, dramatically 
increasing the energy consumption and also the overall operation cost. Also, for the 
solvent coating method, long processing time is needed in order to obtain a desirable 
coating level owing to the viscosity limit of the coating solution. 
Different from the Wurster fluidized bed, Watano [2] designed a rotating fluidized bed 
coater to coat very small solid dosage forms using the aqueous coating method. In their 
study, fine particles (Geldart Group C powder) were used as the core particles, which 
were coated with HPLC aqueous solution. As shown in Figure 4.2, this rotating fluidized 
bed consists of a rotatable cylinder covered with meshes, a plenum chamber and a filter 
placed at the center of the cylinder. During the coating process, the fine particles were 
first fluidized with the support of a strong centrifugal force. Then the aqueous solution 
was sprayed through the nozzle located on the central filter. This study provided a new 
method to coat very small solid dosage forms. However, it still possesses many 
limitations. First of all, large amount of fluidizing hot air is necessary to maintain the 
fluidization of the fine particles and also to evaporate the moisture, significantly 
increasing the energy consumption and overall operation cost. The processing time is still 
very long due to the difficulty of evaporation of water. 
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Figure 4.2 Schematic diagram of the rotating fluidized bed coater 
Driven by these issues, many efforts have been made to develop alternative coating 
techniques to reduce or avoid the use of organic solvents as well as water [3-8]. Details of 
each coating technology can be found in the following reviews [9-12]. 
Some of the earlier attempts [3, 5, 13-15] used liquid plasticizers in the coating process to 
wet the dosages surface, promoting the adhesion of coating powders. Also the liquid 
plasticizer could reduce the glass transition temperature of coating materials to enhance 
the film formation under a lower temperature. However, surplus plasticizer can possibly 
lead to very soft or sticky film, so a careful balance needs to be reached between the 
plasticizer concentration for a sufficient coat thickness and that for a flexible and dry 
coat. Cerea et al. [16] developed a dry powder coating technology without using any 
solvent or plasticizer. In this coating technology, a lab-scale spheronizer was used as the 
coater with a motorized single screw powder feeder and an infrared lamp positioned on 
the top of the spheronizer as a heating source. Coating powders were continuously spread 
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onto the tablets by the powder feeder and film formation was completed in a following 
curing step in a static oven at 80 ◦C for 12 h. The advantage of this technology is that 
there is no sticky film due to the absence of liquid plasticizer. While the long curing time 
(12 h) and high curing temperature (80 ◦C) make it hard to apply in the industry. 
Among these earlier attempts of dry powder coating technology, researchers in 
Bodmeier’ group tried to coat small dosage forms in a Wurster fluidized bed with the 
support of liquid plasticizer [5, 13, 17]. In their study, pellets with a diameter of 0.71-0.85 
mm were coated with different coating materials to achieve drug immediate release, 
sustained release and delayed release. During the coating process, small pellets were 
firstly loaded into the bed, followed by the spraying of liquid plasticizers and feeding of 
coating powders. The plasticizers and coating powders were introduced into the bed 
separately to obtain a good coating powder adhesion. After the adhesion of the coating 
powders was finished, the pellets were unloaded and transported to a curing step for 
another 2 h to 24 h under the predetermined temperature. Those studies provide a method 
to coat small pellets using a powder coating technology with the support of liquid 
plasticizers in a traditional Wurster apparatus. However, similar with liquid coating 
methods using Wurster apparatus, a large amount of fluidizing hot air is necessary during 
the coating process in order to fluidize those small pellets, increasing the energy 
consumption and overall cost. Also this is not a continuous coating process, during which 
a curing step is needed in a different piece of equipment. This could significantly increase 
the processing time. Also the curing temperature and curing time need to be well 
controlled, otherwise a sticky coating film would be obtained because there is no 
fluidization or tumbling for the pellets during the curing step. 
Kablitz [18] designed and developed a new dry powder coating technology to coat small 
pellets using a rotatory fluid bed. In their coating process, the usage of organic solvents 
and water was completely avoided. An enteric coating film was achieved by using 
hydroxypropyl methylcellulose acetate succinate (HPMCAS) as the coating material 
without adding talc as anti-tacking agent. As shown in Figure 4.3, the coating process was 
performed in a rotary fluid bed with a gravimetric powder feeder achieving an exact 
dosage in contrast to a volumetric powder feeder. The coating powders and plasticizers 
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were fed into the rotatory fluid bed simultaneously with a three-way nozzle, which was 
aligned tangential to the pellet bed movement feeding. This dry coating technology has 
many advantages. Firstly, the usage of organic solvents and water was completely 
avoided during the coating process. Although it still need fluidizing hot air to fluidize the 
small dosage forms, the amount of which has been reduced dramatically due to the good 
design. And also the feeding of coating powders and plasticizers could be done 
simultaneously, which could not only increase the coating efficiency but also could 
reduce the processing time. 
 
Figure 4.3 Schematic of a rotary fluid bed granulator: (1) rotor disc; (2) air 
slit; (3) pellet bed (square view); (4) threeway nozzle; (5) powder feeder 
Unfortunately, those advantages have been compromised by the complicated coating 
process and added cost of the coating apparatus, offsetting any cost benefit to switching 
from liquid coating to powder coating, since their technology requires the use of 
completely different coating equipment. In addition, adoption of new equipment not only 
incurs extra capital costs, but also introduces additional complications in operation. The 
pharmaceutical companies would prefer to accept a powder coating process operated in a 
simpler coating apparatus that can be easily adapted from their present apparatus, such as 
pan coaters, for liquid coating.  
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Electrostatic coating has gained tremendous attention as a promising alternative to liquid 
coating in many industries, owing to its advantages in energy saving, high transfer 
efficiency, and environmental friendliness [19]. However, application of electrostatic 
coating in pharmaceutical industry is very limited due to the much weaker electrical 
conductivity of solid dosages. In order to overcome the limitations of those previous 
attempts, the authors’ group developed a novel dry powder coating technology [6]. By 
spraying certain amount of liquid plasticizer onto the surface of the solid dosage forms, 
the electrical resistivity can be dramatically decreased so that the electrostatic coating 
method can be adapted to form an electrical field between the electrostatic gun and the 
grounded substrate, which can direct the powder flow and enhance deposition of charged 
particles. Also a more uniform coating film could be promoted by this technology due to 
the better distribution of deposited particles caused by the repulsive force among the 
charged particles. This dry coating technology utilizes the same coating pan that was 
commonly used for solvent as well as aqueous coating, so that no major equipment 
change would be required with the shift to the new powder coating technology. This 
technology has been successfully applied on the larger solid dosage forms like tablets for 
all common drug release profiles including immediate release [8], sustained drug release 
[20] and delayed drug release [21]. 
The objective of present study is to coat small pellets by using this novel electrostatic dry 
powder coating technology in a pan coater with different coating formulations to 
modulate drug release profiles.  
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Figure 4.4 Schematic diagram of pellet coating study 
 
4.2 Materials and methods 
4.2.1 Materials 
Piroxicam pellets with a particle size of 0.9mm-1.18mm were provided by Gaocheng 
Biotech& Health CO., LTD. Eudragit® EPO, Eudragit® RS/RL, Eudragit® L100-55 and 
Colloidal silicon dioxide (AEROSIL® 200 Pharma) were donated by Evonik Degussa 
Corporation (Germany). Acryl EZE was provided by Colorcon, Inc. (US). It is an enteric 
coating material containing Eudragit® L100-55 developed by Colorcon, Inc. Talc powder 
was purchased from Mallinickrodt Baker Inc. (Canada). Triethyl citrate (TEC) and PEG 
400 were obtained from Caledon Laboratories Ltd. (Ontario, Canada) and EMD 
Chemicals Inc. (Ontario, Canada), respectively. 
4.2.2  Particle size reduction and analyses 
Particle size reduction of coating materials was achieved by using a blade grind mill. A 
particle size analyzer (TSI Corporation, Model 3603, Shoreview, MN, USA) was used to 
confirm the particle size of the coating particles. The particle size at 50 % of total weight 
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fraction was used as the average particle size. Table 4.1 gives the average particle size of 
coating powder used in the present study. 
 
Table 4.1 Average particle size of coating powder 
Coating powder Average particle size (µm) 
Eudragit® EPO 23.3 
Eudragit® RS 48.7 
Eudragit® RL 39.7 
Acryl EZE 20.8 
Talc powder 28.9 
 
4.2.3 Thermal analysis of coating polymers 
Differential scanning calorimetry (DSC) analysis (Mettler Toledo, DSC822, Mississauga, 
Canada) was used to investigate the glass transition temperature of raw coating materials 
and the mixture of coating materials with plasticizers (TEC and PEG 400) of different 
weight ratio (plasticizer/ coating materials). Samples with a weight of 10 mg were tested 
under nitrogen atmosphere with a heating rate of 2 ◦C /min over the temperature range of 
20 to 200 ◦C. 
4.2.4 Angle of repose (AOR) 
Measurement of the angle of repose was carried out to characterize the flowability of 
coating powers before and after the size reduction and also to investigate the influence of 
nano sized additives on the flowability of the three different coating powders by using a 
PT-N Hosokawa Powder Characteristic Tester, following the standardized testing 
procedures of ASTM D6369-08 (ASTM Standard D6369-08, 1999). 
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4.2.5 Electrical resistivity tests  
A batch of 100 g piroxicam pellets was loaded in the pan coater and preheated for 10 
minutes. Then liquid plasticizer, with a flow rate of 0.50 g/min, was sprayed onto the 
surface of the pellets. A given number of pellets was taken out from the pan coater at 
different spraying time intervals (0, 1, 2 and 3 min) to test the electrical resistivity using 
an electrometer (Keithley 610B, Keithley instruments, Inc., USA). These tests were 
operated three times for the accuracy. 
4.2.6 Coating equipment and process 
A
C
D
Ground
B
 
Figure 4.5 Schematic of the electrostatic powder coating system 
(A) liquid plasticizer spray system, (B) coating pan,  
(C) electrostatic spray gun, (D) powder feeder 
As shown in the Figure 4.5, the coating system includes a rotatory coating pan, a liquid 
plasticizer spray system, an electrostatic spray gun and a powder feeder. The rotatory 
coating pan, the same as commonly used for the organic/aqueous coating in the pharma 
industry, is electrically grounded. The liquid plasticizer spray system includes a metering 
pump and an atomizing nozzle. The electrostatic spray gun is applied to regulate and 
charge the coating powder and uniformly spray them onto the surface of the dosage forms 
preloaded in the pan. 
The coating process was performed in three steps. A batch of 100 g pellets were firstly 
loaded into the coating pan and preheated to a given temperature. Then a given amount of 
liquid plasticizer was sprayed onto the surface of the pellets. It is followed immediately 
by spraying dry coating powder. If necessary, repeat those two steps for several times 
until enough particles were deposited on the surface of the pellets. The temperature of the 
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coating pan was maintained as required until the particles deposited on the pellets were 
cured to produce a uniform coating film.  
The coating level (%) of the pellets could be obtained from the weight gain of coated 
pellets divided by the weight of uncoated ones, which is shown in the following equation: 
  
 
Table 4.2 Coating parameters of pellet coating 
Pellet loading 60 g 
Charging voltage 60 kV 
Liquid plasticizer flow rate 0.5 g/min 
Liquid plasticizer spray time 2 min for the first spraying, 0.5 min for the rest 
Atomizing air pressure 100-120 kPa 
Nozzle diameter 0.25 mm 
Powder feed rate 2 g/min 
Powder feed time 3 min 
Pan speed during coating (rpm) 35-40 
Pan speed during curing (rpm) 20-25 
Curing temperature 30 ◦C, 40 ◦C and 50 ◦C 
Curing time interval 0 min, 60 min and 120 min 
 
4.2.7 Scanning electron micrographs 
The surface morphology of the dry powder coated pellets was investigated by the 
scanning electron microscopy (SEM). After sputter coated with gold for 120 s using 
Emitech K550 sputter coater (Emitech Ltd., Ashford, UK), samples were observed with a 
scanning electron microscope at 5.0 kV (S-2600N Hitachi, Ontario, Canada). 
Coating level (%) = 
weight of coated pellets - weight of uncoated pellets 
weight of uncoated pellets
 * 100%
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4.2.8 Calibration curve of piroxicam  
The drug release standard curves of piroxicam at the wavelength of 334 nm, 354 nm and 
353 nm are shown in Figure 4.6, Figure 4.7 and Figure 4.8, respectively. The curves are 
served for the calculation of unknown concentrations of piroxicam samples collected 
from the in-vitro drug release testing. 
 
Figure 4.6 Standard curve of piroxicam (wavelength=334 nm) 
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Figure 4.7 Standard curve of piroxicam (wavelength=353 nm) 
 
Figure 4.8 Standard curve of piroxicam (wavelength=354 nm)  
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4.2.9 Drug release profiles 
Drug release profiles from dry powder coated pellets were obtained by the dissolution 
tests, performed following the United States Pharmacopeia (USP) apparatus (Apparatus 
2, paddle; Huanghai Rcz-6c2, Shanghai, China). The release media were 900 mL of 0.1N 
HCl solution for Eudragit® EPO coated pellets and 900 mL of pH 7.2 phosphate buffer 
solution for Eudragit® RS/RL coated pellets. For Acryl EZE coated pellets, the release 
media were 750 mL of 0.1N HCl solution for the first 2 hours and then pH 6.8 phosphate 
buffer solution by adding 250 mL of 0.2 M tribasic sodium phosphate solution for 
additional 2 hours. At predetermined intervals, samples were withdrawn by a 10 mL 
syringe and followed by refills with the same amount of fresh release medium. After 
being filtered, samples were assayed using an 8453 UV-Visible Spectrophotometer 
(Agilent Technologies, Mississauga, Canada) at a wavelength of 334 nm, 354 nm and 353 
nm at pH 1.2 HCl solution (0.1N), pH 7.2 phosphate buffer solution and pH 6.8 
phosphate buffer solution, respectively. 
4.2.10 Stability test 
Dry powder coated pellets with three different coating materials cured at 50 ◦C for 120 
minutes were placed in HDPE vials (75 mL) and sealed with aluminum film and then 
were stored at 40 ◦C /75% RH for 1 month. The dissolution tests of pellets before and 
after storage were examined. 
4.2.11 Statistical analysis  
Similar with previous chapters, mean ± Standard Deviation (S.D.) values were also used 
to express the experimental results in this chapter. Also the “similarity factor” f2 was used 
to compare the drug release profiles before and after storage in the stability tests. The 
following equation could be used to calculate the value of “similarity factor” f2. 
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In this equation, n is the total number of sampling times, Rt and Tt is the accumulated 
drug release percentage at time point t for the reference and test products, respectively.  
The value of f2 is between 0 to 100, if f2 is larger than 50 (between 50 to 100), these two 
release profiles were considered to be similar. If f2 is close to 100, the two release profiles 
were considered as identical. 
4.3 Coating and film formation 
4.3.1 Flowability improvement 
Nano sized particles of colloidal silicon dioxide (AEROSIL® 200 Pharma) was used as 
the additives to improve the flowability of the micronized coating powders [22-25]. 
Those nano particles were added and blended into the micronized coating powder to form 
a modified sample, which was further characterized to obtain the angle of repose.  
Table 4.3 gives the particle size and angle of repose before and after size reduction of the 
three different coating powders. The angle of repose of the coating powders was 
significantly reduced by adding nano sized colloidal silicon dioxide, indicating an 
improvement of flowability of the coating powders. This table also shows that 0.5 % 
additive based on the weight of coating powder gives the lowest angle repose, which 
would be used in the following coating formulations. 
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Table 4.3 Particle size and angle of repose of coating powders  
before and after adding nano additives 
Coating 
material 
Particle size 
(µm) 
Angle of repose (°) 
0% additive 0.5% additive 1% additive 1.5% additive 
Eudragit® E PO 23.3 46.2±1.24 40.74±0.94 40.98±0.88 41.03±0.76 
Eudragit® RS 48.7 41.3±0.63 40.02±0.69 - - 
Eudragit® RL 39.7 42.8±0.81 40.11±0.71 - - 
Acryl EZE 20.8 47.5±1.38 41.03±0.86 41.12±0.91 41.09±0.87 
 
4.3.2 Coating temperature reduction 
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Figure 4.9 Effect of plasticizer ratio (% w/w, based on polymer) on the glass 
transition temperature of the polymer (A) Eudragit®EPO with PEG 400;  
(B) Eudragit®RL/RS with TEC; (C) Acryl EZE with PEG 400 
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Liquid plasticizer plays a key role in the pharmaceutical industry due to its excellent 
ability to reduce the glass transition temperature and brittleness and increase flexibility of 
the coating polymers. As polymers with very small molecular weight, liquid plasticizers 
can be incorporated with long chains of the coating polymers and enlarge the free volume 
between the chains and makes it easier to move. As a result, the glass transition 
temperature of the polymer can be dramatically decreased. PEG 400 and TEC are widely 
used in the pharmaceutical industry due to their distinguished plasticizing properties, 
health friendliness and low cost. Some previous reports [8, 20, 21] indicated that PEG 
400 was an efficient plasticizer for the Eudragit® EPO and Acryl EZE while TEC was an 
efficient for Eudragit® RL and Eudragit® RS by studying their surface properties and 
compatibility with both tablet core and coating materials.  
Figure 4.9 shows the reduction of the glass transition temperature of the coating polymers 
by different liquid plasticizers using differential scanning calorimetry (DSC). The glass 
transition temperature of Eudragit® EPO was reduced from 53 to 31 ◦C by increasing PEG 
400 weight ratio from 0 to 25% (Figure 4.9 A). By increasing the TEC weight ratio from 
0 to 45%, the glass transition temperature of Eudragit® RL and Eudragit® RS was 
dramatically decreased from around 60 to below 30 ◦C (Figure 4.9 B). For Acryl EZE, its 
glass transition temperature declined from 127 to 55 ◦C (Figure 4.9 C) by increasing the 
PEG 400 weight ratio from 0 to 100 %. 
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4.3.3 Coating powder adhesion 
Ground
Electrostatic spray gun
Negative charged coating powder
Coating powder
Powder feeder
 
Figure 4.10 Coating powder adhesion process for pellet coating 
As has been demonstrated in section 2.2, the electrostatic dry powder coating technology 
utilizes an electrical field to enhance the deposition of coating powder. As shown in 
Figure 4.10, the coating particles are firstly negatively charged at the tip of the 
electrostatic spraying gun by a high voltage, after which the electrical field between the 
tip of the spray gun and the grounded coating pan is generated. Then the charged coating 
particles would flow along to adhere onto the surface of the tumbling pellets following 
the direction of the electrical field. In this process, the surface of drug pellets loaded in 
the coating pan should be electrically conductive to ensure that they are grounded, 
otherwise the electrical charge tends to build up on the pellets so as to impede further 
particle deposition. 1×109 Ωm is said to be the maximum electrical resistivity to allow the 
above process to happen. However, for some of the pharmaceutical solid dosage forms 
including drug pellets used in this study, the electrical resistivity is higher than 1×109 
Ωm, which is too high for the electrostatic spray coating process. 
Fortunately, the presence of liquid plasticizer in the coating process could provide 
substantial support to reduce the electrical resistivity of the drug pellets. As shown in 
Figure 4.11, the original electrical resistivity of drug pellets is around 1×1016 Ωm, and 
with the increase the spraying time of liquid plasticizer (TEC and PEG 400) from 0 to 3 
minutes with a given flow rate (0.50 g/min), the electrical resistivity of pellets declined 
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dramatically from 1×1016 Ωm to 1×107 Ωm-1×108 Ωm, which is suitable for the electrical 
spraying coating process. The reduction of electrical resistivity was hypothesized as an 
increase of surface conduction with the presence of liquid plasticizer [26].  
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Figure 4.11 The effect of liquid plasticizer on electrical resistivity of pellets 
(Liquid plasticizer flow rate: 0.5 g/min, temperature: 50 ◦C) 
 
4.3.4 Film formation 
Film formation in the dry powder coating process resulted from the deformation and 
viscous flow of deposited polymer particles when the temperature is higher than the glass 
transition temperature (Tg) of the coating polymer [14]. 
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Figure 4.12 SEM micrographs of dry Eudragit® EPO powder coated 
piroxicam pellets curing at 50 ◦C for different time intervals                                                        
(A) 0 min, (B) 60 min, (C) 120 min 
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Figure 4.13 SEM micrographs of dry Acryl EZE powder coated piroxicam 
pellets curing for 120 min at different temperatures:  
(A) 30 ◦C, (B) 40 ◦C, (C) 50 ◦C 
 
The effect of curing time and temperature on the film formation was examined by the 
scanning electron microscopy (SEM). As shown in Figure 4.12, there was slight film 
formation at the start of curing due to the low glass transition temperature of Eudragit® 
EPO and relatively high content of plasticizers in the initial coating powder adhesion 
stage (Figure 4.12 A), but some of the deposited particles are still clearly visible on the 
surface of the pellet. After curing for 60 min (Figure 4.12 B), a rough film is formed 
though there are some clear boundaries in the film. When curing time is increased to 120 
min (Figure 4.12 C), boundaries between particles disappeared and the film became 
uniform and smooth. Figure 4.13 provides similar results with different curing 
temperatures (30, 40, and 50 ◦C). By increasing the curing temperature from 30 to 40 and 
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50 ◦C, the boundaries between particles become less and less and film tends to be more 
uniform. As the glass transition temperature of Acryl EZE is much higher than Eudragit® 
EPO’s (Figure 4.9 A&C), the film formation of Acryl EZE is harder than Eudragit® EPO 
under the same coating conditions (Figure 4.12 and Figure 4.13). 
4.4 Immediate release coated with Eudragit® EPO 
Immediate drug release leads to a rapid dissolution of the drug after oral administration, 
which can quickly release the drug to into the human body through the GI tract, making 
the drug effective to the site immediately. One of the most common reasons for the 
coating of immediate drug release solid dosage forms is taste masking. Among the 
common used immediate release coating materials, Eudragit® EPO has a good 
performance on taste masking. Furthermore, Eudragit® EPO is able to dissolve in gastric 
solutions up to pH 5.5 [16]. This implies that it is insoluble in the saliva, but will dissolve 
in the stomach rapidly. 
 
Table 4.4 Coating formulation for immediate release with Eudragit® EPO 
 
Table 4.4 gives the coating formulation for immediate release with Eudragit® EPO. Talc 
powder was added into the coating formulation to prevent sticky coating film. In the 
preliminary experiments we found that it was very easy to get sticky coating film if the 
talc powder was not enough. Consequently, the ratio of talc powder was increased to 79% 
of the total coating formulation. 
In order to investigate the influence of coating level on the drug release profile from 
Eudragit® EPO coated piroxicam pellets, those pellets were coated with two coating 
levels (the lower coating level is 8.28 % and the relatively higher coating level is 19.86 
Ingredient Composition (wt/wt, %) 
Eudragit® EPO 20.0 
Talc 79.0 
Colloidal silicon dioxide 0.5 
Pigment 0.5 
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%). The surface morphology of powder coated pellets with two different coating levels 
were observed by SEM, the results are shown in Figure 4.14. After the coating powder 
adhesion, pellets with both of the two coating levels were cured under 50 ◦C for 120 min. 
As shown in Figure 4.14, all the deposited coating particles disappeared and a continuous 
and uniform coating film was formed for both coating levels, indicating that variations in 
coating level didn’t contribute to the difference of surface morphology under 50 ◦C curing 
for 120 min.  
 
Figure 4.14 SEM micrographs of Eudragit® EPO coated piroxicam pellets 
curing at 50 ◦C, 120 min with different coating level: (A) 8.28%, (B) 19.86% 
The drug release profiles from dry powder coated pellets with different coating materials 
were investigated through the dissolution tests. For the pellets coated by the Eudragit® 
EPO (Figure 4.15), drug release was completed within one hour and variations in coating 
level had no significant effect on drug release. This is because Eudragit® EPO is soluble 
in medium at a pH below 5.5. 
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Figure 4.15 Drug release profile from powder coated pellets  
with Eudragit® EPO 
 
4.5 Sustained release coated with Eudragit® RS/RL 
Sustained drug release could be achieved by coating the solid dosage forms with certain 
coating materials, allowing drug to release over an extended period of time to achieve 
prolonged therapeutic effect after oral administration. Eudragit® RL and Eudragit® RS are 
two commonly used coating materials for sustained release coating, both of which contain 
ethyl acrylate, methyl methacrylate and a small amount of methacrylic acid ester with 
quaternary ammonium groups (trimethyl-ammonioethyl methacrylate chloride) that 
function as salts to assure the permeability of the film. 
Table 4.5 gives the coating formulation for sustained release with Eudragit® RS/RL. 
Three different coating formulations were designed with different Eudragit® RS/RL ratio 
in order to investigate its influence on the drug release rate. 
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Table 4.5 Coating formulation for sustained release  
with Eudragit® RS and Eudragit® RL 
 Ingredient (% w/w) 
Formulation Eudragit® RS Eudragit® RL Talc SiO2, Pigment 
A 53.33% 26.67% 
19.00% 0.5%, 0.5% B 40.00% 40.00% 
C 26.67% 53.33% 
 
4.5.1 Coating level 
Similar with immediate release coating, the influence of coating level on the surface 
morphology and drug release profiles were investigated by coating the piroxicame pellets 
with three different coating levels, which are 13.8 %,17.9 % and 23.5 %. Results are 
shown as the following figures. 
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Figure 4.16 SEM micrographs of Eudragit® RS/RL (1:1) coated pellets curing 
at 50 ◦C, 120 min with different coating levels: (A) 13.8%, (B) 17.9%, (C) 
23.5%, (D) surface morphology of coating level 13.8% pellets 
Figure 4.16 shows the surface morphology of Eudragit® RL and Eudragit® RS coated 
pellets with three different coating levels. Obviously the variations of coating levels 
contribute to the difference of the surface morphology. With the increase of the coating 
level, the surface of the coating film became more uniform. Specifically, the surface of 
the lower coating levels (13.8 % and 17.9 %) coated pellets still exhibited some pores, 
indicating a non-uniform coating film. This might be caused by the less amount of 
coating materials, which was not enough to form a thick and dense coating film. 
Increasing the coating level (with coating level of 23.5 %) could easily overcome this 
phenomenon. Pellets with the highest coating level have the smoothest and most uniform 
coating film.  
The SEM micrograph of the cross section area of powder coated pellets with the coating 
level of 17.9 % and 23.5 % is shown as Figure 4.17. The powder coated piroxicam pellets 
were covered by a continuous coating film. 
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Figure 4.17 SEM micrographs on the cross-section area of Eudragit® RS/RL 
(1:1) coated pellets curing at 50 ◦C for 120 min  
(A: coating level=17.9%, B: coating level=23.5%) 
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Figure 4.18 Drug release profile from powder coated pellets  
with Eudragit® RS/RL at different coating levels 
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Coating level not only has an influence on the surface morphology of the coating film, 
but also could have a big impact on the drug release from the powder coated pellets. Drug 
release profiles from Eudragit® RL/RS (1:1) coated pellets cured under 50 ◦C for 120 min 
are shown in Figure 4.18. Compared to the immediate release coating, the drug release 
from Eudragit® RL/RS coated pellets was extended to more than 10 hours, indicating that 
sustained drug release has been achieved. The difference of coating level contributed 
significantly to the variability of drug release rate. For the pellets with a coating level of 
13.8%, drug release was finished within 10 hours. And when increasing the coating level 
to 17.9%, the cumulative release was 80% after 12 hours. When further increasing the 
coating level to 23.5%, only 30% of the drug came out from the pellets after 12 hours.  
4.5.2 Eudragit® RS /Eudragit® RL ratio 
The difference between Eudragit® RS and Eudragit® RL is that they have different amount 
of quaternary ammonium groups, consequently having a different permeability of coating 
film. Since Eudragit® RL has double content of quaternary ammonium groups as 
Eudragit® RS has, the coating film of Eudragit® RL would have higher permeability. As a 
result, it can be easily predicted that drug release rate from Eudragit® RL coated pellets 
would be faster than from Eudragit® RS coated pellets. A desirable drug release rate 
could be achieved by adjusting the ratio of Eudragit® RS and Eudragit® RL in the coating 
formulation. In order to investigate the influence of the ratio of Eudragit® RS/ Eudragit® 
RL, three different coating formulations with different ratio of Eudragit® RS/RL (1:2, 1:1, 
2:1, mass ratio) under two different coating levels were developed and coated onto the 
piroxicam pellets. 
Figure 4.19 shows the results of drug release profiles from powder coated pellets with a 
coating level of 13.8 % at different Eudragit® RS/ RL ratios. With the increase of the 
Eudragit® RS ratio in the coating formulation, drug release rate became slower and drug 
release completed within 6, 10 and 12 hours for the Eudragit® RS/ RL ratio of 1:2, 1:1 
and 2:1, respectively. This could be explained by less quaternary ammonium groups that 
Eudragit® RS has so as to have less permeability of the coating film. 
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Figure 4.19 Drug release profile from powder coated pellets with Eudragit® 
RS/RL at different RS: RL ratios (Coating level: 13.8%) 
The effect of Eudragit® RS/RL ratio on drug release profiles could be confirmed by the 
results of drug release from powder coated pellets with a higher coating level. Shown as 
Figure 4.20, with a same release time period of 12 hours, the drug released 100 %, 75 % 
and 53 % for Eudragit® RS/RL ratio of 1:2, 1:1 and 2:1, respectively. Similarly, with a 
coating level of 13.8 %, more Eudragit® RS in the coating formulation resulted in a 
slower drug release rate. 
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Figure 4.20 Drug release profile from powder coated pellets with Eudragit® 
RS/RL at different RS: RL ratios (Coating level: 17.9%) 
 
4.6 Delayed release coated with Acryl EZE 
Enteric coating could delay the drug release rather than release immediately after oral 
administration, eliminating stomach irritation and drug decomposition by the acid and 
enzymes [21, 27-34]. The coating materials for delayed drug release are pH dependent 
with high acid resistance. One of most commonly used coating materials that could 
achieve delayed drug release is Acryl-EZE, containing an effective component Eudragit® 
L 100-55. Acryl EZE is fully formulated for an aqueous acrylic enteric coating system for 
the application of an enteric film coating to solid dosage forms such as tablets, granules 
and beads [35-37]. Earlier studies using Acryl EZE as the coating materials to achieve 
drug delayed release focused on the liquid coating method, mainly aqueous coating, 
which possesses many limitations that have been discussed in the previous section. The 
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present study provides a new method to coat small dosage forms like pellets with Acryl 
EZE using a novel electrostatic powder coating technology. 
Table 4.6 gives the coating formulation for delayed release with Acryl EZE. Because 
Acryl EZE is fully formulated developed for enteric coating of solid dosage forms, only 
flowability additives (colloidal silicon dioxide) and pigment were added in the present 
coating formulation. 
Table 4.6 Coating formulation for delayed release with Acryl EZE 
 
In order to investigate the surface morphology of Acryl EZE coated pellets with different 
coating levels, scanning electron microscope (SEM) micrographs were employed in the 
present study. As shown in Figure 4.21, the coating films for both coating levels (10.83 % 
and 26.22 %) are relatively uniform and continuous with few boundaries and porous. The 
variations of the coating level didn’t contribute to the difference of surface morphology of 
Acryl EZE powder coated pellets cured at 50 ◦C for 120 min. 
Ingredient Composition (wt/wt, %) 
Acryl EZE 99.0 
Colloidal silicon dioxide 0.5 
Pigment 0.5 
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Figure 4.21 SEM micrographs of Acryl EZE powder coated pellets curing at 
50 ◦C, 120 min (A) Coating level of 10.83 %, (B) Coating level of 26.22 % 
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Figure 4.22 Drug release profile from powder coated pellets with Acryl EZE  
And for the drug release rate from Acryl EZE powder coated pellets (Figure 4.22), drug 
didn’t release or released very little within the first 2 hours in 0.1 N HCl solutions and 
then came out immediately after adjusting the pH from 1.2 to 6.8 by adding Na3PO4 
solution and the difference of coating level didn’t change the drug release profiles. In 
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order to achieve sufficient acid resistance, 3-4 mg/cm2 polymer weight gain is commonly 
applied to the dosage forms with organic coating [38]. For the dry powder coating 
technology in this study, a coating level of 26.22% (8.34 mg/cm2) was firstly obtained to 
meet the requirement of acid resistance and then decreased the coating level to 10.83% 
(3.45 mg/cm2), which is as low as liquid coating’s but with a shorter processing time and 
a lower overall cost. 
4.7 Stability of powder coated pellets 
The drug release profiles of dry powder coated pellets (cured at 50◦C for 120 min) with 
three different coating materials before and after storage are shown in Figure 4.23, Figure 
4.24 and Figure 4.25. There was no significant difference in the drug release profiles, and 
all the similarity factor f2 values between release profiles of piroxicam from powder 
coated pellets with three different coating materials are larger than 50, which means the 
dry powder coated pellets exhibited excellent stability over 1 month at 40◦C /75% RH. 
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Figure 4.23 Drug release profile from powder coated pellets with Eudragit® 
EPO at 50 ◦C, 120 min (*: after storage at 40 ◦C, 75% RH for 1 month) 
 
Table 4.7 Similarity factor f2 values between release profiles of piroxicam 
from Eudragit® EPO coated pellets before and after storage 
Coating level f2 
8.28 % 80.16 
19.86 % 84.14 
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Figure 4.24 Drug release profile from powder coated pellets with Eudragit® 
RL/RS at 50 ◦C, 120 min (*: after storage at 40 ◦C, 75% RH for 1 month) 
 
Table 4.8 Similarity factor f2 values between release profiles of piroxicam 
from Eudragit® RL/RS coated pellets before and after storage 
Coating level f2 
13.8% 79.49 
17.9% 81.01 
23.5% 84.92 
 
120 
 
0 1 2 3 4
0
20
40
60
80
100
Coating level
 
 
Acryl EZE coated at 50 C, 120 min 
 26.22%
 26.22%(*)
 10.83% 
 10.83%(*)
C
u
m
u
la
ti
ve
 r
el
ea
se
 (
%
)
Time (Hour)
 
Figure 4.25 Drug release profile from powder coated pellets with Acryl EZE 
at 50 ◦C, 120 min (*: after storage at 40 ◦C, 75% RH for 1 month) 
 
Table 4.9 Similarity factor f2 values between release profiles of piroxicam 
from Acryl EZE coated pellets before and after storage 
Coating level f2 
10.83% 81.09 
26.22% 78.24 
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4.8 Conclusion 
 
Figure 4.26 Pictures of electrostatic powder coated pellets  
(A): Eudragit® EPO, (B): Eudragit® RS/RL, (C): Acryl EZE 
In the present study, small solid dosage forms (pellets) were successfully coated with a 
traditional pan coating system using a novel electrostatic dry powder coating technology. 
Three different coating formulations were developed for the pellet coating to achieve 
immediate release, sustained release and delayed release.  
The particle size of the coating powder was first reduced and the flowability of those fine 
coating powders was improved by adding 0.5% nano additives (colloidal silicon dioxide) 
in the coating formulation. 
Different liquid plasticizers were used for different coating materials to reduce the glass 
transition temperature of coating polymers to allow film formation at a low temperature 
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and also served to decrease the electrical resistivity of the drug pellets to allow the 
deposition of coating powder on the surface of pellets.  
The results of SEM illustrated that better film could be formed with longer curing time 
and/ or higher curing temperature. Dissolution tests indicated that drug release profiles 
from those powder coated pellets could be altered as immediate release, sustained release 
and delayed release with suitable coating formulations. For immediate release and 
delayed release, coating level didn’t contribute to the difference of surface morphology as 
well as drug release profiles. However, for sustained release, coating level had a big 
impact on the drug release profiles and also the surface morphology. Higher coating level 
led to a better and more uniform coating level and resulted in a slower drug release rate. 
For Eudragit® RL/RS powder coated pellets, the drug release rate could also be influenced 
by the ratio of Eudragit® RL/RS in the coating formulation, more Eudragit® RL led to a 
faster drug release rate due to the high permeability of the coating film formed by 
Eudragit® RL. 
The pellets coated by the developed novel electrostatic dry powder coating technology 
exhibited an excellent stability with 1 month at 40◦C /75% RH.  
Compared with other coating methods for small solid dosage forms, the present coating 
technology has many advantages. First of all, the usage of fluidized hot air could be 
avoided in the present coating technology, which could dramatically cut the overall cost 
compared to the organic as well as aqueous coating method. Also the coating procedure 
could be shortened to less than 120 minutes, which is much faster than other dry powder 
coating technologies. In addition, the equipment and apparatus employed in this coating 
technology are similar with the ones in the present pharmaceutical industry, which is 
much more acceptable for the pharmaceutical companies when adapting the liquid 
coating methods. In a word, the present dry powder coating technology is well developed 
and promising in pharmaceutical coating industry. 
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5 Osmotic Controlled Release- Elementary Tablet Coating 
A novel electrostatic powder coating was applied to coat elementary osmotic pump 
tablets with powdered cellulose acetate (CA) using a pan coater system. Both water 
soluble drug (salbutamol sulfate) and water insoluble drug (ibuprofen) were use as the 
model drugs. Three steps including preheating, powder adhesion and curing were 
performed to achieve a smooth and uniform coating film which was used as the 
semipermeable membrane of the osmotic pump tablets. Triethyl citrate (TEC) was found 
to be an effective liquid plasticizer for elementary osmotic pump tablet coating, not only 
reducing the glass transition temperature of coating polymer (CA), but also increasing the 
electrical conductivity of those elementary osmotic pump tablets, both of which lead to an 
enhanced coating powder adhesion and film formation. SEM indicated that the uniformity 
of coating film varied significantly with the difference of curing time and temperature. 
The drug release profiles showed that a zero-order drug release was achieved and drug 
release could be controlled over a desirable period of time, such as 12 hours or 24 hours. 
Also the drug release rate was influenced significantly by the coating level while was 
independent of the pH value of release media, agitation speed and the orifice diameter.  
5.1 Introduction 
Conventional drug delivery is usually administered two or three times a day, which 
cannot control drug release rate, leading to large fluctuation in drug plasma concentration. 
It won’t be effective when the drug plasma concentration is lower than minimum 
effective concentration (MEC), while it will cause side effect when close to or higher 
than, the maximum safe concentration (MSC). Constant plasma level can offer a 
therapeutic advantage for many drugs in terms of both efficacy and tolerance of the 
treatment. Sustained release, some others also refer it as “controlled release”, is designed 
to release a drug at a slower rate in order to maintain a more desirable drug concentration 
for a longer period of time. However, it still cannot achieve a constant drug concentration 
over a specific period of time. Consequently it cannot avoid side effects. 
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Figure 5.1 Drug plasma concentration profiles  
for different drug delivery systems 
Osmotic drug delivery system, which is the only drug delivery system that could achieve 
a constant drug plasma concentration over a specific period of time, is the most promising 
drug delivery system. Since it was first reported almost 60 years ago [1], osmotic drug 
delivery system (ODDS) has gained tremendous attention due to its excellent ability of 
controlling the drug release rate over a long period of time. As shown in Figure 5.2, the 
numbers of articles and patents that relate to ODDS has significantly increased during the 
past 20 years, particularly the past 10 years. A great summary of these kinds of work can 
be seen in an excellent review by Malaterre [2]. A typical osmotic drug delivery system 
includes an active pharmaceutical ingredient (API), osmotic agent(s), semipermeable 
membrane and drug delivery orifice(s). Upon the osmotic pump tablets contacting with 
aqueous media, water diffused into the system and osmotic pressure will be generated 
inside, which governs drug release from the delivery orifice at a constant rate. Compared 
to other drug delivery systems, ODDS own a set of distinct advantages. First of all, the 
drug release rate in this system can be governed only by the osmotic agent, which means 
that drug release is independent of the drug’s chemical properties, of the patient’s 
physiological factors or concomitant food intake [2]. Also, the design of the osmotic 
delivery system is simple and easy to operate.  
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Figure 5.2 Publications related to ODDS  
(source: ISI web of Sciences, Pubmed and EMBASE; micropatent, 
espacenet; end date, March 2016) 
As discussed in section 2.2.3, the drug release from ODDS is controlled by an osmotic 
pressure generated inside the ODDS core. As one of the fundamental phenomena in 
biology, osmosis is the movement of a solvent across a semipermeable membrane toward 
a higher concentration of solute. An osmotic flow is generated when two solutions of 
different solute concentrations are separated by a semi-permeable membrane rejecting the 
solute on the one hand, but allowing passage of the solvent molecules on the other hand 
[3].  
The first idea of ODDS came from Rose and Nelson, they proposed an osmotic dispenser 
[4] that is capable of delivering drug solution with a relatively constant rate. Later in 
1970s, Takero Higuchi and Felix Theeuwes improved the osmotic dispenser [5, 6] and 
developed an elementary osmotic pump tablet [7], cooperated with the Alza Corporation, 
which is the first practical example of an osmotic pump based drug release system [2].  
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Figure 5.3 Schematic diagram of elementary osmotic pump 
As shown in Figure 5.3, an elementary osmotic pump consists of the drug, osmotic agent 
and semipermeable membrane. Also there is a drug delivery orifice on the semipermeable 
membrane, which could be obtained by mechanical drilling or laser drilling methods. 
When these elementary ODDS were upon the release media, water would immediately 
diffuse into the core through the semipermeable membrane, dissolving the osmotic agents 
and generating osmotic pressure. Then the drug was dissolved and pushed out by the 
osmotic pressure through the delivery orifice. 
Currently, only solvent coating process can be applied to achieve the semipermeable 
membrane of the ODDS because coating polymers that can be formed to a semipermeable 
membrane have a very high Tg (184.39 
◦C for cellulose acetate), which is too high for the 
aqueous coating. The use of organic solvent suffers from the environmental, 
toxicological, cost- and safety-related issues. Also the concentration of the coating 
solution cannot be too high due to the limitation of viscosity, leading to low coating 
efficiency. In addition, the organic solvent needs to be vaporized in the coating process, 
which is energy and time consuming and could increase the overall cost.  
Recently many efforts have been made to develop solventless coating technologies 
including compression coating, hot-melt coating, supercritical fluid coating and 
photocuring coating, which have been summarized in the following reviews [8-10], but 
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none of them has been applied to form the semipermeable membrane of the ODDS. Also 
it is difficult to apply those technologies in the pharmaceutical industry owing to their 
own limitations. 
The concept of electrostatic powder coating came out in the 1950s in USA, and now it is 
widely used in the metal and wood finishing industries. In this coating process, dry 
powders are firstly charged by an electrostatic spray gun and then move and adhere to the 
grounded substrate surface. Then the grounded substrate with deposited coating powder is 
put in an oven and cured for a certain period of time under high temperature to allow film 
formation. Compared to other solventless coating technologies, electrostatic powder 
coating has many distinctive advantages such as short coating process, highly valued for 
energy savings, and significantly reduced of overall operation cost. Most importantly, 
electrostatic powder coating can enhance the coating powder adhesion so as to increase 
the coating efficiency dramatically and also can well control the coating powder feeding 
and achieve a much more uniform coating film both on coating thickness and surface 
morphology. 
The objective of the present study is to utilize electrostatic powder coating to form the 
semipermeable membrane of the elementary ODDS with powdered cellulose acetate 
(CA), and to characterize the coating powder adhesion and film formation and their 
influence factors in the electrostatic coating process. Both water soluble and water 
insoluble drugs would be used as the model drug so as to analyze the drug release from 
electrostatic powder coated elementary ODDS. 
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Figure 5.4 Schematic diagram of elementary ODDS study 
 
5.2 Materials and methods 
5.2.1 Materials 
Salbutamol sulfate and ibuprofen were provided by Nanjing Pharmaceutical Factory 
(Nanjing, China) and Patheon (Mississauga, Ontario, Canada), respectively. Cellulose 
Acetate was donated by the Eastman Chemical Company (Kingsport, Tennessee, USA). 
Plasdone K-29/32 was purchased from ISP technologies, INC. Sodium Chloride was 
provided by EMD Chemicals Inc. (Gibbstown, NJ, United States). Avicel® 
Microcrystalline cellulose PH-102 was purchased from FMC Corporation (Philadelphia, 
Pennsylvania, United States) and Magnesium Stearate was purchased from Alfa Aesar 
(Haverhill, Massachusetts, USA). Placebo tablets were obtained from Patheon 
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(Mississauga, Ontario, Canada). Triethyl citrate (TEC) was purchased from Caledon 
Laboratories Ltd. (Georgetown, Ontario, Canada). Colloidal silicon dioxide (AEROSIL® 
200 Pharma) was donated by Evonik Degussa Corporation (Essen, North Rhine-
Westphalia, Germany). Talc was purchased from Mallinickrodt Baker Inc. (Center 
Valley, Pennsylvania, United States). 
5.2.2 Preparation of the osmotic pump tablets 
The component of the tablets core includes drug (Salbutamol Sulfate/ ibuprofen), sodium 
chloride, microcrystalline cellulose, PVP and magnesium stearate. The formulation of the 
osmotic pump tablets core can be seen in Table 5.1. 
Table 5.1 Formulation of osmotic pump tablets core 
Ingredient % w/w 
Salbutamol sulfate / Ibuprofen 20% 
Sodium chloride 30% 
Microcrystalline cellulose PH102 43% 
PVP 6.5% 
Magnesium stearate 0.5% 
Those components were mixed using a granulator (Mechanomill MM-20N, OKADA 
SEIKO Co. Ltd, Iwate, Japan) with a speed of 300 rpm for 6 min, followed by adding 
magnesium stearate and mixing for another 3 min with same speed. The ready 
formulation was then compressed into tablets by using a tablet machine with one punch 
(5 mm in diameter) (Shanghai Tianxiang & Chentai Pharmaceutical Machinery Co. Ltd, 
Shanghai, China). The weight for each tablet is 180±2 mg.  
5.2.3 Particle size reduction and analysis 
Particle size reduction of cellulose acetate was complicated by a combination use of a jet 
mill and blade grind mill, prior to use. Particle size of the coating materials was 
confirmed by a particle size analyzer (TSI Corporation, Model 3603, Shoreview, MN, 
USA). The particle size at 50 % of total weight fraction was used as the average particle 
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size. The average particle size of cellulose acetate and talc powder was 26.7 and 28.9 μm, 
respectively. 
Table 5.2 Average particle size of coating materials 
Materials Average particle size (µm) 
Cellulose acetate 26.7 
Talc 28.9 
 
5.2.4 Angle of repose (AOR) 
Measurement of the angle of repose was carried out to characterize the flowability of 
coating powers before and after the size reduction and also to investigate the influence of 
nano sized additives on the flowability of CA powders by using a PT-N Hosokawa 
Powder Characteristic Tester, following the standardized testing procedures of ASTM 
D6369-08 (ASTM Standard D6369-08, 1999). 
5.2.5 Differential scanning calorimetry (DSC) 
The glass transition temperature of cellulose acetate and mixture of coating material and 
plasticizer (TEC) with different ratios were confirmed by differential scanning 
calorimetry (DSC) analysis (Mettler Toledo, DSC822, Mississauga, Canada). The 
samples (8-12mg) were tested at a heating rate of 2 ◦C /min over the temperature range of 
20 to 200 ◦C under nitrogen atmosphere. 
5.2.6 Electrical resistivity test 
A batch of 20 g of osmotic pump tablets and 60 g of placebo tablets were loaded in the 
pan coater and preheated for a certain time. Then liquid plasticizer (0.6 g/min) was 
sprayed onto the surface of the tablets. At different spraying points (0, 1, 2, 3 and 4min), 
three tablets were taken out and used as sample to test the electrical resistivity using an 
electrometer (Keithley 610B, Keithley instruments, Inc., USA). These tests were operated 
in duplicate. 
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5.2.7 Powder coating process 
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Figure 5.5 Schematic diagram of the electrostatic powder coating system 
(A) Liquid plasticizer, (B) liquid plasticizer metering pump,  
(C) coating pan, (D) electrostatic spray gun, (E) powder feeder 
A laboratory scale electrostatic dry powder pan coater system was used to complete the 
powder coating process. This coating system includes a stainless steel pan of 14 cm 
diameter and four aluminum baffles inside the wall to promote a better tumbling 
movement of the tablets, an electrostatic spray gun, a powder feeder and a liquid spray 
nozzle (Figure 5.5).  
The coating process includes three steps. First is preheating. Before coating, placebo 
tablets and osmotic pump tablets were mixed together and loaded into the coating pan and 
then preheated for 20 min at certain temperature. Second is the powder adhesion. In this 
process, liquid plasticizer and powder were fed into the coating pan alternately. Firstly, 
the liquid plasticizer was sprayed onto the surface of the tablets for a predetermined time 
period. The flowrate of liquid plasticizer can be controlled by a liquid metering pump 
(Fluid Metering Inc., USA). Then a predetermined amount of coating powders was fed 
and sprayed on the surface of the tablets immediately after the feeding of liquid 
plasticizer using an electrostatic spray gun (Nordson Corporation, USA). The last step is 
curing and film forming. After the feeding of liquid plasticizer and coating powder, the 
tablets were further cured for a predetermined time to allow film formation. In this 
process, curing time and temperature are two critical parameters. Table 5.4 gives the 
coating process parameters. 
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The coating level (%) of the tablets could be obtained from the weight gain of coated 
tablets divided by the weight of uncoated tablets. Placebo tablets were used to maintain 
the volume of substrates and conserve osmotic pump tablets at the same time. 
The coating powder contains CA, talc powder, nano silica and pigment. The formulation 
can be seen in Table 5.3. 
Table 5.3 Formulation of the coating powder 
Ingredient % w/w 
Cellulose acetate 80% 
Talc powder 19% 
Pigment 0.5% 
SiO2 (Nano) 0.5% 
 
Table 5.4 Coating process parameters of elementary ODDS coating 
Tablet loading 60 g 
Charging voltage 0 kV, 20 kV, 40 kV, 60 kV, 70 kV 
Liquid plasticizer flow rate 0.8 g/min 
Liquid plasticizer spray time 0 min, 1 min, 2 min, 3 min and 4 min 
Atomizing air pressure 300-320 kPa 
Nozzle diameter 0.25 mm 
Powder feed rate 3 g/min 
Powder feed time 2 min 
Pan speed during coating (rpm) 28-32 
Pan speed during curing (rpm) 10-15 
Curing temperature 40 ◦C, 50 ◦C and 60 ◦C 
Curing time interval 0 min, 60 min and 120 min 
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5.2.8 Scanning electron micrographs 
Scanning electron microscopy (SEM) was used to investigate the surface morphology of 
the dry powder coated tablets with different coating conditions. Under an argon 
atmosphere, samples were firstly sputter coated with gold for 120 s using Emitech K550 
sputter coater (Emitech Ltd., Ashford, UK), and then were observed with a scanning 
electron microscope at 5.0 kV ×3.0k (S-2600N Hitachi, Ontario, Canada). We also 
observed the cross-sectional part the film, by doing so the thickness of the film with 
different coating levels could be evaluated.  
5.2.9 Creation of drug delivery orifice 
There are several methods to create a delivery orifice in the osmotic drug delivery system 
including mechanical drill [11], laser drilling [12, 13], indentation [14, 15]. In this study, 
we use a mechanical drill method to create the drug delivery orifice with different 
diameters (200 µm, 500 µm and 900 µm).  
5.2.10 Calibration curves of salbutamol sulfate and ibuprofen 
The calibration curve of salbutamol sulfate was already obtained in Chapter 3, which can 
be seen in Figure 3.4. 
For ibuprofen, a standard stock solution with a concentration of 200 ppm (μg/ml) was 
prepared by dissolving ibuprofen in PBS solution with a pH value of 7.2. And then it was 
diluted with pH 7.2 PBS solution separately to obtain the solution with a concentration of 
12.5, 25, 50, 80, 100, 160 respectively. A 8453 UV-Visible Spectrophotometer (Agilent 
Technologies, Mississauga, Canada) was used to find the maximum absorbance, which is 
at 222 nm. Then the absorbance was obtained at 222 nm against pH 7.2 PBS solution as 
blank. The calibration curve was prepared by plotting absorbance versus concentration 
(ppm) of ibuprofen. 
The calibration curve of ibuprofen at the wavelength of 222 nm is shown as Figure 5.6. 
This curve would be used to calculate the unknown concentrations of ibuprofen released 
from electrostatic powder coated elementary ODDS. 
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Figure 5.6 Calibration curve of ibuprofen in PBS with a pH 7.2 at 222 nm 
5.2.11 Dissolution tests 
The release profile of the drug from osmotic pump tablets before and after being coated 
with various coating conditions was obtained using the United States Pharmacopeia 
(USP) apparatus (Apparatus 2, paddle; Huanghai Rcz-6c2, Shanghai, China). Phosphate 
buffer solution with different pH value (1.2, 5.8 and 7.2) was chose as the release media. 
The release tests with 6 tablets in 6 vessels with 900 ml release media were performed at 
37 ◦C at a certain stirring speed. A 10 ml syringe was used to withdraw samples from 
each vessel at predetermined intervals and then fresh medium with equal volume was 
injected into the vessels. Samples were assayed using an 8453 UV-Visible 
Spectrophotometer (Agilent Technologies, Mississauga, Canada) at a wavelength of 276 
nm for salbutamol sulfate and 222 nm for ibuprofen. 
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5.2.12 Stability test 
Electrostatic dry powder coated elementary ODDS (both salbutamol sulfate and 
ibuprofen) cured at 60 ◦C for 120 minutes were placed at in HDPE vials (75 mL) and 
sealed with aluminum film and then were stored at 40 ◦C /75% RH for 1 month. The 
dissolution tests of those elementary ODDS before and after storage were examined. 
5.2.13 Statistical analysis 
Similar with Chapter 3, the experimental results in this chapter were also expressed as 
mean ± Standard Deviation (S.D.) values. While the “similarity factor” f2 was not only 
used to compare the drug release profiles before and after storage in the stability tests, but 
also was used to compare the drug release profiles with different orifice diameters, pH 
values and agitation speed. The following equation could be used to calculate the value of 
“similarity factor” f2. 
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In this equation, n is the total number of sampling times, Rt and Tt is the accumulated 
drug release percentage at time point t for the reference and test products, respectively.  
The value of f2 is between 0 to 100, if f2 is larger than 50 (between 50 to 100), these two 
release profiles were considered to be similar. If f2 is close to 100, the two release profiles 
were considered as identical. 
5.3 Coating and film formation 
5.3.1 The plasticizing effect of the liquid plasticizer 
Plasticizer is widely used in pharmaceutical industry due to its excellent ability to 
increase flexibility and to reduce the brittleness, glass transition temperature (Tg) of the 
polymers [16]. As reported in the previous literature, the film formation in dry powder 
coating technology is achieved through the deformation and viscous flow of polymer 
particles when the temperature is below the glass transition temperature (Tg) [17]. 
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However, some polymers, which are widely used as the functional coating materials in 
pharmaceutical industry, have a relatively high Tg. For instance, cellulose acetate is 
commonly used as the water-insoluble semipermeable membrane of osmotic dosage 
forms, while its glass transition temperature (EastmanTM Cellulose Acetate 398-10) is 
around 184◦C. In order to apply this material in the electrostatic dry powder coating 
process, liquid plasticizer is necessary to decrease the Tg under a safe range for the drugs.  
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Figure 5.7 Plasticizing effect of liquid plasticizers on the coating powder 
Tg of pure CA and the mixture of CA and liquid plasticizers of TEC with different ratio 
were investigated by DSC. The plasticizing effect of the liquid plasticizer can be seen in 
the Figure 5.7. The Tg of pure CA was 184 
◦C. With the increase of plasticizers/CA ratio, 
the Tg of CA decreased dramatically. When the ratio increased to 0.8, the Tg of CA 
decreased to 49◦C, which was suitable for the electrostatic dry powder coating process.  
5.3.2 Flowability improvement 
Nano sized particles of colloidal silicon dioxide (AEROSIL® 200 Pharma) were used as 
the additives to improve the flowability of the micronized cellulose acetate powders. 
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Those nano particles were added and blended into the micronized coating powder to form 
a modified sample, which were further characterized to obtain the angle of repose.  
Table 5.5 gives the particle size and angle of repose before and after size reduction of the 
cellulose acetate powders. The angle of repose of the CA powders was significantly 
reduced by adding nano sized colloidal silicon dioxide, indicating an improvement of 
flowability of the coating powders. This table also tells that 0.5% additive based on the 
weight of coating powder gives the lowest angle repose, which would be used in the 
following coating formulations. 
 
Table 5.5 Particle size and angle of repose of cellulose acetate powder 
before and after adding nano additives 
Coating material 
Particle 
size (µm) 
Angle of repose (°) 
0% additive 0.5% additive 1% additive 1.5% additive 
Cellulose acetate 26.7 48.4±1.11 40.94±0.64 41.02±0.68 41.08±0.77 
 
5.3.3 Powder adhesion 
In the electrostatic spray powder coating process, the electrical field is used to assist the 
powder adhesion. With an electrostatic spray corona charging gun, the coating powder 
could be firstly negatively charged and then followed by the electrical field between the 
electrostatic gun and the grounded coating pan to the direction of the electrical force and 
then deposited onto the surface of the rotated osmotic pump tablets. Apparently the 
osmotic pump tablets should have a low enough electrical resistivity (below 1×109 Ωm) 
[17] to allow the above process happen. Unfortunately, the electrical resistivity of these 
osmotic pump tablets was extremely high and larger than 1×1015 Ωm.  
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Figure 5.8 The effect of liquid plasticizer  
on the electrical resistivity of osmotic pump tablets  
(Liquid plasticizer: TEC, flow rate: 0.5 g/min, temperature: 60◦C) 
In this study, liquid plasticizer was sprayed onto the surface of the tablets to decrease the 
electrical resistivity. Figure 5.8 showed the relationship between the amount of liquid 
plasticizer and the electrical resistivity of the tablets. From this figure, we can see that 
without liquid plasticizer, the electrical resistivity of these osmotic pump tablets was 
larger than 1×1015 Ωm. While with the increase of the liquid plasticizer sprayed, the 
electrical resistivity decreased dramatically and when the spray time increased to 4 min, 
the electrical resistivity decreased to less than 108 Ωm, which could be very suitable for 
the electrostatic dry powder coating process.  
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Figure 5.9 The effect of charging voltage  
on the coating powder adhesion rate 
Charging voltage of the electrostatic gun and the liquid plasticizer are two critical factors 
that could have a big influence on the coating powder adhesion during the electrostatic 
powder coating process. The influence of charging voltage on the coating powder 
adhesion rate is shown in Figure 5.9. When the charging voltage was increased from 0 to 
60 kV, coating powder adhesion rate was increased from 58.8% to 90.1%. While further 
increasing the charging voltage to 70 kV, the coating powder adhesion rate didn’t 
increase any more. As we discussed before, the coating powder adhesion obtained at 0 V 
reflected the particle deposition caused by sprayed liquid plasticizer. Spraying liquid 
plasticizer onto the surface of the tablets could generate capillary force between the 
interface of liquid plasticizer and coating powders, enhancing and promoting the coating 
powder adhesion. Higher coating powder adhesion rate obtained with increasing the 
charging voltage to 60 kV indicates that the coating powder adhesion was enhanced by 
the electrical field between the tip of the electrostatic gun and the coating pan. The 
coating powder adhesion rate was not increased after the electrical charge reached a 
certain value. This can be explained by the increased cumulative charge of the coating 
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layer and back ionization caused by the higher charging voltage, which could reduce the 
powder deposition. 
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Figure 5.10 The effect of liquid plasticizer  
on the coating powder adhesion rate 
The other influence factor that could have an impact on the coating powder adhesion is 
the liquid plasticizer sprayed on to the surface of the solid dosage forms. As shown in 
Figure 5.10, when there was no liquid plasticizer sprayed, the coating powder adhesion 
rate was only 38.7 % with a charging voltage of 60 kV, which is too low to produce a 
good coating film. When increasing the liquid plasticizer spray time from 0 min to 2 min, 
the coating powder adhesion rate significantly increased from 38.7 % to 82.7 %. Further 
increase of the liquid plasticizer spray time to 3 and 4 min led to a slight increase of the 
coating powder adhesion rate to 90.1 % and 93.9 %, respectively. However, surplus 
liquid plasticizer (spraying time was 4 min) would lead to a sticky coating film although 
the coating powder adhesion rate was increased. So, when the liquid plasticizer (TEC) 
flowrate is 0.5 g/min, the spray time could be optimized as 3 min. 
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From Figure 5.8, Figure 5.9 and Figure 5.10 it could be concluded that in the electrostatic 
powder coating process, the coating powder adhesion could be influenced by both the 
charging voltage of the electrostatic spray gun and the liquid plasticizer. For the charging 
voltage of electrostatic spray gun, high voltage leads to back ionization while low voltage 
couldn’t provide enough powder to obtain high powder adhesion rate. From the 
experimental results, the charging voltage could be optimized as 60 kV according to 
Figure 5.10. While for the liquid plasticizer, when the flow rate is 0.5 g/min, the spray 
time needs to be 2 min or more than 2 min to guarantee that the electrical resistivity of 
those elementary ODDS is close to or below 109 Ωm so as to achieve a high coating 
powder adhesion rate. However, sticky film was observed when the spray time was 
increased to 4 min. Consequently, the liquid plasticizer spray time could be optimized as 
3 min with a flowrate of 0.5 g/min.  
5.3.4 Film formation 
The deformation and viscous flow of deposited polymer particles at the temperature 
higher than the glass transition temperature (Tg) of the polymer result in the film 
formation, which was called dry sintering theory in the previous literature [17]. In dry 
powder coating process, after the powder adhesion, curing is a critical step for the 
deposited polymer particles to coalesce together to form a uniform film.  
An attempt was made here to disclose effects of curing time on the film formation of 
polymer particles by using scanning electron micrographs. The SEM micrographs of the 
coated osmotic pump tablets at different curing time intervals are shown in Figure 5.11. 
From the figure we can conclude that a longer curing time allowed the deposited polymer 
particles to form a better and smoother coating film. Before the curing started (Figure 
5.11-A), we can clearly see the deposited polymer particles on the surface of the tablets 
with a small portion of coalescence due to the high content of TEC in the powder 
adhesion stage. With the curing time increased to 60 min (Figure 5.11-B), most of the 
deposited particles disappeared and a larger extent of film was formed. However, we can 
still see some uncured particles and the film was relatively rough. When the curing time 
became 120 min (Figure 5.11-C), the film was smoother and more uniform in comparison 
with those cured in 60 min.  
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Figure 5.11 SEM micrographs of CA powder coated elementary ODDS 
curing at 60 ◦C for different time intervals: (A) 0 min, (B) 60 min, (C) 120 min 
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Figure 5.12 SEM micrographs of CA powder coated elementary ODDS 
curing for 120 min at different temperatures: (A) 40 ◦C, (B) 50 ◦C, (C) 60 ◦C 
Similar results were seen in Figure 5.12 with different curing temperatures. When the 
curing temperature was increased from 40 to 50 and 60 ◦C, coating film became more and 
more uniform. When the curing temperature was low (40 ◦C), the film formed after 120 
min curing was very rough and not continuous. This is because the curing temperature is 
still lower than the glass transition temperature of the coating polymer, making it difficult 
for the movement of the polymer chains and segments of the chains. When the curing 
temperature was increased to 50 ◦C, the coating film was still not continuous with obvious 
pores and boundaries. When the curing temperature was further increased to 60 ◦C, the 
coating film became uniform and continuous.  
It could be concluded from Figure 5.11and Figure 5.12 that a continuous and uniform 
coating film could be achieved after curing for 120 min at 60 ◦C. As shown in Figure 
5.13, the coating film is quite smooth and uniform from a bigger view. 
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Figure 5.13 SEM micrographs of CA powder coated elementary ODDS 
curing for 120 min at 60 ◦C (Coating level: 3 %) 
 
Figure 5.14 SEM micrographs of cross section area of CA powder coated 
elementary ODDS curing for 120 min at 60 ◦C (Coating level: 3 %) 
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Figure 5.14 gives a SEM micrograph of cross section area of CA powder coated 
elementary ODDS with a coating level of 3 %. The thickness of the coating film is 
approximately 80 µm. Figure 5.15 and Figure 5.16 and show the pictures of CA powder 
coated elementary ODDS before and after drug release. 
 
Figure 5.15 Pictures of CA powder coated elementary ODDS curing for 120 
min at 60 ◦C (Before release; coating level: 6.8%) 
 
 
Figure 5.16 Pictures of CA powder coated elementary ODDS curing for 120 
min at 60 ◦C (After release; coating level: 6.8%) 
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5.4 Controlled release of salbutamol sulfate 
Salbutamol sulfate (SS) is widely used to treat asthma and chronic bronchitis [18]. It is 
absorbed through the gastrointestinal (GI) tract [19, 20] with an immediate release. With 
a short elimination half-life (2-4 h), it may not be effective if it is not taken several time a 
day. So there is a strong clinical need for a designed delivery system to control the release 
of salbutamol sulfate at a desirable rate over a prolonged time period. 
The release profiles of salbutamol sulfate from electrostatic dry powder coated 
elementary ODDS tablets and its factors including coating level, orifice diameter, pH 
value of dissolution media and agitation speed were studied with in vitro dissolution tests.  
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Figure 5.17 The effect of coating level on the release profiles of salbutamol 
sulfate from powder coated elementary ODDS  
(Orifice diameter: 500 µm, agitation speed: 50 r/min, pH: 7.2) 
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Powder coated elementary ODDS with different coating levels (0%, 3%, 4% and 6.8%) 
were used to investigate the effect of coating level on the drug release. As the Figure 5.17 
showed, upon the bare tablets contacting with aqueous media, drug released immediately 
and completely within 1 h. On the other hand, drug released 100% in 14 h, 80% in 24 h 
and 25% in 24 h from the tablets with a coating level of 3%, 4% and 6.8%, respectively. 
It was clearly evident that increased coating level resulted in an increase of membrane 
thickness which led to reduced water influx and decreased drug release rate. 
  
Table 5.6 Thickness of the coating film 
Coating level Thickness of tablet core, mm (SD) Thickness of coating film, mm (SD) 
3% 
3.87 (0.01) 
0.08 (0.01) 
4% 0.10 (0.01) 
6.8% 0.13 (0.02) 
 
Unlike coating level, the size of drug delivery orifice had little effect on the release 
profiles with the same coating level and same release conditions. As shown in Figure 
5.19, there is no big difference between the release profiles of salbutamol sulfate from 
electrostatic powder coated elementary ODDS. And the similarity factor f2 values 
between each drug release profiles with different orifice diameter are 80.89, 82.63 and 
81.54, all of which are bigger than 50, indicating that those drug release profiles are 
similar with each other. In other words, release of salbutamol sulfate from electrostatic 
powder coated elementary ODDS is independent with pH values of the release media. 
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Figure 5.18 Micrograph of drug delivery orifice of powder coated 
elementary ODDS with a diameter of 500 µm 
As reported in the previous literature, there was a range for the size of delivery orifice, 
which must be larger than a minimum size Amin to minimize hydrostatic pressure inside 
the osmotic system for the reason that large hydrostatic pressure may lead to the 
deformation of the ODDS, resulting in unpredictable drug delivery. Also it must be 
sufficiently smaller than a maximum size Amax to minimize the solute diffusion through 
the orifice [21]. Equations provided by Theeuwes [7] can be used to estimate the 
minimum size Amin and maximum size Amax. 
There are several methods that could be used to create the drug delivery orifice including 
mechanical drilling [11], laser drilling [22] and indentation method [14]. 
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Figure 5.19 The effect of orifice diameter on the release profiles of 
salbutamol sulfate from powder coated elementary ODDS  
(Coating level: 4%, agitation speed: 50 r/min, pH: 7.2) 
 
 
Table 5.7 Similarity factor f2 values between release profiles of salbutamol 
sulfate from CA powder coated elementary ODDS  
with different orifice diameter 
 f2 
Orifice diameter 1&2 80.89 
Orifice diameter 1&3 82.63 
Orifice diameter 2&3 81.54 
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Figure 5.20 The effect of pH value of dissolution media on the release 
profiles of salbutamol sulfate from powder coated elementary ODDS 
(Coating level: 3%, orifice diameter: 500 µm, agitation speed: 50 r/min) 
 
The difference in pH value of drug release media apparently does not contribute 
significantly to the variability in drug release properties, as samples with different pH 
value of the release media have been shown to have a similar release profile in Figure 
5.20. The similarity factor f2 values between each drug release profile with different pH 
value are 83.36, 81.83 and 78.89, all of which are bigger than 50, indicating that those 
drug release profiles are similar with each other. In other words, drug release from those 
electrostatic powder coated elementary ODDS is independent with the pH value of the 
release media. 
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Table 5.8 Similarity factor f2 values between release profiles of salbutamol 
sulfate from CA powder coated elementary ODDS with different pH values 
 f2 
pH 1.2 & pH 5.8 83.36 
pH 1.2 & pH 7.2 81.83 
pH 5.8 & pH 7.2 78.89 
 
Like the pH of drug release media, the agitation speed has little influence on the drug 
release properties (As shown in Figure 5.21). The similarity factor f2 values between each 
drug release profiles with different agitation speed are 79.02, 84.73 and 80.88, all of 
which are bigger than 50, indicating that those drug release profiles are similar. So it can 
be concluded that drug release from those electrostatic powder coated elementary ODDS 
is almost independent of the agitation speed. 
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Figure 5.21 The effect of agitation speed on the release profiles of 
salbutamol sulfate from powder coated elementary ODDS (Coating level: 
3%, orifice diameter: 500 µm, pH: 7.2) 
 
Table 5.9 Similarity factor f2 values between release profiles of salbutamol 
sulfate from CA powder coated elementary ODDS  
with different agitation speed 
 f2 
50 rpm & 100 rpm 79.02 
50 rpm & 150 rpm 84.73 
100 rpm & 150 rpm 80.88 
 
5.5 Controlled release of ibuprofen  
As an anti-inflammatory drug (NSAID), ibuprofen is widely used for treating pain, fever, 
and inflammation [23, 24] with large demand all over the world. Previous studies 
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reported that the usual therapeutic concentration of ibuprofen in human blood is around 
50 mg/L, and the toxic effect appears above 250 mg/L [25]. If the plasma concentration is 
too high, it will cause many problems such as depression of the central nervous system, 
respiratory and gastrointestinal problems and acute renal failure [25]. So many drug 
delivery systems have been developed to release ibuprofen at a controlled rate over a 
desirable time period [26]. Ozdemir and Sahin [11] designed an ODDS for the release of 
ibuprofen using organic solvent coating to achieve the semipermeable membrane. 
While in the present study, a novel electrostatic powder coating technology was applied 
to coat fine powders of cellulose acetate onto ODDS with ibuprofen to form a 
semipermeable membrane so as to achieve a controlled release of ibuprofen. 
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Figure 5.22 The effect of coating level on the release profiles of ibuprofen 
from powder coated elementary ODDS  
(Orifice diameter: 500 µm, agitation speed: 50 r/min, pH: 7.2) 
In order to investigate the effect of coating on the release of ibuprofen from electrostatic 
powder coated elementary ODDS, drug release profiles with different coating levels (0%, 
5.5%, 7.8% and 10.6%) were confirmed by dissolution tests and are shown in Figure 
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5.22. For those uncoated ODDS, ibuprofen released immediately and completely within 1 
h. On the other hand, drug released 100% in 12 h, 100% in 24 h and 50% in 24 h from the 
tablets with coating levels of 5.5%, 7.8% and 10.6%, respectively. In other words, higher 
coating level leads to a slower drug release rate, which means the release rate of 
ibuprofen from those powder coated elementary ODDS could be adjusted by changing 
the coating level of the semipermeable membrane. 
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Figure 5.23 The effect of orifice diameter on the release profiles of 
ibuprofen from powder coated elementary ODDS  
(Coating level: 7.8 %, agitation speed: 50 r/min, pH: 7.2) 
From part 4.6 we already know that the diameter of the delivery orifice has no influence 
on the release rate of salbutamol sulfate from powder coated elementary ODDS. In this 
part, ibuprofen was used as the model drug, which is water slightly soluble. Figure 5.23 
shows the effect of the orifice diameter on the release of ibuprofen from powder coated 
elementary ODDS. The overall release rate of ibuprofen from elementary ODDS with 
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different orifice diameter is the same within 24 hours. However, larger orifice diameter 
resulted in a slightly faster release rate during this period. 
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Figure 5.24 The effect of pH value on the release profiles of ibuprofen from 
powder coated elementary ODDS  
(Coating level: 7.8 %, orifice diameter: 500 µm, agitation speed: 50 r/min) 
Figure 5.24 shows that the difference in pH of release media does not contribute to the 
variability in the release of ibuprofen from powder coated elementary ODDS, which 
means that the release of ibuprofen from powder coated elementary ODDS is independent 
of the pH of the release media. 
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Figure 5.25 The effect of agitation speed on the release profiles of 
ibuprofen from powder coated elementary ODDS  
(Coating level: 4%, orifice diameter: 500 µm, pH: 7.2) 
Similar to the pH of the release media, agitation speed also had no influence on the 
release of ibuprofen from powder coated elementary ODDS, as can be seen in Figure 
5.25. Therefore, it can be predicted that the mobility of the gastrointestinal tract hardly 
affects the release of ibuprofen from powder coated elementary ODDS. 
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Table 5.10 Similarity factor f2 values between release profiles of ibuprofen 
from CA powder coated elementary ODDS 
 with different orifice diameters, pH value and agitation speed 
 f2 
Orifice diameter 1&2 77.83 
Orifice diameter 1&3 70.12 
Orifice diameter 2&3 78.24 
pH 1.2 & pH 5.8 78.63 
pH 1.2 & pH 7.2 81.79 
pH 5.8 & pH 7.2 82.68 
50 rpm & 100 rpm 84.12 
50 rpm & 150 rpm 83.91 
100 rpm & 150 rpm 79.77 
 
The similarity factor f2 values between each release profiles of ibuprofen from 
electrostatic powder coated elementary ODDS with different orifice diameters, different 
pH values and different agitation speed are bigger than 50, indicating that those release 
profiles are similar with each other. So it can be concluded that the release of ibuprofen 
from electrostatic powder coated elementary ODDS is independent of the orifice 
diameter, pH and agitation speed. 
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Figure 5.26 Relationship between drug release rate and coating level 
Drug release from electrostatic powder coated osmotic tablets was independent with the 
delivery orifice diameter and release conditions including pH of the release media and 
agitation speed, while it varied with the difference of coating level. The relationship 
between drug release rate and the coating level is shown as Figure 5.26. Compared with 
Salbutamol sulfate (SS), a higher coating level was needed for controlling the release of 
ibuprofen (IB) at a same release rate due to its low water solubility. By controlling the 
coating level, a desirable drug release period such as 12 hours (8.33 %/h) or 24 hours 
(4.167 %/h) could be achieved for both SS and IB. 
5.6 Stability of powder coated elementary ODDS 
The release profiles of salbutamol sulfate and ibuprofen from electrostatic dry powder 
coated elementary ODDS (cured at 60 ◦C for 120 min) before and after storage are shown 
in Figure 5.27 and Figure 5.28. The similarity factor f2 values are shown in Table 5.11 
and Table 5.12. 
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For salbutamol sulfate, the similarity factor f2 values are 83.19, 81.37 and 82.66 for the 
coating level of 3%, 4% and 6.8%, respectively, which are bigger than 50, indicating that 
those electrostatic dry powder coated elementary ODDS (salbutamol sulfate) with 
micronized cellulose acetate exhibited an excellent stability over 1 month at 40 ◦C /75% 
RH. 
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Figure 5.27 Release profiles of salbutamol sulfate from CA powder coated 
elementary ODDS cured at 60 ◦C, 120 min  
(*: after storage at 40 ◦C, 75% RH for 1 month) 
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Table 5.11 Similarity factor f2 values between release profiles of salbutamol 
sulfate from powder coated elementary ODDS before and after storage 
Coating level f2 
3% 83.19 
4% 81.37 
6.8% 82.66 
While for ibuprofen, the similarity factor f2 values are 84.89, 82.44 and 83.57 for the 
coating level of 5.5%, 7.8% and 10.6%, respectively, which are bigger than 50, also 
indicating an excellent stability of those electrostatic dry powder coated elementary 
ODDS (salbutamol sulfate) with micronized cellulose acetate exhibited over 1 month at 
40 ◦C /75% RH. 
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Figure 5.28 Release profiles of ibuprofen from CA powder coated 
elementary ODDS cured at 60 ◦C, 120 min  
(*: after storage at 40 ◦C, 75% RH for 1 month) 
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Table 5.12 Similarity factor f2 values between release profiles of ibuprofen 
from powder coated elementary ODDS before and after storage 
Coating level f2 
5.5% 84.89 
7.8% 82.44 
10.6% 83.57 
 
5.7 Kinetic modeling of drug release 
In order to investigate drug release kinetics from those powder coated elementary ODDS, 
the release data of both salbutamol sulfate and ibuprofen with different coating levels 
were fitted to various mathematical models including Zero-order, First-order and Higuchi 
model. The best goodness of fit test (highest R2) were taken as the criteria for selecting 
the most appropriate model. 
 
Table 5.13 Summary of the mathematical modeling on release profiles of 
salbutamol sulfate and ibuprofen from powder coated elementary ODDS 
Drug Coating level 
Mathematical models 
Zero-order First-order Higuchi 
R2 Slope R2 Slope R2 Slope 
Salbutamol 
sulfate 
3% 0.997 7.29 0.942 -0.142 0.893 28.3 
4% 0.997 3.55 0.958 -0.068 0.933 23.25 
6.8% 0.998 1.18 0.994 -0.014 0.903 5.87 
Ibuprofen 
5.5% 0.986 9.23 0.901 -0.233 0.909 32.95 
7.8% 0.993 4.46 0.937 -0.103 0.931 22.44 
10.6% 0.999 2.31 0.995 -0.011 0.918 11.91 
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As shown in Table 5.13, zero-order release model has the highest value of R2 among all 
the kinetic models applied, which means that both salbutamol sulfate and ibuprofen 
release from powder coated elementary ODDS with zero-order drug release kinetics. 
5.8 Conclusion 
In this chapter, elementary osmotic pump tablets were successfully coated using 
electrostatic powder coating with powdered cellulose acetate (CA). This novel coating 
technology utilized an electrostatic gun to spray coating powders, created an electrical 
field between the gun and the osmotic pump tablets so as to direct the movement of 
coating powders towards the tablets, leading to a better coating powder adhesion. Triethyl 
citrate (TEC) was an effective liquid plasticizer for osmotic pump tablet coating due to its 
high efficiency in reducing the glass transition temperature (Tg) of coating polymer (CA), 
thus film formation could be achieved under a relatively low temperature. Also spraying 
liquid plasticizer could increase the electrical conductivity of osmotic pump tablets so as 
to promote the coating powder adhesion through the electrostatic gun. Film formation 
could be influenced by the curing conditions such as curing time and temperature. Higher 
curing temperature and longer curing time led to a better coating film.  
Both water soluble drug (salbutamol sulfate) and water insoluble drug (ibuprofen) were 
used as the model drugs in the elementary ODDS coating. Results of dissolution tests 
indicated that the release rate of both drugs from electrostatic powder coated elementary 
ODDS varied with different coating levels while was independent with the diameter of 
delivery orifice, pH vale of the release media and the agitation speed. Results from the 
kinetic modeling on drug release from electrostatic powder coated elementary ODDS 
demonstrated that the release of both salbutamol sulfate and ibuprofen followed a zero 
order drug release kinetics. 
All the above results indicated that electrostatic powder coating is a promising alternative 
for the ODDS coating in pharma industry. Considering that those osmotic dosage forms 
currently can only be coated by organic solvent coating, this study has made a big 
breakthrough on the ODDS coating, avoiding all the limitations related to organic 
solvents. 
166 
 
Bibliography 
1. Rose, S. and J. Nelson, A continuous long term injector. Aust. J. Exp. Biol. Med. 
Sci., 1955. 33: p. 415-421. 
2. Malaterre, V., et al., Oral osmotically driven systems: 30 years of development 
and clinical use. European Journal of Pharmaceutics and Biopharmaceutics, 2009. 
73(3): p. 311-323. 
3. Herrlich, S., et al., Osmotic micropumps for drug delivery. Advanced Drug 
Delivery Reviews, 2012. 64(14): p. 1617-1627. 
4. Rose, S. and J.F. Nelson, A Continuous Long-Term Injector. Austral. J. Biol., 
1955. 33: p. 415-420. 
5. Higuchi, T., Osmotic dispenser with collapsible supply container, 1973: US 
Patent 3760805  
6. Higuchi, T. and F. Theeuwes, Osmatic dispensing device for releasing beneficial 
agent, 1974: US Patent 3845770. 
7. Theeuwes, F., Elementary Osmotic Pump. Journal of Pharmaceutical Sciences, 
1975. 64(12): p. 1987-1991. 
8. Bose, S. and R.H. Bogner, Solventless pharmaceutical coating processes: A 
review. Pharmaceutical Development and Technology, 2007. 12(2): p. 115-131. 
9. Sauer, D., et al., Dry powder coating of pharmaceuticals: A review. International 
Journal of Pharmaceutics, 2013. 457(2): p. 488-502. 
10. Luo, Y.F., et al., Dry coating, a novel coating technology for solid pharmaceutical 
dosage forms. International Journal of Pharmaceutics, 2008. 358(1-2): p. 16-22. 
11. Ozdemir, N. and J. Sahin, Design of a controlled release osmotic pump system of 
ibuprofen. International Journal of Pharmaceutics, 1997. 158(1): p. 91-97. 
12. Theeuwes, F., Saunders, R. J. and  Mefford, W. S., U. Patent, Editor 1978: US. 
13. Xie, Y.C., et al., Synchronized and controlled release of multiple components in 
silymarin achieved by the osmotic release strategy. International Journal of 
Pharmaceutics, 2013. 441(1-2): p. 111-120. 
14. Santus, G. and R.W. Baker, Osmotic Drug-Delivery - a Review of the Patent 
Literature. Journal of Controlled Release, 1995. 35(1): p. 1-21. 
167 
 
15. Liu, L.X. and B.J. Che, Preparation of monolithic osmotic pump system by 
coating the indented core tablet. European Journal of Pharmaceutics and 
Biopharmaceutics, 2006. 64(2): p. 180-184. 
16. Rowe, R.C. and S.F. Forse, The Effect of Plasticizer Type and Concentration on 
the Incidence of Bridging of Intagliations on Film-Coated Tablets. Journal of 
Pharmacy and Pharmacology, 1981. 33(3): p. 174-175. 
17. Kablitz, C.D. and N.A. Urbanetz, Characterization of the film formation of the dry 
coating process. European Journal of Pharmaceutics and Biopharmaceutics, 2007. 
67(2): p. 449-457. 
18. Sinchaipanid, N., et al., Design of salbutamol EOP tablets from pharmacokinetics 
parameters. Pharm Dev Technol, 2003. 8(2): p. 135-42. 
19. Wu, T., et al., Formulation optimization technique based on artificial neural 
network in salbutamol sulfate osmotic pump tablets. Drug Dev Ind Pharm, 2000. 
26(2): p. 211-5. 
20. Chaibva, F.A., S.M. Khamanga, and R.B. Walker, Swelling, erosion and drug 
release characteristics of salbutamol sulfate from hydroxypropyl methylcellulose-
based matrix tablets. Drug Dev Ind Pharm, 2010. 36(12): p. 1497-510. 
21. Verma, R.K., B. Mishra, and S. Garg, Osmotically controlled oral drug delivery. 
Drug Development and Industrial Pharmacy, 2000. 26(7): p. 695-708. 
22. Theeuwes, F., R.J. Saunders, and W.S. Mefford, Process for forming outlet 
passageways in pills using a laser, 1978: US Patent 4088864. 
23. The American Society of Health-System Pharmacists. Retrieved Jan 2016. 
24. Sanchez-Sanchez, A., et al., pH-responsive ordered mesoporous carbons for 
controlled ibuprofen release. Carbon, 2015. 94: p. 152-159. 
25. Flanagan, R.J., Guidelines for the interpretation of analytical toxicology results 
and unit of measurement conversion factors. Annals of Clinical Biochemistry, 
1998. 35: p. 261-267. 
26. Vallet-Regi, M., F. Balas, and D. Arcos, Mesoporous materials for drug delivery. 
Angewandte Chemie-International Edition, 2007. 46(40): p. 7548-7558. 
 
 
168 
 
6 Osmotic Controlled Release- Porosity Tablet Coating 
In the present study, a novel porosity osmotic drug delivery system was formed using an 
electrostatic powder coating technology. Coating powders containing powdered cellulose 
acetate (CA), pore forming agent and other excipients were electrostatically deposited 
onto the surface of osmotic pump tablet cores with an electrostatic spray gun, followed by 
a curing step to allow those deposited particles to coalesce and form a coating film. As a 
liquid plasticizer, triethyl citrate (TEC) was used in the coating process to reduce the 
glass transition temperature of the coating polymer (CA) and also to increase the 
electrical conductivity of the osmotic pump tablet cores, both of which led to enhanced 
powder adhesion and film formation. In the curing process, temperature and curing time 
were found to be critical factors. SEM indicated that longer curing time and/ or higher 
curing temperature resulted in more uniform and continuous coating film. The drug 
release profiles showed that drug release from those powder coated porosity ODDS was 
independent of pH of the release media and agitation speed. Modeling of the drug release 
profiles indicate that drug release from powder coated porosity ODDS followed zero-
order drug release kinetics. The drug release rate could be controlled by adjusting the 
coating level and/-or pore forming agent ratio in the coating formulation.  
6.1 Introduction 
As one of the most promising oral drug delivery systems, osmotic drug delivery system 
(ODDS) has gained tremendous attention in recent years and a significantly increasing 
number of articles and patents have been reported within this area. The original idea of 
ODDS came from Rose and Nelson in 1955 [1]. Later it was improved by Higuchi and 
Theeuwes in 1970s [2, 3]. The first practical ODDS was also developed by them, which 
was called elementary osmotic pump tablet [4], in cooperation with the Alza Corporation 
[5]. This elementary ODDS contains active agent, osmotic agent and other excipients, 
coated with an outlay semipermeable membrane. A delivery orifice is necessary to be 
drilled on the semipermeable membrane, through which the active agent is released. 
Although this simple design and easy controlled ODDS led to a quite success in the 
commercialization, it may cause irritation to the gastro-intestinal tract (GI tract) due to 
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the dose dumping resulting from non-uniform coating and high local drug concentration 
around the drug delivery orifice. 
In order to overcome this problem, a novel osmotic drug delivery system has been 
developed recently [6], which is called porosity osmotic drug delivery system (ODDS). In 
this novel system, a semipermeable membrane contains water soluble leachable pore 
forming agent. Micropores could be formed in situ immediately after the coated porosity 
ODDS is exposed to water, through which the drug release could be achieved. The dose 
dumping could be minimized or eliminated, and also the local drug concentration could 
be decreased to a safe range due to the uniform distribution of the drug release aperture 
on the semipermeable membrane. 
Drug
Osmotic agent
Micropores as drug delivery orifices
Semipermeable membrane
 
Figure 6.1 Schematic representation of porosity ODDS 
 
Presently the semipermeable membrane of the porosity ODDS is achieved by organic 
solvent coating method, involving spraying a coating solution, which is formed by adding 
coating polymers into an organic solvent, onto the surface of the porosity ODDS cores. 
The coating film is formed after the organic solvent is evaporated out of the system. 
Although this organic solvent coating could form a relatively uniform coating film, it 
does cause many problems due to the toxicity and environmental related concerns. Also 
the concentration of the coating solution cannot be too high due to the viscosity 
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limitation, leading to a low coating efficiency. In addition, the organic solvent needs to be 
vaporized in the coating process, which is energy and time consumptive and could 
increase the overall cost.  
In order to overcome the limitations of those earlier attempts, researchers from Western 
University have developed a novel electrostatic dry powder coating technology [7]. In 
this novel powder coating technology, an electrostatic spray gun is utilized to spray the 
coating powder to the surface of the solid dosage forms, followed by a curing step to 
allow deposited coating particles to coalesce and form a continuous coating film. An 
electrical field between the electrostatic gun and the grounded substrate (solid dosage 
forms) could be generated, directing the powder flow and enhancing the coating powder 
adhesion. By using this novel technology, tablets have been successfully coated with 
several commonly used coating materials to achieve immediate drug release [8], 
sustained drug release [9] and delayed drug release [10], respectively.  
The objective of the present study is to apply this electrostatic powder coating to form the 
semipermeable membrane of the porosity ODDS and to characterize the coating process 
including the coating powder adhesion and film formation and their influence factors, and 
also to make the drug release rate more controllable by adjusting the pore forming agent 
ratio in the coating formulation. 
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Figure 6.2 Schematic diagram of porosity ODDS study 
 
6.2 Materials and methods 
6.2.1 Materials 
Salbutamol sulfate was provided by Nanjing Pharmaceutical Factory (Nanjing, China). 
Cellulose Acetate was donated by the Eastman Chemical Company (Kingsport, 
Tennessee, USA). Plasdone K-29/32 was purchased from ISP technologies, INC. Sodium 
Chloride and Polyethylene Glycol 3350 (PEG 3350) were provided by EMD Chemicals 
Inc. (Gibbstown, NJ, United States). Avicel® Microcrystalline cellulose PH-102 was 
purchased from FMC Corporation (Philadelphia, Pennsylvania, United States) and 
Magnesium Stearate was purchased from Alfa Aesar (Haverhill, Massachusetts, USA). 
Placebo tablets were obtained from Patheon (Mississauga, Ontario, Canada). Triethyl 
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citrate (TEC) was purchased from Caledon Laboratories Ltd. (Georgetown, Ontario, 
Canada). Colloidal silicon dioxide (AEROSIL® 200 Pharma) was donated by Evonik 
Degussa Corporation (Essen, North Rhine-Westphalia, Germany). Talc was purchased 
from Mallinickrodt Baker Inc. (Center Valley, Pennsylvania, United States). 
6.2.2 Preparation of the osmotic pump tablets 
The component of the tablets core includes active ingredient (salbutamol sulfate), osmotic 
agent (sodium chloride and lactose), microcrystalline cellulose, PVP and magnesium 
stearate. The formulation of the osmotic pump tablets core can be seen as Table 6.1. 
 
Table 6.1 Formulation of porosity ODDS core 
Ingredient  % w/w 
MCC 53% 
Salbutamol sulfate 20% 
NaCl 20% 
PVP 6.5% 
Magnesium stearate 0.5% 
 
Those components were mixed and dry granulated using a high shear granulator 
(Mechanomill MM-20N, OKADA SEIKO Co. Ltd, Iwate, Japan) with a speed of 300 
rpm for 6 min, followed by adding magnesium stearate and mixing for another 3 min with 
same speed. The ready formulation was then compressed into tablets by using a tablet 
machine with one punch (5 mm in diameter) (Shanghai Tianxiang & Chentai 
Pharmaceutical Machinery Co. Ltd, Shanghai, China). The weight for each tablet is 
180±2 mg.   
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6.2.3 Powder coating process 
CB
D
E
A
Ground
 
Figure 6.3 Schematic diagram of the electrostatic powder coating system  
(A) Liquid plasticizer, (B) liquid plasticizer metering pump, (C) coating pan,  
(D) electrostatic spray gun, (E) powder feeder 
The coating process was performed in a laboratory scale electrostatic dry powder pan 
coater system, which includes a coating pan, an electrostatic spray gun, a powder feeder 
and a liquid spray system (atomizing nozzle and metering pump) (Figure 6.3). Osmotic 
pump tablets (20 g) and placebo tablets (60 g) were firstly loaded into the coating pan and 
preheated for a certain time period. Then liquid plasticizer was sprayed onto the surface 
of those tablets, which was immediately followed by the spraying of the coating powders 
by the electrostatic spray gun (Nordson Corporation, USA). By doing this coating powder 
adhesion was achieved, after which there was a curing step under a certain temperature, 
allowing those deposited coating particles to coalesce and form a continuous coating film. 
The flowrate of liquid plasticizer can be controlled by a liquid metering pump (Fluid 
Metering Inc., USA).  
The coating level (%) of the osmotic pump tablets could be obtained from the weight gain 
of coated tablets divided by the weight of uncoated tablets. Placebo tablets were used to 
maintain the volume of substrates and conserve osmotic pump tablets at the same time. 
The coating formulation contains cellulose acetate (CA), talc powder, nano silica and 
pigment. The formulation can be seen in Table 6.2. 
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Table 6.2 Formulation of the coating powder 
 Ingredient (% w/w) 
Formulation Cellulose acetate PEG 3350 Talc SiO2, Pigment 
A 90% 0% 
9% 0.5%, 0.5% 
B 85% 5% 
C 80% 10% 
D 75% 15% 
 
Table 6.3 Coating parameters of porosity ODDS coating process 
Tablet loading 80 g 
Charging voltage 0 kV, 20 kV, 40 kV, 60 kV, 80 kV 
Liquid plasticizer flow rate 0.5 g/min 
Liquid plasticizer spray time 0 min, 1 min, 2 min, 3 min and 4 min 
Atomizing air pressure 300-320 kPa 
Nozzle diameter 0.25 mm 
Powder feed rate 3 g/min 
Powder feed time 3 min 
Pan speed during coating (rpm) 28-32 
Pan speed during curing (rpm) 10-15 
Curing temperature 40 ◦C, 50 ◦C and 60 ◦C 
Curing time interval 0 min, 60 min and 120 min 
 
6.2.4 Scanning electron micrographs 
The surface morphology of the dry powder coated tablets with different coating 
formulations and coating parameters was observed by using a scanning electron 
microscopy (SEM, S-2600N Hitachi, Ontario, Canada). Before the observation, samples 
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were firstly sputter coated with gold for 120 s using an Emitech K550 sputter coater 
(Emitech Ltd., Ashford, UK).  
6.2.5 Dissolution tests 
The release of salbutamol sulfate from porosity ODDS before and after being coated with 
various core formulations and different coating formulations and coating parameters were 
investigated using the United States Pharmacopeia (USP) apparatus (Apparatus 2, paddle; 
Huanghai Rcz-6c2, Shanghai, China). Phosphate buffer solution with different pH value 
(1.2, 5.8 and 7.2) was chosen as the release media. The release tests with 6 tablets in 6 
vessels with 900 ml release media were performed at 37 ◦C at a certain agitation speed. 
Samples were withdrawn by using a 10 ml syringe from each vessel at predetermined 
time intervals, followed by the injection with the same volume of fresh medium into the 
vessels. Then those samples were assayed using an 8453 UV–Visible Spectrophotometer 
(Agilent Technologies, Mississauga, Canada) at a wavelength of 276 nm for salbutamol 
sulfate. 
6.2.6 Stability test 
Electrostatic dry powder coated porosity ODDS (cured at 60◦C for 120 minutes) were 
placed in HDPE vials (75 mL) and sealed with aluminum film and then were stored at 40 
◦C /75% RH for 1 month. Dissolution tests of those porosity ODDS before and after 
storage were carried out. 
6.2.7 Statistical analysis  
Similar with previous chapters, mean ± Standard Deviation (S.D.) values were also used 
to express the experimental results in this chapter. And the “similarity factor” f2 was not 
only used to compare the drug release profiles before and after storage in the stability 
tests, but also was used to compare the drug release profiles with different release 
conditions such as pH values of the release media and agitation speed. The value of f2 is 
between 0 to 100, if f2 is larger than 50 (between 50 to 100), these two release profiles 
were considered to be similar. If f2 is close to 100, the two release profiles were 
considered as identical. 
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The following equation could be used to calculate the value of “similarity factor” f2. 
 

















 100
1
1log50
5.0
1
2
2
n
t
tt TR
n
f    (6.1) 
In this equation, n is the total number of sampling times, Rt and Tt is the accumulated 
drug release percentage at time point t for the reference and test products, respectively.  
6.3 Coating powder adhesion 
From chapter 5 we know that by spraying a certain amount of liquid plasticizer (TEC) 
onto the surface of the osmotic pump tablets, the electrical resistivity of those tablets 
could be reduced from 1×1015 Ωm to below 1×109 Ωm, which is suitable for the 
electrostatic spray process [11].  
In a powder coating process, in order to form a continuous and uniform coating film, 
enough coating powders should be firstly deposited onto the surface of the substrate. In 
the present study, the powder adhesion rate was the weight gain of the tablets after the 
coating powder spraying process divided by the total weight of the sprayed coating 
powders.  
Powder adhesion rate=weight gain of the tablets/total weight of sprayed powders*100% 
In the electrostatic powder coating process, the powder adhesion rate could be influenced 
by many factors, among which, charging voltage of the electrostatic spray gun and liquid 
plasticizers are the most critical ones.  
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Table 6.4 The effect of charging voltage on the coating powder adhesion 
rate (liquid plasticizer: 0.5 g/min for 3 min) 
Charging voltage (kV) Powder adhesion rate (%) 
0 57.38 
20 81.82 
40 88.78 
60 91.73 
80 90.18 
The influence of charging voltage of the electrostatic spray gun on the powder adhesion 
rate is shown in Table 6.4. When the charging voltage was 0, the powder adhesion rate 
was 57.38 %, which was contributed by the spraying of the liquid plasticizer [10, 12]. 
When increasing the charging voltage from 0 to 60 kV, the powder adhesion rate 
increased to around 91.73 %, indicating that the coating powder adhesion was enhanced 
by the electrical field between the tip of the electrostatic gun and the coating pan. Further 
increasing of the charging voltage to 80 kV slightly reduced the powder adhesion rate to 
90.18%. This is because the higher charging voltage could cause an increased cumulative 
charge of the coating layer and back ionization, which could reduce the powder 
deposition. 
It could be concluded from these results that the charging voltage could be optimized as 
60 kV in the coating process.  
Besides the charging voltage of the electrostatic gun, liquid plasticizer could also play a 
significant role to produce a good powder adhesion so as to achieve continuous and 
uniform coating film.  As shown in Table 6.5, without liquid plasticizer, the powder 
adhesion rate was less than 34.81% with a charging voltage of 60 kV. By increasing the 
liquid plasticizer spraying time from 0 to 3 min, the powder adhesion rate was 
dramatically increased to around 91.73 %. This could be explained by the capillary force 
between coating powders and the surface of those dosage forms caused by the liquid 
plasticizers [8, 11, 13]. Although further increase of the spraying time of liquid plasticizer 
(4 min) led to an increase of the powder adhesion rate, surplus liquid plasticizer caused 
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sticky film. So the spraying time of the liquid plasticizer (TEC) in this present study 
could be optimized to 3 min with a flowrate of 0.5 g/min. 
 
Table 6.5 The effect of liquid plasticizer on the coating powder adhesion 
rate (Charging voltage: 60 kV) 
Liquid plasticizer spray time (min, 0.5 g/min) Powder adhesion rate (%) 
0 34.81 
1 64.44 
2 79.99 
3 91.73 
4 92.49 
 
6.4 Surface morphology of the coating film 
In the electrostatic powder coating process, the film formation comes from the 
deformation and viscous flow of deposited polymer particles at the temperature higher 
than the glass transition temperature (Tg) of the polymer [11]. Consequently, it is critical 
to have a curing step after the powder adhesion for the deposited polymer particles to 
coalesce together to form a continuous and uniform coating film. And in this curing 
process, temperature and time play a significant role in turning the deposited particles 
into coating film. Scanning electron micrographs (SEM) was used to observe the surface 
morphology of the coating film formed at different curing temperature with different 
curing time periods. 
As shown in Figure 6.4, a better coating film could be achieved with a longer curing time, 
allowing the deposited coating particles to coalesce and form a better and smoother 
coating film. The deposited particles could be clearly seen before the curing step was 
started (Figure 6.4-A), which was disappeared gradually after cured for 60 min (Figure 
6.4-B). After being cured for 120 min, most of those particles disappeared and a 
continuous and uniform coating film was achieved (Figure 6.4-C). 
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Figure 6.4 SEM micrographs of CA powder coated ODDS curing at 60◦C for 
different time intervals: (A) 0 min, (B) 60 min, (C) 120 min 
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The effect of curing temperatue on the film formation could be seen in Figure 6.5. The 
curing time for all the three SEM pictures were same (120 min). It could be concluded 
from this figure that higher curing temperature led to a more uniform coating film.  
 
Figure 6.5 SEM micrographs of CA powder coated ODDS curing for 120 min 
at different temperatures: (A) 40 ◦C, (B) 50 ◦C, (C) 60 ◦C 
 
6.5 In vitro drug release 
Drug release from porosity ODDS is controlled by various factors such as osmotic 
pressure, coating thickness, pore forming agents in the core formulation, permeability of 
the coating film and solubility of drug [14]. The release profiles of salbutamol sulfate 
from electrostatic dry powder coated porosity ODDS and its factors including coating 
level, osmotic agent ratio in the core formulation, permeability of the coating film, pH 
value of dissolution media and agitation speed were studied with in vitro dissolution tests. 
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The thicknesses of the coating film with different coating levels were measured by using 
a digital vernier caliper, and the result is shown in Table 6.6.  
Table 6.6 Thickness of the coating film 
Coating level Thickness of tablet core, mm (SD) Thickness of coating film, mm (SD) 
3.2% 
3.87 (0.01) 
0.07 (0.01) 
4% 0.10 (0.01) 
6.3% 0.13 (0.02) 
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Figure 6.6 Effect of coating level on release of salbutamol sulfate from 
electrostatic powder coated porosity ODDS  
(Agitation speed: 50 r/min, pH: 7.2, pore former ratio: 10 %) 
As shown in Figure 6.6, coating level (thickness of coating film) has a big impact on the 
release rate of salbutamol sulfate from powder coated porosity ODDS. Drug release from 
uncoated ODDS completed within 1 hour. Increase in the coating level resulted in 
decrease of release rate of salbutamol sulfate. For the coating level of 3.2 %, drug release 
was completed within 14 hours. When the coating level was increased to 4 %, the release 
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of salbutamol sulfate was finished with 24 hours. When further increasing the coating 
level to 6.3 %, only 70 % drug was released within 24 hours. The slower drug release rate 
with higher coating level could be explained by the reduced water influx owing to the 
thicker coating film. 
Besides the thickness of coating film, the permeability of the coating film could also have 
a big influence on the drug release rate from powder coated porosity ODDS. In order to 
assess this effect, ODDS were coated with coating formulations containing different pore 
former ratio. Drug release profiles from those coated porosity ODDS are shown as Figure 
6.7. When there was no pore former in the coating formulation, the release of salbutamol 
sulfate completed within 10 hours and there was burst release around 4 hours, indicating 
that the coating film was broken at that moment. This is because the coating film cannot 
withstand both the hydrostatic pressure and osmotic pressure caused by the water influx 
inside the tablet core, leading to a film crack. When the pore former was added into the 
coating formulation, the release of salbutamol sulfate from powder coated porosity 
ODDS was well controlled. With the increase of the pore former ratio in the coating 
formulation, the drug release became faster. As shown in Figure 6.7, when the pore 
former ratio was 5 %, drug released only 55.31 % within 24 hours. After increasing the 
pore former ratio to 10 % and 15 %, drug release completed within 24 hours and 12 
hours, respectively. 
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Figure 6.7 The effect of pore former ratio in the coating formulation on the 
release of salbutamol sulfate from electrostatic powder coated porosity 
ODDS (Coating level: 4%; agitation speed: 50 r/min, pH: 7.2) 
From results above, the release of salbutamol sulfate from powder coated porosity ODDS 
could be controlled within 24 hours with a coating level of 4 % and 10 % pore former in 
the coating formulation. 
Figure 6.8 shows the SEM micrographs of CA powder coated porosity ODDS before and 
after drug release with different pore former ratio in the coating formulation. Before drug 
release, a continuous and uniform coating film was observed under SEM, while after the 
drug completely released from the ODDS, micropores with a uniform distribution could 
be seen clearly on the surface of the coating film. The increase of pore former ratio in the 
coating formulation led to an increase of the micropores. 
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Figure 6.8 SEM micrographs of CA powder coated porosity ODDS before 
and after drug release with different pore former ratio  
(A: before drug release, B: 5%, C: 10%, D: 15%) 
 
The effect of pH value of the release media and agitation speed on the drug release from 
powder coated porosity ODDS was also investigated, which are shown in Figure 6.9 and 
Figure 6.10. Also the similarity factor f2 values between each pH value and agitation 
condition are shown in Table 6.7 and Table 6.8. There is no large difference between 
drug release profiles with different pH value of release media and agitation speed and 
also the similarity factor f2 values are all larger than 50, indicating that the release of 
salbutamol sulfate from electrostatic powder coated porosity ODDS is independent of the 
pH of the release media and agitation speed. 
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Figure 6.9 Effect of pH of dissolution media on release of salbutamol 
sulfate from electrostatic powder coated porosity ODDS (Coating level: 4%, 
agitation speed: 50 r/min, pore former ratio: 10 %) 
 
Table 6.7 Similarity factor f2 values between release profiles of salbutamol 
sulfate from CA powder coated porosity ODDS with different pH values 
 f2 
pH 1.2 & pH 5.8 80.44 
pH 1.2 & pH 7.2 82.92 
pH 5.8 & pH 7.2 84.84 
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Figure 6.10 Effect of agitation speed on release of salbutamol sulfate from 
electrostatic powder coated porosity ODDS  
(Coating level: 4%, pH value: 7.2, pore former ratio: 10 %) 
 
Table 6.8 Similarity factor f2 values between release profiles  
of salbutamol sulfate from CA powder coated porosity ODDS  
with different agitation speed 
 f2 
50 rpm & 100 rpm 82.22 
50 rpm & 150 rpm 84.24 
100 rpm & 150 rpm 79.94 
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6.6 Stability of powder coated porosity ODDS 
The release profiles of salbutamol sulfate from electrostatic dry powder coated porosity 
ODDS (cured at 60◦C for 120 min) before and after storage are shown in Figure 6.11. The 
similarity factor f2 values are shown in Table 6.9. The similarity factor f2 values are 83.1, 
81.33 and 78.67 for the coating level of 3.2 %, 4% and 6.3%, respectively. All the three 
values are bigger than 50, indicating that those electrostatic dry powder coated porosity 
ODDS with cellulose acetate exhibited an excellent stability over 1 month at 40◦C /75% 
RH. 
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Figure 6.11 Release profiles of salbutamol sulfate  
from CA powder coated porosity ODDS cured at 60 ◦C, 120 min  
(*: after storage at 40 ◦C, 75% RH for 1 month) 
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Table 6.9 Similarity factor f2 values between release profiles of salbutamol 
sulfate from powder coated porosity ODDS before and after storage 
Coating level f2 
3.2 % 83.1 
4% 81.33 
6.3% 78.67 
 
6.7 Mathematical modeling of drug release profiles 
In order to investigate the release kinetics of salbutamol sulfate from those powder coated 
porosity ODDS, drug release data with different coating levels were fitted to various 
mathematical models including Zero-order, First-order and Higuchi model. The best 
goodness of fit test (R2) were taken as criteria for selecting the most appropriate model 
[15]. As shown in Table 6.10, the value of R2 of Zero-order release model was found to 
be highest among all the kinetic models applied, which means the release of salbutamol 
sulfate from powder coated porosity ODDS is zero-order drug release kinetics. 
 
Table 6.10 Summary of the mathematical modeling of release profiles of 
salbutamol sulfate from powder coated porosity ODDS 
Coating levels 
Mathematical models 
Zero-order First-order Higuchi 
R2 Slope R2 Slope R2 Slope 
3.2 % 0.994 7.7 0.890 -0.194 0.907 30.15 
4% 0.984 4.54 0.932 -0.113 0.933 23.25 
6.3% 0.994 3.04 0.982 -0.048 0.909 15.29 
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6.8 Conclusion 
In this chapter, porosity osmotic drug delivery systems were successfully formed using a 
novel electrostatic dry powder coating technology. Coating powders containing 
micronized cellulose acetate (CA) and pore former (PEG 3350) were electrostatically 
deposited onto the surface of the ODDS cores with an electrostatic spray gun and 
coalesced to a continuous coating film with a curing step. Liquid plasticizer played a key 
in the coating process by reducing the glass transition temperature of the coating polymer 
(CA) and also increasing the electrical conductivity of the ODDS cores, both of which 
could enhance the coating powder adhesion and promote the film formation. Curing 
temperature and time also had a big impact on the film formation. Higher curing 
temperature and longer curing time led to more uniform and continuous coating film. 
Results of dissolution tests indicated that drug release rate from electrostatic powder 
coated porosity ODDS varied with different coating levels and different pore former ratio 
in the coating formulation while it was independent with the pH vale of the release media 
and the agitation speed. Drug release data with different coating levels were fitted with 
different mathematical models including zero-order, first-order and Higuchi model. The 
results indicated that zero order model gave the highest R2, which means the release of 
salbutamol sulfate from those powder coated porosity ODDS followed a zero-order drug 
release kinetics. 
Based on those results, it can be concluded that porosity ODDS could be successfully 
formed using electrostatic powder coating technology, eliminating limitations caused by 
the organic solvent and water such as high energy consumption, long processing time and 
health and environment related concerns.  
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7 In-Depth Characterization of Powder Coating Process 
In the previous chapters, a novel electrostatic powder coating technology has been 
applied to coat solid dosage forms such as tablets and pellets as well as osmotic drug 
delivery systems (ODDS) to modify drug release profiles. The present study aims to 
provide a fully and more in-depth characterization on the electrostatic powder coating 
process, providing a general discussion on the influence factors. Two main steps are 
included in the coating process, coating powder adhesion and film formation. Using 
elementary osmotic pump tablet coating and pellet coating as examples, this study 
illustrated these two procedures and their influence factors including preheating, charging 
voltage, liquid plasticizers, particle size of coating powders, curing temperature and 
curing time. Also this study provided a screening method to choose liquid plasticizer for 
different coating materials. 
7.1 Brief introduction  
Emerged from sugar coating, pharmaceutical coating process has generally been 
transformed from solvent coating, which is based on the solution of coating materials in 
an organic solvent, to an environmental friendly aqueous coating process. Organic 
solvents are toxic and flammable, causing toxicity and environmental related issues. Also 
the concentration of coating solution cannot be too high due to the viscosity limit, 
otherwise it may block the spray nozzle. As a result, it takes a very long processing time 
to achieve a thick coating film. In addition, the whole process needs a large amount of 
organic solvents and the after-treatment and recovery of the organic solvent are very 
expensive, which could significantly increase the overall cost. 
Although aqueous coating can avoid theses disadvantages and begins to dominate the 
pharmaceutical coating area, it still possesses many limitations. Firstly, evaporation of 
water is energy and time consumptive, dramatically increasing the overall cost. Also for 
the coating materials with high glass transition temperature, aqueous coating cannot be 
applied because it is very difficult to form a film under a relatively low temperature.  
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In order to overcome those limitations, many dry coating methods [1-5] have been 
developed recently including compression coating [6-9], hot-melt coating [10-15], 
supercritical fluid coating [16, 17], photocuring coating [18, 19] and dry powder coating 
[20-26]. 
The novel electrostatic powder coating technology developed by Zhu’s group [27-31] has 
been able to differentiate itself from other counterparts owing to its simpler coating 
apparatus that can be easily adapted from the present apparatus such as pan coater 
systems for liquid coating. By applying this novel electrostatic powder coating 
technology, several coating formulations have been developed for tablet coating to 
achieve immediate release [30], sustained release [31] and delayed release [32]. Also it 
has been extended to coat novel dosage forms such as osmotic drug delivery systems 
(ODDS) including elementary ODDS and porosity ODDS. Small solid dosage forms such 
as pellets [27] also have been successfully coated by using this powder technology. 
However, there are still some fundamental details in the electrostatic powder coating 
process which remain unclear. For example, PEG 400 is widely used as the plasticizer for 
cellulose acetate in liquid coating. However, it is not efficient when being used in this 
powder coating process. Hence it is necessary to find a screening method for liquid 
plasticizer, which is critical for this electrostatic powder coating. A full understanding on 
the whole coating process could provide a better control to the whole electrostatic powder 
coating process, bringing many benefits to the industrial applications and prospective 
research in the future. Consequently, this chapter focused on the illustration and in-depth 
characterization of the electrostatic powder coating process, including coating powder 
adhesion and film formation mechanism and their influence factors.  
7.2 Materials and methods 
7.2.1 Materials 
Piroxicam pellets with a particle size of 0.9 mm-1.18 mm were provided Gaocheng 
Biotech& Health CO., LTD. Salbutamol sulfate was provided by Nanjing Pharmaceutical 
Factory (Nanjing, China). Cellulose Acetate was donated by the Eastman Chemical 
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Company (Kingsport, Tennessee, USA). Plasdone K-29/32 was purchased from ISP 
technologies, INC. Eudragit® EPO, Eudragit® RS/RL and Colloidal silicon dioxide 
(AEROSIL® 200 Pharma) were donated by Evonik Degussa Corporation (Essen, North 
Rhine-Westphalia, Germany). Acryl EZE was provided by Colorcon, Inc. (US). Talc 
powder was purchased from Mallinickrodt Baker Inc. (Canada). Plasdone K-29/32 was 
purchased from ISP technologies, INC. Sodium Chloride and Polyethylene Glycol 400 
(PEG 400) were provided by EMD Chemicals Inc. (Gibbstown, NJ, United States). 
Avicel® Microcrystalline cellulose PH-102 was purchased from FMC Corporation 
(Philadelphia, Pennsylvania, United States) and Magnesium Stearate was purchased from 
Alfa Aesar (Haverhill, Massachusetts, USA). Placebo tablets were obtained from Patheon 
(Mississauga, Ontario, Canada). Glycerol and triethyl citrate (TEC) were obtained from 
Caledon Laboratories Ltd. (Georgetown, Ontario, Canada). Talc was purchased from 
Mallinickrodt Baker Inc. (Center Valley, Pennsylvania, United States). 
7.2.2 Particle size reduction and analysis 
Before the coating process, the particle size of the coating materials was firstly reduced 
by using a blade grind mill and then it was investigated by a particle size analyzer (TSI 
Corporation, Model 3603, Shoreview, MN, USA). The average particle size in this study 
is the size at 50 % of total weight fraction, which is given by Table 7.1. 
Table 7.1 Average particle size of the coating materials 
Coating materials Average particle size (µm) 
Cellulose acetate 26.7 
Eudragit® EPO 23.3 
Eudragit® RS 48.7 
Eudragit® RL 39.7 
Acryl EZE 20.8 
Talc powder 28.9 
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7.2.3 Preparation of the osmotic pump tablets 
Table 7.2 shows the formulation of the osmotic tablet core, including drug (salbutamol 
sulfate), osmotic agent (sodium chloride), microcrystalline cellulose, PVP and 
magnesium stearate.  
Table 7.2 Formulation of osmotic pump tablets core 
Ingredient % w/w 
Salbutamol sulfate 20% 
Sodium chloride 30% 
Microcrystalline cellulose PH102 43% 
PVP 6.5% 
Magnesium stearate 0.5% 
Those components were mixed using a granulator (Mechanomill MM-20N, OKADA 
SEIKO Co. Ltd, Iwate, Japan) with a speed of 300 rpm for 6 min, followed by adding 
magnesium stearate and mixing for another 3 min with same speed. The ready 
formulation was then compressed into tablets by using a tablet machine with one punch 
(Shanghai Tianxiang & Chentai Pharmaceutical Machinery Co. Ltd, Shanghai, China).  
7.2.4 Contact angle measurements 
The contact angles of the liquid plasticizers (Glycerol, TEC and PEG 400) on the osmotic 
pump tablet cores and compacts of coating powders (CA) were determined by the sessile 
drop method. In order to measure the contact angle of liquid plasticizer on the compact of 
the coating powders, those coating powders were firstly compressed into flat-faced 
compacts with a hardness of 6.0 N at a same compression force using a single punch 
tablet machine (First Pharmacy Machine, Shanghai, China). When measuring the contact 
angle, samples were firstly placed on an adjustable platform and then the droplets of 
liquid plasticizers were dropped on the surface with a micrometer syringe. The contact 
angle was determined by measuring the tangent to the curve of the droplet on the surface 
of the sample (n=6). 
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7.2.5 Electrostatic powder coating process 
The electrostatic powder coating process was performed in a laboratory scale pan coating 
system, which consists a rotatory coating pan, a powder feeder, an electrostatic spray gun 
(Nordson Corporation, USA) and liquid plasticizer spray system. After being loaded into 
the coating pan, tablets (60 g osmotic pump tablets) or pellets (60 g piroxicam pellets) 
were preheated for 10 min at a certain temperature. Then a certain amount of liquid 
plasticizer (TEC or PEG 400) was sprayed onto the surface of the solid dosage forms, 
immediately followed by the spray of coating powders by the electrostatic spray gun to 
achieve coating powder adhesion. The process of loading liquid plasticizer and coating 
powder can be repeated several times to obtain a higher coating level. After finishing the 
coating powder adhesion, keep the temperature of the coating pan for a certain period of 
time to allow deposited coating particles to coalesce and form a uniform coating film. 
A
C
D
Ground
B
 
Figure 7.1 Schematic of the electrostatic powder coating system  
(A) liquid plasticizer spray system, (B) coating pan,  
(C) electrostatic spray gun, (D) powder feeder 
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Table 7.3 Coating powder formulations 
Ingredients 
Formulation (w/w, %) 
A B C D 
Eudragit® EPO 20 0 0 0 
Eudragit® RS 0 40 0 0 
Eudragit® RL 0 40 0 0 
Acryl EZE 0 0 80 0 
Cellulose acetate 0 0 0 80 
Talc powder 79 19 19 19 
Pigment 0.5 0.5 0.5 0.5 
SiO2 (Nano) 0.5 0.5 0.5 0.5 
 
7.2.6 Scanning electron micrographs 
Scanning electron microscopy (SEM) was used to observe the coating film achieved by 
the electrostatic powder coating process. Samples were firstly sputter coated with gold for 
120 s using Emitech K550 sputter coater (Emitech Ltd., Ashford, UK) and then they were 
observed with a scanning electron microscope at 5.0 kV (S-2600N Hitachi, Ontario, 
Canada). 
7.2.7 Dissolution test 
Drug dissolution tests were performed by following the United States Pharmacopeia 
(USP) apparatus (Apparatus 2, paddle; Huanghai Rcz-6c2, Shanghai, China). For osmotic 
pump tablets, the release media was 900 mL of pH 7.2 phosphate buffer solution. By 
using a 10 mL syringe, samples were withdrawn and filtered (refilled with the same 
amount of fresh release medium) at predetermined intervals and assayed using an 8453 
UV-Visible Spectrophotometer (Agilent Technologies, Mississauga, Canada) at a 
wavelength of 276 nm. For pellets, the release media were 900 mL of 0.1N HCl solution 
for Eudragit® EPO coated pellets and 900 mL of pH 7.2 phosphate buffer solution for 
198 
 
Eudragit® RS/RL coated pellets. For Acryl EZE coated pellets, the release media were 
750 mL of 0.1N HCl solution for the first 2 hours and then pH 6.8 phosphate buffer 
solution by adding 250 mL of 0.2 M tribasic sodium phosphate solution for additional 2 
hours. At predetermined intervals, samples were withdrawn by a 10 mL syringe and 
followed by refills with the same amount of fresh release medium. After being filtered, 
samples were assayed using an 8453 UV-Visible Spectrophotometer (Agilent 
Technologies, Mississauga, Canada) at a wavelength of 334 nm, 354 nm and 353 nm at 
pH 1.2 HCl solution (0.1N), pH 7.2 phosphate buffer solution and pH 6.8 phosphate 
buffer solution, respectively. 
7.3 Coating powder adhesion and influence factors 
For dry powder coating, in order to achieve a continuous and uniform coating film, 
coating powders need to be firstly deposited onto the surface of the solid dosage forms 
with a uniform distribution. There should be enough binding force between the coating 
particles and the surface of the solid dosage form so that those particles could be held 
firmly and then turned into a coating film after coalescing. However, extra energy needs 
to be provided in order to bind the coating particles and the solid dosage forms together. 
Basically in the earlier attempts [21, 23, 33] of powder coating technology, heating and 
liquid plasticizer are normally used to enhance the coating powder adhesion.  
The extra-benefit that an electrostatic powder coating method could bring is better 
powder adhesion due to the better controlling of coating powder spraying by using an 
electrostatic spray gun. In the electrostatic powder coating process developed by Zhu’s 
group, the coating powder adhesion is enhanced by the combination of preheating, liquid 
plasticizers and electrostatic spray gun, which could be confirmed by the following 
results. The coating powder adhesion rate could be calculated according to the following 
equation. 
Powder adhesion rate=
Tablet weight gain after spraying of coating powder
Total weight of the sprayed coating powders
*100%
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7.3.1 Preheating 
In the electrostatic powder coating process, loaded solid dosage forms are firstly 
preheated to a certain temperature. This would increase the surface temperature of the 
solid dosage forms to a predetermined value, enhancing the deposition of the coating 
powders. Figure 7.2 shows the influence of preheating time on the coating powder 
adhesion rate during the pellet coating process. The weight of loaded pellets was 60g, the 
predetermined temperature is 60 ◦C. The liquid plasticizers were PEG 400 and TEC with 
a flowrate of 0.5 g/min for 2 min. The charging voltage of the electrostatic gun was 60 
kV. Without preheating, the powder adhesion rates for all the three coating formulations 
were very low (below 80 %). After preheating the uncoated pellets for 5 and 10 min, the 
powder adhesion rate was significantly increased to more than 90 %. This is because the 
surface temperature of the pellets increased, leading to a promoted coating particle 
deposition. Further increasing the preheating time to 15 min and 20 min led to a slight 
increase of the powder adhesion rate. Table 7.4 shows the relationship between the 
surface temperature of the pellets and the preheating time. The surface temperature of 
those loaded pellets reached 50 ◦C after being preheated for 10 min, indicating that 50 ◦C 
is a suitable temperature for the pellet coating process with these three coating 
formulations containing Eudragit® EPO, Eudragit® RS/RL and Acryl EZE. 
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Figure 7.2 The influence of preheating time on the powder adhesion rate 
during the pellet coating (Pellet loading: 60 g, plasticizer: 0.5 g/min for 2 
min, charging voltage: 60 kV) 
 
Table 7.4 The relationship between the preheating time and the surface 
temperature of pellets 
Preheating time (min) Surface temperature of the pellets (◦C) 
0 25 
5 43 
10 50 
15 56 
20 60 
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7.3.2 Charging voltage of the electrostatic gun 
In powder coating, coating powders are fed into the coating pan by using an electrostatic 
spray gun, by which an electrical field could be created between the gun and the 
grounded stainless steel coating pan, significantly promoting the movement of those 
negatively charged coating particles towards to the surface of the solid dosage forms in 
the pan. However, for this to occur, there is a prerequisite that those solid dosage forms 
must possess enough electrical conductivity, because for more conductive cores, the 
negative charge of the deposited particles will dissipate quickly due to grounding, 
allowing additional layers of coating powder to deposit onto the surface of the dosage 
forms. On the other hand, if the dosage forms are less conductive, the electrical charge 
tends to build up on the surface so as to impede further particle deposition [30]. However, 
most pharmaceutical dosage forms have low electrical conductivity due to containing the 
excipients with high electrical resistivity [4]. Fortunately, liquid plasticizer could be used 
to increase the electrical conductivity of the solid dosage forms during the coating 
process.  
While after ensuring the satisfactory requirements of electrical conductivity of the dosage 
forms, charging voltage turns out to be a big impact factor that affects the coating powder 
adhesion rate during the coating process. The influence of charging voltage on the coating 
powder adhesion rate in the pellet coating is shown in Figure 7.3. When the charging 
voltage was increased from 0 to 60 kV, coating powder adhesion rates for those three 
different coating formulations dramatically increased from around 70 % to larger than 
90%. While further increasing the charging voltage to 70 kV, the coating powder 
adhesion rates didn’t increase any more. As discussed before, the coating powder 
adhesion obtained at 0 V reflected the particle deposition caused by sprayed liquid 
plasticizer. Spraying a certain amount of liquid plasticizer onto the surface of the tablets 
could wet the dosage surface, generating capillary force between the interface of liquid 
plasticizer and the coating powders so as to enhance the coating powder adhesion. A 
higher coating powder adhesion rate obtained with increasing the charging voltage to 60 
kV indicates that the coating powder adhesion was enhanced by the electrostatic force 
generated by the electrical field between the tip of the electrostatic gun and the coating 
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pan. However, the powder adhesion rate was not increased when further increasing the 
charging voltage to 70 kV. This can be explained by the increased cumulative charge of 
the coating layer and back ionization caused by the higher charging voltage, which could 
reduce the powder deposition. 
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Figure 7.3 Influence of charging voltage of electrostatic gun on the powder 
adhesion rate during the pellet coating process (Pellet loading: 60 g, 
temperature: 50 ◦C, plasticizer: 0.5 g/min for 2 min) 
 
7.3.3 Liquid plasticizer 
Based on the results of previous chapters it could be concluded that liquid plasticizer 
plays a significant role in the electrostatic powder coating process. It can not only reduce 
the electrical resistivity of the dosage form surface, but also could wet the surface of the 
solid dosage forms and produce capillary force between the interface of liquid plasticizer 
and coating powders so as to enhance the coating powder adhesion. Most importantly, 
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spraying a certain amount of liquid plasticizer could dramatically reduce the glass 
transition temperature of the coating materials so as to minimize the coating temperature, 
protecting the drug from burning by high temperatures. For example, TEC and PEG 400 
are effective plasticizers for cellulose acetate and Acryl EZE, respectively.  
As shown in Figure 7.4, spraying TEC onto the surface of the ODDS forms could 
significantly increase the coating powder adhesion rate. But the situations were totally 
different for the other two plasticizers (PEG 400 and Glycerol). After spraying PEG 400 
and glycerol for 2 min, there was just a slightly increase of the coating powder adhesion 
rate from less than 20 % to 53 % and 32 %, respectively, which were much smaller than 
the increase caused by spraying of TEC (more than 90 %). 
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Figure 7.4 Influence of liquid plasticizers on the powder adhesion rate 
during the elementary ODDS coating process (tablets loading: 60 g, 
temperature: 60 ◦C, plasticizer: 0.5 g/min for 3 min, charging voltage: 60 kV) 
This difference could be confirmed by the SEM micrographs. Figure 7.5 shows the SEM 
micrographs of CA powder coated ODDS with different plasticizers, TEC, PEG 400 and 
Glycerol, both without curing and after being cured for 120 min at 60 ◦C. For those CA 
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powder coated ODDS without curing (Figure 7.5, part 1), the tablets were taken out 
immediately after the coating powder adhesion and observed with SEM. When the 
plasticizers were glycerol and PEG 400, the deposited coating particles are clearly there 
on the surface of the dosage forms without any coalesce and film formation. On the other 
hand, for TEC, there were already some coalesce and some the deposited coating particles 
disappeared. This could be explained by the quick film formation caused by the 
preheating and spraying liquid plasticizer. After 120 min curing step, the situation didn’t 
change too much for the first two plasticizers (glycerol and PEG 400). Deposited coating 
particles were still there and became even less. This might be caused by the tumbling of 
the coating, reducing the number of the deposited coating particles from the surface of the 
dosage forms. However, for TEC, a continuous and uniform coating film has been formed 
after 120 min curing. All the above results indicated that TEC is the effective plasticizer 
for the coating of ODDS forms with cellulose acetate. 
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Figure 7.5 SEM micrographs of CA powder coated ODDS with different 
plasticizers A: Glycerol, B: PEG 400, C: TEC  
(1: without curing, 2: after curing for 120 min at 60 ◦C) 
The plasticizers used in the pharmaceutical coating are usually small compounds with 
low molecular weights and functional groups that can interact with the coating polymers 
so as to decrease the intermolecular cohesive forces between polymer chains. As a result, 
the polymer segmental mobility and free volume could be increased, and the glass 
transition temperature of the polymer could be reduced [34]. To be effective, one 
plasticizer must be compatible with the coating polymer [34, 35]. Several methods could 
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be used to predict plasticizer-polymer compatibility including glass transition temperature 
(Tg) measurement by DSC and testing the mechanical properties of the plasticized 
polymer film. 
While for powder coating, the situation is different. Taking the cellulose acetate for 
example, PEG 400 is a widely used plasticizer for ODDS coating with cellulose acetate. 
But the above results confirmed that PEG 400 was not efficient in powder coating for 
cellulose acetate.  
Those previous results suggested that coating powder adhesion is the key to achieve an 
acceptable coating film. A suitable liquid plasticizer in powder coating not only could 
reduce the glass transition temperature of the coating polymer, but also should be able to 
enhance the coating powder adhesion. Consequently, the spreading behavior of a liquid 
plasticizer on the surface of the dosage forms becomes critical. 
Contact angles can provide information regarding the interactions between the surface of 
the tablet core and the liquid plasticizers (i.e. spreading behavior and wettability) [32], 
also the interactions between the coating powders and the liquid plasticizers (i.e. 
compatibility) [34, 35].  
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Figure 7.6 Contact angles of different liquid plasticizers  
on the osmotic tablet cores and coating powder compacts 
The spreading behavior of these three liquid plasticizers on both the surfaces of tablet 
core and coating powder compact was investigated by measuring the contact angle. As 
illustrated in Figure 7.6, TEC showed the lowest contact angles on both surfaces of the 
tablet core (23o ± 1.6 o, n = 6) and the coating powder compacts (14 o ± 1.7 o, n = 6). PEG 
400 showed significant increase in the contact angles on both surfaces of tablet cores (33 o 
± 2.1 o) and compacts of coating powders (26 o ± 2.3 o), indicating that PEG 400 had less 
affinity to both surfaces of tablet cores and coating powders than TEC. Compared to the 
first two plasticizers, glycerol has the highest contact angles on both surfaces of the tablet 
core (45 o ± 2.4 o, n = 6) and the coating powder compacts (35 o ± 2.1 o, n = 6), suggesting 
that glycerol has the least affinity to both surfaces of tablet cores and coating powder 
among those three plasticizers. 
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Figure 7.7 Relationship between the contact angle on tablet core and the 
powder adhesion rate in the ODDS coating process (Tablets loading: 60 g, 
temperature: 60 ◦C, plasticizer: 0.5 g/min for 3 min, charging voltage: 60 kV) 
In order to further investigate the influence of the spreading behavior of the liquid 
plasticizers on the coating powder adhesion rate, the relationship between the contact angle 
of the plasticizer on tablet core and the powder adhesion rate is shown as Figure 7.7. With 
the lowest contact angle, spraying TEC in the coating process resulted in the highest powder 
adhesion rate. While with the increase of the contact angle on the tablet core, the powder 
adhesion rate decreased dramatically, indicating that the wetting of the polymer during the 
process is critical, enhancing coating powder adhesion. 
Consequently, in order to be an effective liquid plasticizer, the following requirements 
should be considered. First, the liquid plasticizer should be able to reduce the glass 
transition temperature (Tg) of the coating polymer. Second, spraying the liquid plasticizer 
onto the surface of the dosage forms should increase the electrical conductivity of those 
dosage forms. Also the liquid plasticizer needs to have a suitable spreading behavior 
(wettability) on the surface of the dosage forms. These three requirements could be used 
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as the screening criteria to select liquid plasticizer in powder coating with different 
coating materials. 
7.4 Film formation and influence factors 
Similar to aqueous coating, film formation of dry powder coating also relies on the 
deformation and viscous flow of coating polymers [21]. As being reported from previous 
studies, the deposited coating particles have to coalesce during the curing step, allowing 
the film formation during the dry powder coating process [2, 30]. The influence factors 
include particle size of the coating materials, curing temperature and curing time.  
Pellet coating with three different coating formulations was used to illustrate those 
influence factors. 
7.4.1 Particle size  
Figure 7.8 shows the relationship between the particle size of the coating material (Acryl 
EZE) and the acid resistance of the enteric coating film. 
Characterized as the percent of drug release in 0.1 N HCl solution during the first 2 h, 
acid resistance is the most important quality in enteric coating that qualifies the coating 
film. And according to the United States Pharmacopoeia (USP), a good coating should 
only allow less than 10 % of drug release in the first 2 h in the acid medium. 
As shown in Figure 7.8, different particle size resulted totally different acid resistance of 
those enteric coating films formed by Acryl EZE. When the particle size of the Acryl 
EZE was 168 µm, the cumulative drug release for the first 2 h was more than 40 %, 
which was too much for an enteric coating film. With the decrease of coating particle size 
from 168 µm to 101 µm, the cumulative release was declined to 14 %. When further 
reducing the particle size to 53 µm and 20.8 µm, the cumulative drug release was 
decreased to 3 % and 0.3%, respectively, which is very good enteric coating film. 
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Figure 7.8 Influence of particle size of the coating powders  
on the acid resistance of enteric powder coated pellets 
From Figure 7.8 it could be concluded that using finer particles in the electrostatic 
powder coating process resulted in more uniform and smooth coating film with 
satisfactory function of acid resistance. In the electrostatic powder coating process, those 
deposited coating particles have to coalesce during the curing step so as to allow film 
formation. For aqueous coating processes, coalescence is driven by the presence and 
subsequent removal of water which creates capillary forces between each particle. The 
process of coalescence for electrostatic dry powder coating is similar, although the 
capillary force is achieved by the liquid plasticizer. 
Huang [36] proposed an equation to evaluate the time (t) required for two powder 
particles to coalesce during coating process, which is directly related to the viscosity of 
the powder coating µ, the radius of the particles (dp) and the surface tension of the coating 
γ where k is a constant describing the process [2]. 
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
 pdk
t                                                   (7.1) 
According to equation 7.1, diameter of the coating particles is positive related to the time 
required for two particles to coalesce during the coating process. Larger particle size 
would result in a longer time to coalesce, leading to rougher and non-uniform coating 
film with the same curing time as finer coating particles. This could be confirmed by the 
results of acid resistance of enteric coating film with different coating particle sizes. 
Specifically for electrostatic powder coating, the particle size of the coating powders 
could also influence the coating efficiency by affecting the charging efficiency during the 
coating process. Misev [37] carried out a study on the relationship between charging 
efficiency and particle size and obtained equation 7.2:  
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In the equation, E is the electric field to which the particles are subjected, ε0 is the 
permittivity of free space while εr is the relative permittivity of powder particles, ρ0 is the 
density of the particle and dp is the coating particle diameter. According to this equation, 
a higher charging efficiency could be achieved by using a smaller coating particle. Also a 
smaller particle has a larger specific surface area, which could make the wetting much 
easier by the liquid and softening and melting by heat, so as to enhance the coating 
powder adhesion and film formation. 
7.4.2 Curing time and curing temperature 
The effect of curing time and curing temperature on the film formation can be illustrated 
by the acid resistance test of Acryl EZE coated pellets. As shown in Figure 7.9, when the 
curing temperature was 30 and 40 ◦C, drug released more than 80% and 60% (cured 60 
min) and decreased some when the curing time was increased to 90 and 120 min, but still 
more than 10%. That is because the curing temperature was lower than the Tg of the 
coating polymer, which makes it hard for the deformation and viscous flow of deposited 
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polymer powders. However, when the curing temperature was increased to 50◦C, which is 
close to or higher than the glass transition temperature, film formation of deposited 
polymer powders became much easier and the drug released only 12 % for a curing time 
of 60 min and further reduced to 5 % and 0.4 % by increasing the curing time to 90 and 
120 min. (Figure 7.9). 
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Figure 7.9 Influence of curing time and temperature on the acid resistance 
of Acryl EZE coated pellets (Curing level: 10.83%; Drug release media: 0.1N 
HCl solution; Agitation speed: 100 rpm) 
 
7.5 Conclusions 
In this chapter, the electrostatic powder coating process was in-depth characterized, 
providing a full and better understanding on the coating powder adhesion and film 
formation during the coating process.  
Using pellet coating as example, the coating powder adhesion process was analyzed and 
the influence factors including preheating and charging voltage were investigated. The 
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results indicated that preheating the loaded pellets for a certain time could provide extra 
energy to enhance coating powder adhesion. Increasing the charging voltage could also 
promote deposition of coating particles. 
Using elementary osmotic pump tablet coating as an example, the influence of liquid 
plasticizers on the powder adhesion rate was analyzed. It was found that different liquid 
plasticizers resulted in totally different powder adhesion rate. Compared to glycerol and 
PEG 400, TEC achieved the highest powder adhesion rates, which could be explained by 
the polymer-plasticizer compatibility and the spreading behavior of liquid plasticizer on 
the surface of the dosage forms. From the results of contact angle measurement and the 
SEM micrographs, it could be concluded that of the three plasticizers, TEC has the best 
compatibility with cellulose acetate and also has a wider spreading on the surface of the 
dosage forms. By doing the contact angle measurement and SEM, a suitable liquid 
plasticizer could be found for a certain coating material. 
Using pellet coating as example, the film formation process was also illustrated in this 
chapter. After coating particles being deposited on the surface of the dosage forms, a 
curing step is needed to allow coating particles coalesce and form a continuous, uniform 
and functional acceptable coating film. It was found that in the electrostatic coating 
process, particle size and curing temperature and time are the main influence factors that 
affect the film formation process. Finer coating powders, higher curing temperature and 
longer curing time led to a more uniform and smoother coating film. 
The above results indicated that this electrostatic powder coating technology could be 
well controlled and is ready for the industrial application as long as those influence 
factors could be manipulated including preheating, charging voltage of the electrostatic 
spray gun, liquid plasticizers and their screening, particle size of coating powders, curing 
temperature and curing time.  
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8 Conclusions and Recommendations 
8.1 Conclusions 
A novel electrostatic powder coating technology was successfully utilized to coat 
pharmaceutical solid dosage forms including tablets, small pellets and osmotic drug 
delivery systems with different coating formulations. By doing so the drug release was 
successfully modified as sustained release, controlled release and delayed release. 
Compared with the liquid coating methods currently used in the present pharma industry, 
this electrostatic powder coating technology eliminates the usage of organic solvent and 
water so as to avoid all the limitations caused by those liquids such as toxicity, health and 
environmental related concerns, high energy consumption, and long processing time. This 
electrostatic powder coating also has many other advantages such as simpler coating 
apparatus that can be easily adapted from the present ones such as pan coater systems for 
liquid coating. Consequently, the proposed new technology, as a substitute of liquid 
coating, is promising and readily acceptable in the pharmaceutical industry.  
Electrostatic powder coating was firstly expanded to tablet coating for sustained drug 
release with ethylcellulose (EC), which is difficult to coat due to its high glass transition 
temperature (Tg). Lactose and triethyl citrate (TEC) are two effective plasticizers for EC, 
which could dramatically reduce the Tg of EC, guaranteeing that the whole coating 
process was under a relatively low temperature so as to protect drug from high 
temperature. Spraying liquid plasticizer onto the surface of the tablets also increased the 
electrical conductivity of those dosage forms, leading to an enhanced coating powder 
adhesion with the electrostatic spray gun. With the support of these two plasticizers, a 
continuous, uniform and functional acceptable coating film could be formed under 60 ◦C 
for around 120 min. Pore forming agent (PVA-g-PEG) was added in the coating 
formulation to increase the permeability of the EC coating film, leading to a faster drug 
release rate. The drug release rate could be adjusted by changing the coating level and 
pore forming agent ratio in the coating formulation. The stability tests indicated that EC 
powder coated tablets using powder coating technology exhibited excellent stability over 
1 month at 40 ◦C /75% RH. 
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Small pellets were also successfully coated by electrostatic powder coating with 
optimized coating parameters and curing conditions. Polyethylene glycol (PEG) 400 and 
triethyl citrate (TEC) were used as the liquid plasticizers to reduce the Tg of the coating 
polymers, as well as to decrease the electrical resistivity of the drug pellets, enhancing the 
coating powder adhesion and promoting the film formation under a low curing 
temperature. Three different coating formulations were developed for pellet powder 
coatings containing Eudragit® EPO, Eudragit® RL/RS and Acryl EZE, achieving 
immediate release, sustained release and delayed release, respectively. For immediate 
release and delayed release, the results of dissolution tests indicated that coating level 
didn’t contribute to the difference of surface morphology as well as drug release profiles. 
However, for sustained release, coating level had a big impact on the drug release profiles 
as well as the surface morphology. Higher coating level led to a better and more uniform 
coating film and a slower drug release rate. For Eudragit® RL/RS powder coated pellets, 
drug release rate could also be influenced by the ratio of Eudragit® RL/RS in the coating 
formulation; more Eudragit® RL led to a faster drug release rate due to the high 
permeability of the coating film formed by Eudragit® RL. Those powder coated pellets 
with these three coating formulations by using dry powder coating technology exhibited 
excellent stability, with 1 month at 40◦C /75% RH. Compared with pellet coating based 
on organic solvent and water in a fluidized bed, powder coating of pellets could 
significant reduce energy consumption without using large amounts of fluidizing hot air. 
Particularly, as the most promising oral drug delivery system, osmotic drug delivery 
systems (ODDS) were also successfully coated by applying powder coating, which is a 
big breakthrough in pharma coating. Elementary osmotic pump tablets were firstly 
prepared and coated with micronized cellulose acetate by using powder coating. Both 
water soluble drug (salbutamol sulfate) and water slightly soluble drug (ibuprofen) were 
used as the model drugs in the tablet core formulation. Triethyl citrate (TEC) was found 
to be an efficient liquid plasticizer for ODDS coating with cellulose acetate, not only 
reducing the glass transition temperature, but also increasing the conductivity of the 
ODDS dosage forms. With the support of TEC, a continuous, uniform and functional 
acceptable coating film was obtained with optimized coating conditions and curing 
parameters. Controlled drug release with a desirable time period (12 hours and 24 hours) 
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was achieved. Drug release rate from powder coated tablets varied with different coating 
levels, while this was independent of the diameter of delivery orifice, pH of release media 
and agitation speed. Results from the kinetic modeling on drug release from electrostatic 
powder coated elementary ODDS demonstrated that both salbutamol sulfate and 
ibuprofen released with zero order drug release kinetics. 
Electrostatic powder coating was also utilized to form porosity osmotic drug delivery 
systems (ODDS) by coating the ODDS core with a mixture of cellulose acetate and pore 
forming agent (Polyethylene glycol 3350). Similar with elementary ODDS coating, TEC 
was used as the liquid plasticizer to reduce the coating temperature and enhance the 
coating powder adhesion. Drug controlled release with a desirable time period (12 hours 
and 24 hours) was achieved by adjusting the coating level and pore former ratio in the 
coating formulation. Drug release rate was independent of the pH of release media and 
the agitation speed. After being fitted with different mathematical models including zero-
order, first-order and Higuchi model, it was found that the drug release from porosity 
ODDS formed by powder coating followed zero-order drug release kinetics. 
More in-depth characterization was carried out to fully illustrate powder coating process, 
which is related to two steps: coating powder adhesion to the surface of the dosage forms 
and film formation. It was found that coating powder adhesion was a prerequisite and 
particularly critical to achieve an acceptable coating film. The adhesion of coating 
powders could be improved by doing the following: preheating the loaded solid dosage 
forms, applying a suitable liquid plasticizer in the coating process and utilizing the 
electrostatic spray gun to feed the coating powders with a suitable charging voltage. After 
adequate coating particles deposited on the surface of the dosage forms, a curing step is 
needed to allow coating particles to coalesce and form a continuous, uniform and 
functional acceptable coating film. It was found that in the powder coating, particle size, 
curing temperature and time are the main influence factors that affect the film formation 
process. Finer coating powders, higher curing temperature and longer curing time led to a 
smoother and more uniform coating films. 
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Liquid plasticizer plays a key role in the powder coating process, not only reducing the Tg 
of coating polymers, but also increasing the electrical conductivity of the dosage forms, 
both of which could enhance coating powder adhesion and promote film formation. 
However, difficulties exist in selecting the most suitable liquid plasticizer for each 
different coating polymer. The present study found that the contact angles of a liquid 
plasticizer on the coating powder compact and surface of dosage forms not only reflect 
the compatibility of this plasticizer with the coating polymer, but also indicate the 
spreading behavior of this liquid plasticizer on the surface of dosage forms. Together with 
differential scanning calorimetry (DSC) analysis and electrical resistivity test, contact 
angle measurement could be used to screen liquid plasticizers for powder coating with 
different coating materials. 
Compared with previous coating technologies, the advantages of this powder coating 
process include eliminating organic solvent and water currently used in the present 
pharma coating, significant energy and time savings, significant reduction of air handling 
and cleaning requirements. Consequently, the proposed new technology, as a substitute of 
liquid coating, is promising and readily acceptable in the pharmaceutical industry.  
8.2 Recommendations 
Despite those comprehensive studies that have been done in the present study, further 
experiments remain necessary for a thorough understanding of this electrostatic powder 
coating technology. Some recommendations are listed below as future perspective. 
Powder coating has been applied to most of the solid dosage forms including tablets, 
pellets, osmotic pump tablets. Yet very small dosage forms, such as drug particles 
(diameter < 800 µm), haven’t been tried so far. Considering the difference between small 
drug particles and larger dosage forms, further studies need to be carried out. 
In addition, moisture sensitive drugs always bring troubles to the current liquid coating 
but they are very suitable for powder coating. Details need to be obtained on how to apply 
powder coating to those moisture sensitive products, which may play a key role in 
adopting this novel technology in the pharmaceutical industry. 
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